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Production of large numbers of desirable human cell types in the laboratory is 
one of the major goals of stem cell research. Current experimental approaches have 
focused on the strategy of recapitulating the events of normal embryogenesis in 
culture, by treating cells – either tissue stem cells or pluripotent stem cells (iPS/ES 
cells) – with cocktails of growth factors, matrix proteins or pharmacological agents. 
This is challenging and often requires weeks or months of elaborate cell culture 
regimes. An alternative approach is the forced expression of master regulatory 
transcription factors; this can bypass developmental programs and drive conversion to 
the target cell type. Each of these strategies is inefficient and unreliable. Recently a 
new opportunity has arisen to exploit synthetic transcription factors (sTFs) to program 
and reprogram cell fate. To create such sTFs the CRISPR/Cas9 system is repurposed 
through tethering of catalytically dead Cas9 to various transcriptional regulatory 
effector domains (e.g. VP16, KRAB).   
In this thesis, we have explored sTFs as tools to reset transcriptional regulatory 
networks in neural stem cells and mouse embryonic fibroblasts. We tested 
transcriptional activation of key neural lineage target genes (e.g Olig2, Sox10 and 
Nkx6.2).  We designed and validated a series of sTFs that could effectively activity 
these. We have found that activation of Sox10 by dCas9-VP160 in mouse neural stem 
cells can increase the amount of arising oligodendrocyte and oligodendrocyte 
precursors cells during the differentiation. 
The activity of sTFs strongly depends on cellular context: i.e.  a specific sTF 
might work well in one cell type but not another. Importantly, these biological barriers 
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are not easily overcome by increasing the strength of the sTF – either through levels 
or types of effector domains used. Our data inspecting single cells suggests that 
multiplex delivery of sTFs can indeed cooperate by both increasing the number of cells 
that activated the gene of interest and increasing the level of transcriptional activation 
in a given cell. To fully exploit these new technologies, we therefore developed a new 
construction pipeline that allows easy and efficient assembly of multiple sTFs. Using 
this approach, we were able to successfully activate three different target genes from 
a single expression plasmid (Olig2, Sox10 and Nkx6.2) in fibroblasts. These sTFs we 
able to force fibroblast transdifferentiation towards oligodendrocyte lineage. Future 
studies will explore further how to exploit these sTFs to augment or replace current 
reprograming strategies.  
 12 
Lay summary 
Many human diseases, such as multiple sclerosis and Parkinson’s disease, 
manifest by loss or disruption to the specialized brain cells in the body. One way in 
which we can treat such illnesses is by replacing lost cells with new ones generated in 
lab and transplanted into patients. However, a reliable source of those highly 
specialised cells is difficult to achieve. Therefore, such cell replacement therapies have 
not become used in the clinic. For multiple sclerosis, there is a need to produce 
oligodendrocytes – the cells that wrap an insulating like sheath around the nerves in 
the brain. 
One approach to make the desired cells is by converting more abundant and 
easy to grow cells into the specialized cells. For example, clinicians could take some 
of patients’ skin cells – which easily replenish and expand in the laboratory culture 
dish – program them into oligodendrocytes in the laboratory by resetting the patterns 
of gene activity: turning key specialised genes ‘on’ and the non-desired host genes 
‘off’. Some experimental studies have shown this is possible in the lab culture dish; 
however, the process is still largely inefficient, unreliable and costly. 
In this work, we have investigated an emerging strategy to reset specialised 
cell types. This approach is based on taking control of the cells’ genes by using 
artificially created transcription factors – the key proteins involved in switching on and 
off gene activity. Recently it became possible to produce such synthetic transcription 
factors (sTFs) using a new technology called CRISPR.  Here we explore how well 
these technologies can work in neural stem cells and what the key parameters are for 
making them work effectively. We build a new set of tools to work with and deliver 
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these sTFs, and provide a proof-of-principle by taking control of genes involved in 
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Synthetic biology is providing a wealth of new tools to engineer mammalian 
cells. Some of the key areas under investigation are genetically encoded computing 
circuits, programming of cellular type and functions, and fully synthetic artificial 
chromosomes that can carry large cargoes (Li & Weiss 2017). These advanced 
technologies will underpin a myriad of new applications across diverse fields, e.g. food 
production, fuel production and medicine (Khalil & Collins 2010).  
Efficient methods to rapidly and robustly experimentally direct mammalian 
cell type identity is a key challenge of stem cell biology. This is vital if new cell 
therapies are to become a common practise in the clinic, as current approaches are 
inefficient and unreliable. Given the increasing burden of neurodegenerative disease 
across the globe, neuroscience is one area that would particularly benefit by such 
developments. Routine production of neuronal or glial cell types in the laboratory is a 
major aspiration of the field. Two examples are dopaminergic neurons to treat 
Parkinson’s disease and oligodendrocyte progenitors to treat demyelinating diseases 
such as multiple sclerosis (Ben-Hur 2011). However, current strategies to generate 
such cells through human ES or iPS cell differentiation involve long, complex and 
unreliable de-differentiation and differentiation protocols. These methods normally try 
to recapitulate developmental events in vitro. 
What determines the identity of one cell type versus another? At the 
fundamental level a cell type is defined by its patterns of gene expression; it is a long 
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checklist of which genes are ‘ON/OFF’. So, what if we developed experimental 
approaches that enable simultaneously to switch genes ON and OFF? Could this be 
used to shift cell type identity? Based on the findings from the field of nuclear 
reprograming – either by nuclear transfer, cell fusion or overexpression of master 
regulatory transcription factors – this would seem possible (Sparman et al. 2009). 
However, these reprograming strategies are highly inefficient. Recent developments 
in synthetic transcription factor technologies suggest this might provide an alternative 
approach. This is the major topic of this thesis.  
CRISPR technologies are now widely used to edit mammalian genomes; i.e to 
cut, tag, repair and insert genetic material. However, they can also be repurposed as 
new synthetic transcription factors.  Nuclease dead variants of Cas9 (dCas9) can be 
fused to a transcriptional regulatory domain. These have been shown to be able to 
activate and repress target genes in mammalian cells. Although this technology is still 
in its infancy, it is likely to become an important tool in mammalian stem cell and 
synthetic biology. There could be important applications for generating cells for cell 
replacement therapies. 
Our goal is to test the effectiveness of these synthetic transcription factors 
(sTFs) in programing and reprograming neural cell types. In this introduction, I will 
discuss relevant areas; first, existing methods to program cell types; second, genome 
editing technologies, with an emphasis on the CRISPR system and its repurposing to 
make synthetic transcription factors; and finally, the molecular and cellular 




1.2 Programing and reprograming cell types 
Efficiently controlling mammalian cell type identity has been a major objective 
of stem cell biologists and significant progress has been made (J. Xu et al. 2015). In 
this thesis, we will be using following terminology, which is mainly based on changes 
that occur in respect to cell potency. These are: programing (or differentiation) and 
forward programing, in which cells transit from higher potency to lower potency 
through more or less developmentally-relevant stages; reprograming, which is 
conceptually similar but mechanistically different from de-differentiation, where cells 
moves from lower potency to higher potency; direct reprograming (also known as 
transdifferentiation or direct lineage conversion) in which one somatic cell (low 
potency) can be directly converted to another somatic or progenitor cell (usually of 
different lineage but not necessarily) without going back to pluripotency (Fig.1-1). 
However, these terms are often used loosely and mean different things to different 
people. When applicable, we will present those in relevant parts of this introduction 
and try to be specific in terms of this project. This thesis is focussed on differentiating 
neural stem cells to oligodendrocytes (programing) and transdifferentiating fibroblasts 




Figure 1-1 | Schematic of cell state changes during development or through experimental 
programing, focussing on the neural lineage.  





















1.2.1 Cell differentiation during development and in vitro 
Cellular differentiation is defined as the process during which cell becomes 
more specialized to perform specific functions. Pluripotent cells of the blastocyst 
(equivalent of embryonic stem cell cultures) transit into multipotent tissue-specific 
progenitors (e.g neural stem cells) and these generate terminally differentiated progeny 
(e.g. oligodendrocytes). As differentiation is accompanied by a loss of potency to 
generate different cell types, it is important that a subset of adult cells is retained in a 
stem cell state. These adult tissue stem cells continue to proliferate and differentiate in 
order to maintain tissue homeostasis or provide a source of new and healthy cells to 
replace damaged or diseased tissues. It was thought that this process is irreversible; 
essentially unidirectional. While this is true under most circumstances, it became 
evident from decades of research into nuclear reprograming that this can be reversed 
experimentally – most clearly demonstrated by the studies of Shinya Yamanaka for 
the production of iPS cells (Takahashi et al. 2006). 
Differentiation is often guided by external inductive signals, such as growth 
factors, hormones and morphogens. Cells exposed to such molecules activate various 
signalling pathways which then can result in cell type change; often these are signals 
that are used during normal development and to some extent are recapitulated in the 
culture dish. The timing, levels, duration and combination of many inductive cues 
determines the precise trajectory of differentiation. Detailed differentiation protocols 
have been developed for mouse embryonic stem cells, enabling differentiation to a 
range of specific lineages, including derivatives of all three major germ layers: 
reviewed in (Murry & Keller 2008); iPSCs (Mertens et al. 2016) and NSCs (Massirer 
et al. 2011; Glaser et al. 2007). Lastly, differentiation process can be facilitated by 
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overexpression of specific master regulators, a process termed forward programing. 
Such transitions have been demonstrated to be faster and give more homogenous 
outcome compared to simple addition of differentiation inducing culture medium 
(Pawlowski et al. 2017). It is not clear if forward programing is just an enhancement 
of differentiation process or if it relies on novel intermediate stages and transcriptional 
networks. 
In addition to external stimulus, another important consideration is internal 
capacity of cell to respond appropriately – their competence. Such cell autonomous 
programs unfold during development with defined timing and this influences the way 
in which signalling pathways are read out (Singh et al. 2015; Llorens-Bobadilla et al. 
2015). The ability of a cell to read out signals is heavily influenced by its lineage – 
events from earlier in development are recorded as epigenetic memory limiting options 
for further shifts in cell type. Therefore, while regulation at transcription level (via 
transcription factors) is crucial for understanding cell competency and process of cell 
type conversion, epigenetic control and mechanisms behind it are as, if not more, 
important to consider. In fact, epigenetic information works hand-in-hand with DNA 
sequence (genetic information) to regulate gene transcription and therefore cell 
identity.  
Epigenetic control can be exerted both via modifications to DNA and histones 
- proteins wrapped around DNA (Fig. 1-2). While DNA directly can only be modified 
by methylation, which is often associated with transcription repression, histone tails 
and core proteins have a larger number of possible modifications. Histone acetylation, 
phosphorylation and ubiquitination has been linked to transcription activation, while 
sumoylation is linked to repression. Importantly, histone methylation has been linked 
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to both transcription repression and activation depending on the context of present 
enzymes and other modifications (Zhang & Reinberg 2001). All these modifications, 
essentially create a local gene environment that determines what kind of factors can 
access DNA at specific locations and time. In such a way, epigenetics plays a key role 
in cell’s competence and identity, as it influences the potential for genes to be activated 
or repressed. 
 
Figure 1-2 | Epigenetic modifications and nucleosome structure.  
Nucleosome, a fundamental DNA organization unit, is composed of eight core histone proteins, their 
tails and additional linker histone subunit (H1). Such core is wrapped around (twice) by around 146 
base pairs of DNA. Multiple epigenetic modifications can take place on histone tails as well as core 





















Control of stem cell differentiation in the laboratory is a major challenge, but 
is essential for their application in regenerative medicine. Thus, understanding the 
transcriptional, signalling and epigenetic processes that control normal development 
is important, as this can help direct efforts to differentiate stem cells in the culture dish 
(Ebina & Rossi 2015; Neman & de Vellis 2012). Although this approach has a lot of 
potential, it is hugely limited by the need for complex cocktails of signals, patient-
specific pluripotent cells, stepwise protocols and the long time required (often months) 
to transit from immature cells to the desired terminally differentiated cell type (Wang 
et al. 2013). 
1.2.2 Reprograming reverses differentiation to generate pluripotent stem cells 
In the mid 20th century it was still unclear whether the process of differentiation 
was irreversible and whether it involved the removal of certain genetic sequences. This 
was tested directly by Gurdon et al. in 1962. In these experiments, Gurdon  removed 
nucleus from Xenopus eggs by UV enucleation and then transplanted nucleus from 
somatic cell into these eggs (Gurdon J.B., 1962). Surprisingly, this gave fertile male 
and female adult frogs. This demonstrated for the first time that genetic information is 
not lost during differentiation and that somatic nucleus can become pluripotent in 
appropriate environment. 
This and other work led to the studies by Yamanaka, who demonstrated 
reprograming of the somatic cell to become induced pluripotent stem cells (iPSCs) by 
overexpression of four transcription factors Oct4, Sox2, Klf4 and c-Myc (known 
together as OSKM factors). From the perspective of cell potency, such reprograming 
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can be classified as an example of complete de-differentiation where somatic or 
multipotent cells of specific lineage are turned back to pluripotent state.  
During recent years the mechanisms behind iPSC reprograming has been 
actively pursued. In the current model, two distinct phases of reprograming have been 
described: stochastic initiation phase and deterministic maturation-stabilization phase 
(Buganim et al. 2013). During initial stages, cells undergoing reprograming show 
increased proliferation, epigenetic and metabolic changes and initiation of 
mesenchymal-to-epithelial transition (MET). This early stage seems to happen in 
unpredictable and stochastic fashion and therefore be very inefficient. Later stage 
(stabilization of new phenotype) involves activation of key pluripotency genes, 
changes in cytoskeleton, chromosome re-organization and silencing of OSKM 
transgenes. During this stage, OSKM factors are able to bind and activate most of 
pluripotency-related genes (Soufi et al. 2012). 
Development of iPSCs reprograming protocols to a large extent solved the 
problem of a lack of patient-specific pluripotent cells and is therefore a very important 
advance for regenerative medicine. From a cell therapy perspective, while 
differentiation protocols are long and not completely understood, the main limitation 
usually was lack of starting material – pluripotent cells which could be forced to 
differentiate. With the development of iPSC, this major hurdle was overcome. iPSCs 
have been reported to be a viable source for generating specific somatic cells for 
transplantations (Li et al. 2015; Polentes et al. 2012). Despite these remarkable 
discoveries, the efficiency and fidelity of iPSCs has remained extremely low, and long 
incubation times in culture are required (Robinton & Daley 2012). Moreover, teratoma 
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formation remains an important risk if differentiation process is incomplete or reversed 
after transplantation. 
1.2.3 Transdifferentiation: direct reprograming of somatic cells 
A third way of cell type programing is transdifferentiation, also known as direct 
lineage conversion or direct reprograming; this involves a transition from one somatic 
cell to another somatic or multipotent cell of same or different lineage without 
returning to pluripotent state. Transdifferentiation was first reported in late 20th century 
by Davis et al. when he successfully converted mouse fibroblasts to stable myoblasts 
by overexpression of MyoD cDNA (Davis et al. 1987). To date, a number of somatic-
to-somatic transitions have been demonstrate by other groups (Kikuchi 2015; 
Vierbuchen et al. 2010; Vierbuchen & Wernig 2011). One good example of 
transdifferentiation has been reported by Yang et al. in 2013 study where they 
successfully converted rat fibroblasts into OPC-like cells. By overexpression of just 
three master transcription factors (Sox10, Olig2 and Zfp536), they managed to obtain, 
on average, 15.6% O4-positive cells at the end of 20 days long protocol. These cells 
were capable of differentiating into CNP-positive cells and myelinating neurons when 
transplanted into mice incapable of endogenous myelination (Yang et al. 2013). 
Excellent review on the historical progress of transdifferentiation has been written by 
Xu and colleagues (Xu et al. 2015). 
Transdifferentiation mechanisms are still poorly understood but some insights 
have been made. Firstly, transdifferentiation can either happen directly or involve 
initial step of de-differentiation. For example, during lens regeneration in adult newt, 
pigment epithelium cells initially show signs of de-differentiation as demonstrated by 
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the loss of pigment and increased proliferation. This if followed by activation of 
various genetic programs (similar to ones used in lens development) and cells’ 
transdifferentiation (Tsonis et al. 2004). One difficulty in such cases is the similarity 
of the transdifferentiation process to that of de-differentiation followed by the 
differentiation. The clear distinction is hard to make. On the other hand, 
transdifferentiation from fibroblasts to muscle cells by overexpression of MYOD 
seems to avoid intermediate stem cell-like proliferative stage (Davis et al. 1987). 
Instead, transdifferentiating cells seem to enter into unnatural intermediate state. As 
work in B cell transdifferentiation has shown, this stage partly reassembles original 
and partly final cell (Xie et al. 2004). Interestingly, it is still not clear how much 
different is this intermediate unnatural state to that intermediate phase observed during 
reprograming. Both seems to possess a mixture of original (somatic) and new 
(pluripotent in case of reprograming, and somatic in case of transdifferentiation) genes. 
Mechanically, it could be that reprograming and direct reprograming work in a similar 
fashion. Secondly, epigenetic remodelling is an important process for 
transdifferentiation. It has been shown that transdifferentiation requires pioneering 
transcription factors to directly access nucleosomes and then coordinate recruitment 
and binding of secondary factors (Iwafuchi-Doi et al. 2014). Thirdly, it seems that 
transdifferentiation might be two-step process: initiation followed by maintenance of 
a new cell fate. Some of the evidence suggesting this comes from hepatocyte 
transdifferentiation to biliary epithelial cells. While cells which completed 
transdifferentiation process stay as epithelial cells, other cells which are still 
undergoing the process can return back to hepatocyte fate if stimulus is removed 
(Tarlow et al. 2014). Lastly, while cell division seems to be a critical requirement and 
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an enhancing condition during iPSCs reprograming (Hanna et al. 2009), it is not 
required during transdifferentiation of fibroblasts into neural cells (Iwafuchi-Doi et al. 
2014; Fishman et al. 2015). 
While transdifferentiation might become very important method for some 
applications, it comes with its downsides. For example, while we can easily expand 
pluripotent cells (and therefore generate enough of them to be used for cell therapy), 
expansion of somatic cells is more difficult. Such limitation would mean that 
potentially reprogramming (dedifferentiation) followed by differentiation might be 
better approach for off-the shelf cell therapies. That being said, transdifferentiation has 
a lot of potential for in vivo cell modulation and reprogramming. For example, in vivo 
reprogramming of astrocytes (or other supportive and replicative cells) to OPCs in MS 
patients could potentially treat patients without a need to take cells out for in vitro 
culture for processing. 
 
1.2.4 Master transcription factors and their mode of action. 
Common to each discussed transition is the clear need to trigger new patterns 
of gene expression and associated gene regulatory networks. These are controlled by 
cell type specific transcription factors – often termed master regulators. Be it by 
activation of these master regulators by growth factors, or direct overexpression of 
them (Fig. 1-3), these transcription factors are central to defining cell identity in every 
cell type transition. Therefore, it is important to understand how these transcription 
factors operate and what makes them unique. 
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Figure 1-3 | Two most common approaches to induce cell type change.  
Most commonly, programing and reprograming events are achieved either by using a cocktail of specific 
growth factors (which when activate specific master regulators) or by overexpressing key master 



















All of the discussed transitions have been successfully induced by the 
overexpression of some key master regulatory genes; reprograming (Takahashi et al. 
2006); transdifferentiation (Najm et al. 2013; Yang et al. 2013); differentiation (Yao 
et al. 2014; Maire, Buchet, Kerninon, Deboux, Baron-Van Evercooren, Nait-
Oumesmar, et al. 2009; Liu et al. 2007; Wang, Suyog U. Pol, et al. 2014). Although 
the mechanisms are probably somewhat unique for each conversion but some light has 
been shed on the general principles of how these master regulators generally work.  
Firstly, transcription factors that will be able to drive the transition are usually 
specific to the cell lineages involved. Most studies investigating new cell type changes 
usually begin by screening panels of lineage-specific master regulators to identify the 
optimal combinations. Clear examples are MYOD in muscle transdifferentiation, 
SOX10 in oligodendrocyte transdifferentiation, OCT4 in iPSC reprograming. 
Secondly, many of master transcription factors involved in cell type changes act as 
pioneer factors and are able to bind some of closed chromatin regions (Iwafuchi-Doi 
& Zaret 2016). These factors can bind partially repressed low-signal chromatin by 
binding some of the surface motifs on nucleosomes, displacing some of the linker 
histones and making nucleosomes accessible in such a way (van Oevelen et al. 2015; 
Soufi et al. 2015). One excellent study have investigated how Ascl1 acts as pioneering 
factor in first 48 hours post its expression (Wapinski et al. 2017). This group reports, 
based on ATAC-seq data, that nucleosomes are shifted from Ascl1 target sites in first 
36 hours. Importantly, all of the nucleosome forms (mono-, di- and tri-) are affected. 
However, even pioneer factors do not seem to be able to target actively repressed 
chromatin regions (Iwafuchi-Doi & Zaret 2016). Thirdly, each master regulator might 
play a distinct role during different stages of programing. For example, during 
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transdifferentiation from MEFs to neurons – triggered by overexpression of Ascl1, 
Brn2 and Mytl1 – Ascl1 plays a key pioneering role and is able to induce immature 
neurons by itself. Meanwhile, it has been shown that Brn2 only has a supportive role 
and contributes to the neuronal maturation stage (Vierbuchen et al. 2010).  
Another example comes from OSKM factors. c-Myc has been shown to act as 
enhancing factor which is replaceable (Nakagawa et al. 2007) or even redundant 
(Wernig et al. 2008) while Oct4 seems to be critical: it cannot be removed or 
substituted (Feng et al. 2009). Consequently, it becomes clear why only having all 
required factors together allows an efficient cell type transition. Fourthly, both timing 
and levels of master transcription factors are critical. In the study by Sokolik et al., it 
has been showed that unless overexpression of Brn2 is 100-fold or more over the basal 
line, mESCs do not differentiate to NSC (Sokolik et al. 2015). Moreover, if >100-fold 
overexpression is not maintained for more than 5 hours, Nanog does not get repressed 
and differentiation cannot occur. The authors hypothesize that such restrictions allow 
cells to distinguish signals to differentiate from transcriptional noise. Other groups 
have reported that iPSC reprograming efficiency is highest if OCT3/4 levels were high 
and SOX2 levels were low (Papapetrou et al. 2009). All of these are important lessons 
which needs to be considered when optimizing new ways for inducing cell type 
conversions. 
1.2.5 New ways of inducing cell type changes. 
New experimental approaches to steer cell fate specification are also being 
developed, such as use of small pharmacological agents (Shi et al. 2008; Hou et al. 
2013) and miRNAs (Zhao et al. 2012; Kuypers et al. 2016; Zhao et al. 2010; Budde et 
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al. 2010). Lately, a new method which makes use of synthetic transcription factors 
(sTFs) has been successfully tested (Black et al. 2015). This offers the exciting 
prospect of more fine-tuned control of target gene expression patterns. This is a major 
focus of thesis and is discussed in detail in the next section. 
1.3 Genome editing technologies and synthetic transcription factors 
1.3.1 Introduction to genome editing tools – Zinc finger nucleases, TALENs and 
CRISPR-Cas9 
Genome editing is one of the most exciting new technologies now used widely 
by biologists to systematically dissect the functions and interactions of various genes 
and proteins. It enables precise engineering of DNA sequences at any desired location 
in the genome. The emergence of effective genome editing required developments in 
designer nucleases – also known as synthetic nucleases. These can be ‘engineered’ to 
bind at specific sites in the genome and introduce double–strand breaks (DSBs). DSBs 
are typically repaired by the non-homologous end joining (NHEJ) pathway, which is 
error-prone, and therefore can introduce random mutations at the target site. 
Alternatively, homologous recombination (HR) can be used in which a DNA template 
replaces the region surrounding the DSB (Fig. 1-4C). There are a number of different 
formats, or architectures, upon which such synthetic nucleases can be built. Zinc finger 
nucleases (ZFN) were the first designer nucleases to emerge. A key technological 
development was the discovery by Srinivasan Chandrasesegaran that fusion of the 
DNA binding domain of a ZFN to the FokI restriction enzyme can create a novel fusion 
protein with specific DNA binding and effective DNA endonuclease activity (Kim et 
al. 1996). These new synthetic sequence-specific nucleases bound DNA via zinc finger 
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domains, in which each domain recognized 3 base pair spans; as the ‘rules’ for 
predicting target sequence of synthetic domains were developed, it became possible to 
target this to specific sites. However, ZFN exhibited high off-target effect and 
cytotoxicity (Kim et al. 2009) and the design and construction of the DNA binding 
domain was often difficult. 
Transcription-activator-like effector (TALE) proteins emerged as an 
alternative architecture. TALEs when fused to the Fok1 domain can create nucleases 
named TALENs (Boch et al. 2009). TALENs have advantage over ZFNs because each 
TALE domain recognizes individual base pairs and therefore have higher target-
specificity and lower off-target effects and are easier to design. Furthermore, while 
early TALEs were unable to bind methylated DNA, development in the field allow 
these nucleases to target even methylated DNA (Scott et al 2014). Unfortunately, 
TALENs are still demanding to construct at scale, as each time new nuclease is 
constructed a modular assembly of repeated domains is required. So, protein 
engineering and the need to create unique plasmids was a hurdle. Although a number 
of protocols have been designed to make TALE assembly more efficient and 
straightforward (Cermak et al. 2011; Reyon et al. 2012), this still requires a significant 
investment and expertise. 
Most recently another genome editing platform, termed CRISPR/Cas9, has 
rapidly overtaken ZFN and TALENs as the preferred technology for genome editing 
(Lander 2016). Cluster of regularly interspaced palindromic repeats (CRISPR) and 
CRISPR-associated protein 9 (Cas9) (herein referred to as CRISPR) is responsible for 
bacterial immune response to viral infection (Mojica et al. 2005; Bolotin et al. 2005; 
Gasiunas et al. 2012; Jinek et al. 2012). It was fully repurposed for use in mammalian 
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cells for genome editing in 2013 (Cong et al. 2013; Mali, Esvelt, et al. 2013). In the 
following sub-section I discuss CRISPR technologies in detail as they form the core 
technology used in this thesis. 
 
Figure 1-4 | Graphical representation of CRISPR-Cas9 system and principles of DNA damage 
repair which are exploited for gene editing.  
(A) Cas9 nuclease forms a complex with a guide RNA and scans the genome for complementary DNA 
sequence. (B) Upon detecting sequence of interest, Cas9/gRNA opens double helix and initiates DNA 
strand cutting using two separate nuclease domains. This generates a double-strand break at the site. 
(C) Graphical representation of how double-strand breaks can be repaired. NHEJ results in 
insertion/deletion mutations at the loci of interest; alternatively, HR repair allows more elaborate 
modification (i.e. tagging) of the site by replacement of sequence with exogenous DNA. New techniques 
have been developed to favour one or another repair mechanism, allowing greater control over genome 
















1.3.2 Biology of CRISPR-Cas9 
The mechanism behind CRISPR-Cas9 has been intensively studied for over a 
decade. The system is composed of a Cas9 RNA-guided nuclease and separate guide 
RNA (gRNA), which itself is a combination of crRNA (CRISPR targeting RNA) and 
tracrRNA (trans-activating crRNA). crRNA is complementary to a target sequence, or 
protospacer, and protospacer has to have an appropriate PAM (protospacer adjacent 
motif) sequence at its 3’ end to be a valid target for CRISPR-Cas9 (Fig. 1-4).  
Cas9 protein forms a complex together with gRNA (Tsai & Joung 2016). This 
is followed by the search for matching PAM sequences across the genome. Each time 
a PAM sequence is encountered, Cas9-gRNA loosely binds the DNA but does not 
initiate the cutting. Cas9 therefore quickly scans extremely large spans of DNA. If the 
sequence adjacent to the PAM matches the crRNA then Cas9 protein undergoes 
confirmation change, which significantly increases binding affinity of Cas9-gRNA to 
the target sequence and leads to cleavage of the DNA. Importantly, the correct PAM 
sequence is used as a checkpoint at multiple stages of this process – from initial search 
to the process of cleaving DNA (Sternberg et al. 2014). One of the key steps for this 
process success is an ability of Cas9 to reach and bind even hard-to-access DNA 
sequences. Large parts of the genome are constantly in highly compact chromatin state, 
known as heterochromatin. Fortunately Cas9 can indeed access and cleave at such sites 
(Polstein et al. 2015). However, there is evidence that nucleosomes can interfere with 
Cas9 functionality (Hinz et al. 2015; Horlbeck et al. 2016; Isaac et al. 2016), which 
could partly explain why some gRNAs have such variable functionality in distinct cell 
types. For example, in the study by Horlbeck and colleagues it has been reported that 
Cas9 not only cannot cut DNA if nucleosomes are introduced, but dCas9 cannot even 
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bind such DNA (Horlbeck et al 2015). If nucleosome remodelling enzymes are added 
(such as yChd1), Cas9 recovers its ability to cut such DNA, demonstrating strong 
negative impact of nucleosomes on Cas9 functionality. 
Compared to TALENs and ZFNs, CRISPR-Cas9 has some salient features that 
are experimentally desirable. CRISPR-Cas9 is a much more scalable tool as it does not 
require construction of new proteins to target different sequences in the genome; new 
sites can be targeted by simply acquiring a different gRNAs. Such plasmids can be 
easily made and also can be amenable to large scale library preparations for pooled 
screens. While both TALE and ZFN cleavage requires dual binding as heterodimers, 
wild type Cas9 operates as nuclease (Kim 2016); this means there are fewer restrictions 
on choice of target sites.  
To date, CRISPR has been used for a large number of different applications. 
Generally, these can be segregated into two main areas: (i) genome editing by 
introducing or removing DNA sequences (random point mutations, tags/reporters, 
landing pads, modified genes etc.) and (ii) various non-cleaving manipulations 
performed by dead Cas9 or dCas9 (Wang et al. 2016). dCas9 is mutant version of Cas9 
whose both catalytic sites have been mutated to completely remove nuclease activity. 
dCas9 has been successfully used to image genetic locus (Chen et al. 2013), analyse 
protein-genome interactions (Fujita & Fujii 2013), and activate or repress gene 
transcription by acting as synthetic transcription factors (sTFs). 
Understandably, CRISPR use for genome editing came with initial concerns 
about off-target effects when used in mammalian cells. These concerns stemmed from 
the speculations that bacterial protein would misbehave in context of much larger 
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mammalian genome and that monomeric nature of Cas9 nuclease would result in more 
off-target DSB. Great efforts have been made to explore these potential limitations 
(Slaymaker et al. 2016; Kim et al. 2015) and to create tools to circumvent such 
problems. One example is the creation of artificial nickase Cas9 by mutating one of its 
catalytic nuclease domains, such that only one strand is cleaved. This has been used to 
improve target specificity, as two nicks on each strand that are in close proximity 
(<100bp) are less likely to occur on off-target site compared to a single DSB. This has 
been demonstrated in mouse embryos by Shen et al. After targeting Ar gene with wild-
type Cas9, at least three off-target sites have been cleaved. However, if nickase Cas9 
and two sgRNA were used, no detectable off-target effects were seen (Shen et al. 
2014). Similar results have been reported by other groups as well (Kim et al. 2015). 
That being said, other studies have reported that up to 60 non-specific cuts (of 
frequency as high as 10%) can be identified for some of the targets/gRNAs (Tsai et al 
2016). Furthermore, current sequencing limitations might mask some very infrequent, 
but still therapeutically very important, off-target cut sites. That being said, to date it 
seems that off-target effects are not a major problem for use of CRISPR and especially 
not for CRISPRa (Cho et al. 2014).  
1.3.3 Synthetic transcription factors 
A synthetic transcription factor, or sTF, is an engineered artificial protein 
containing a DNA binding domain and separate effector domain which can activate or 
repress transcription. When these proteins are targeted to promoters or enhancers using 
engineered DNA binding domains (TALE-TFs or ZF-TFs) or gRNAs (CRISPR-TFs), 
gene transcription can be regulated. These sTFs can be deployed in various 
applications, from alleviating diseases by manipulating gene expression to inducing 
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cell type changes (Himeda et al. 2016). For example, sTFs have been used to 
upregulate dystrophyn to treat Duchenne muscular dystrophy and upregulate y-globin, 
which is epigenetically silenced in sickle cell disease (Gersbach & Perez-Pinera 2014). 
Zinc-finger sTF which activated VEGF, increased wound healing better in comparison 
to overexpression of VEGF (Rebar et al. 2002). Examples like these make this new 




Figure 1-5 | Schematic of a dCas9-VP160 sTF with its’ partners and potential advantages of 
sTFs.  
(A) One of the most common dCas9-based sTFs used to date are dCas9-VP160. Its transcription 
activating domain VP16 is a viral protein that is capable of attracting various partners which are required 
for transcription initiation. (B) Summary of the potential advantages of using sTFs rather than cDNA 



























ZFNs, TALEs and CRISPR have all been successfully used as sTFs (Sander & 
Joung 2014). There are a number of advantages of using sTFs to activate endogenous 
genes, rather than the typical approach of ectopic cDNA overexpression via plasmids 
or viral vectors (Fig.1-5B). Firstly, transcription activation with sTFs targets the 
endogenous gene, and therefore will be amenable to ‘natural’ levels and splice forms 
of the protein product. Secondly, it can be used to target several different genes for 
repression and activation in multiplex. Moreover, it should be possible to scale-up and 
modulate dozens and even hundreds of target genes at the same time. Thirdly, 
considering the extent of potential modifications (hundreds of genes repressed and 
activated), it might be possible that transient treatment would be sufficient to induce a 
permanent effect that is epigenetically stable. Fourthly, by making use of different 
gRNAs and effectors it would be possible to ‘tune’ activation levels to those desired if 
need be. Lastly, genes activated by sTFs would undergo endogenous feedback loops 
to have more physiological control over their activity, which is useful in some 
experimental or therapeutic contexts.  
While the functionality of TALE-sTFs and ZFN-sTFs strongly depend on 
DNA-binding domain design, in the case of CRISPR-sTFs optimal design of gRNAs 
is critical, yet still poorly understood, aspect. Early work suggested that the best area 
to target sTF binding for achieving optimal activation is -450 to -50 base pairs 
upstream of transcription start site (TSS) and best region for repressing genes is -50 to 
+300 bp from the TSS, where 0 represents TSS (Gilbert et al. 2014). Nevertheless, 
efficient activation has been achieved targeting different areas and even enhancers 
(Hilton et al. 2015). Importantly, in some cases targeting intron sequences was 
essential for successful transcriptional activation, as in case of Mytl1 in MEFs (Black 
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et al. 2016). These rules are therefore a good starting point, but are not universal or 
highly predictive. As it is evident, knowing and targeting genes around the TSS 
increases chances for successful transcription modification; however, defining the TSS 
is itself not a clear task. Not only do databases only give predication of TSS location 
but often different databases contradict each other. Moreover, a distinct TSS might be 
used in different cell types. Thus, context is important. It has been shown that 
FANTOM5 database gives the best predictions to date, and that optimizing TSS 
predication can give a 54% chance to identify a functional gRNA (Radzisheuskaya et 
al. 2016). That being said, other databases only lack behind by couple percents, 
suggesting that database choice is not main current limitation. Furthermore, tools have 
been developed to predict gRNA functionality based on its’ sequence and this has 
shown to improve sTF function (H. Xu et al. 2015). Other studies have showed that 
gRNA sequence should not contain stretches of four (or more) uracils (Nielsen et al. 
2013) and that repetitive nucleotides decrease gRNA functionality (Gilbert et al. 
2014). Lastly, it has been proposed that pools of multiple gRNAs targeting the same 
proximal promoters trigger higher activation levels compared to use of individual 
gRNAs (Bikard et al. 2013; Mali, Yang, et al. 2013; Perez-Pinera et al. 2013). 
Interestingly, although significantly outnumbered, there are few studies providing 
evidence that using multiple gRNAs to target same gene has a negative rather than 
positive effect (Shao et al 2018). However, as we do not yet know if extremely high 
levels of activation are essential, or even desirable, to achieve functional changes (e.g. 
cell type programing), it remains to be seen if single or pooled gRNAs will be most 
effective. This is one of the central questions addressed in this thesis. 
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1.3.4 Effectors used with synthetic transcription factors 
Another important, part of sTF design is the type of effector domain used. 
Neither TALEs nor CRISPR-Cas9 could act as sTFs if a potent transcriptional 
activator would not be attached. The strength of an effectors is potentially one of the 
most critical features of sTFs if they are to be used in programing. 
A number of different transcription activating domains (TADs) have been 
successfully used to activate genes (Table 1-1). One of the most commonly used 
activation domains is the VP16 viral protein (Triezenberg et al. 1996) which interacts 
with multiple transcriptional components (Fig.1-5A), including TATA-binding 
protein, TFIIB and SAGA complex among many (Hall & Struhl 2002; Hirai et al. 
2010). Although it seems to operate effectively in most instances, activation levels for 
some genes and in some cells are relatively low. Some improvement in activation 
potential was observed if multiple copies of VP16 were fused together, namely VP64 
(4 copies of VP16) and VP160 (10 copies of VP16). To date, it seems that strongest 
activators are ones which combines a set of different effector, namely VPR and SAM 
(synergistic activation mediator) systems. A side-by-side comparison of these TADs 
has been conducted in the past (Chavez et al. 2016). While most of the work  in the 
field is done focusing on these effectors, further effort is undertaken to investigate if 
activation potential can be increased even further by designing better effectors (Zhou 
et al. 2018). 
dCas9-VPR, which stands for dCas9 tethered to VP64-p65-Rta fusion 
complex, was developed by Chavez et al (Chavez et al 2015). After screening more 
than 20 known domains involved in transcription, three most potent activators were 
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identified: VP64, p65 and Rta. When used together, this combination (VPR) strongly 
outperformed VP64 in activating a number of different genes in HEK293TT cells. 
Importantly, while NEUROD1 activation in iPSC with dCas9-VP64 had no functional 
effect, activation with dCas9-VPR resulted in iPSC differentiation to neurons. This 
was one of the earliest examples demonstrating that the strength of the TAD is critical 
aspect to consider in functional experiments.  
Another important development in TAD construction was assembly of SAM 
system by Konermann and colleagues (Konermann et al. 2014). This study reported 
two important observations. First, it has shown that TADs can be attached to gRNAs 
instead of dCas9 protein and that TAD placement have an impact on TADs’ 
functionality. TAD attachment to gRNAs was made possible by the fact that a part of 
gRNA stem loop remains exposed even after dCas9/gRNA complex formation. By 
engineering RNA-protein interacting intermediates (MS2 protein), they have managed 
to attach TADs to gRNAs. Interestingly, this has shown slight improvement in gene 
activation potential as compared to same TAD being attached to dCas9 protein. 
Second, an important observation in this study was that although increasing the 
variation of TADs have a beneficial effect on gene activation potential, but only to the 
extent. Addition of p65 and HSF1 to VP64 increased the activation potential in 
comparison to VP64 alone, however any further modifications were not beneficial. 
The repertoire of validated transcription repression domains (TRD) is not as 
diverse as activators. Currently, Krüppel associated box (KRAB) is the main 
repressive domain used (Gilbert et al. 2014). It has been showed to reshape the 
epigenetic landscape of the promoter and thereby repress transcription. Besides 
KRAB, the other common repressive dCas9 version is one without any domain. dCas9 
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can physically interfere with polymerase activity. Interestingly, use of CRISPR-dCas9 
as a repression system seems to be more specific than RNAi-based repression, as single 
mismatch have detrimental effect for dCas9 but not for RNAi (Gilbert et al. 2014). 
This means that repression with dCas9 would have lower off-target effects compared 
to RNAi based methods for gene repression.  
The capability to engineer functional sTFs strongly relies on the knowledge of 
biology of promoters and transcription machinery. This topic is discussed in the next 
section.  
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Effectors Description Reference 
VP16 Herpes Simplex Viral protein 
which helps recruit host genes 
for viral gene activation 
Triezenberg et al. 1996 
Hall & Struhl 2002 
VPR 
combination 
VP64 (VP16 copies) p65 (part 
of NFkB TF) Rta (Epstein-Barr 
virus R transactivator; 
complements VP16) 
combination 
Chavez et al. 2015 




VP64, p65, HSF1 combination Konermann et al. 2014 
p300 Histone acetylation (H3K27) Hu et al. 2014 
KRAB Induce heterochromatin 
formation by recruiting HP1, 
SETDB1 and other 
Lupo et al. 2013 
Schultz et al. 2002 
Groner et al. 2010 
Table 1-1 | Common effectors used in synthetic transcription factors. 
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1.3.5 Core promoters and transcription machinery in eukaryotes 
The core promoter is the genomic location where DNA transcription initiates. 
Core promoters lie between -450 and -40bp from TSS, as deletion of this region has 
been shown to diminish promoter activity in reporter plasmids (Cooper et al. 2005). 
The size of the core promoter varies from around 40bp to 150bp and it can be 
composed of multiple elements. These include: TATA box, Initiator (Inr), TFIIB 
recognition element (BRE), polypyrimidine initiator (TCT), motif ten element (MTE), 
downstream promoter element (DPE), downstream core element (DCE). Each 
occupies a distinct position within core promoter and have different functionality 
(Fig.1-6A). Many of these elements are bound directly by TFIID, either via the TATA-
binding protein (TBP) domains or TBP-associated factors (TAFs). Importantly, many 
promoters do not contain all of these elements. For example, TATA-boxes, which for 
long have been thought to be a key binding region in every promoter, are only present 
in approximately 30% of human promoters (Yang et al. 2007). While many functions 
that these elements perform remain unknown, our knowledge of them is increasing. 
For example, only Inr and TATA elements can initiate transcription by themselves 
(Smale et al. 1998), while DPE seems to act similarly to TATA in TATA-less 
promoters by locking PIC proximal to TSS.   
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Figure 1-6 | Structure of core promoters and graphical representation of transcription 
machinery assembly.  
(A) Core promoters consist of a number of elements, each playing a distinct role. However, there is 
variety in the composition of each promoter. (B) The transcription machinery assembles in stages. 
































A second key feature of any promoter is transcription start site or TSS. This is 
a sequence within the promoter where transcription usually starts. If a promoter has an 
Inr element it usually lies within TSS. This region has been shown to be nucleosome-
free (Nishida et al. 2006), which is important for transcription machinery and 
transcription regulation. Importantly, many promoters have more than one TSS and 
these are can be distributed within 100bp region (Carninci et al. 2006; Suzuki et al. 
2001). Often, promoters with multiple TSS’s lack TATA-boxes, have CpG islands and 
are associated with constitutively expressed housekeeping genes; by contrast 
promoters with a unique TSS often have TATA-boxes and are associated with tissue-
specific expressed genes. 
It is clear that even core promoter architectures are very complex. Another 
layer of complexity and diversity is added when these promoters have to be tissue- or 
cell-specific. To achieve that, a large number of new factors and their binding 
sequences are introduced into promoter and enhancer sequences. Moreover, some 
genes are actually associated with more than one promoter (Sandelin et al. 2007). 
Such features allow production of different products (different introns/exon 
compositions), differential transcriptional response in different tissues etc. 
In addition to promoters, another important element to consider for sTF 
functionality is the quality of the basal transcription machinery. Transcription in 
eukaryotes and prokaryotes has been widely studied. Eukaryotic cells have three 
different polymerases – Pol I, Pol II and Pol III – that are responsible for transcribing 
rRNA precursors, protein-coding regions and small non-coding RNAs, respectively 
(Sainsbury et al. 2015). Although transcription is controlled at many levels, the 
initiation stage seems to be the most critical and rate limiting. The general transcription 
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factor TFIID, which contains TATA-box binding protein (TBP) and TBP-associated 
factors (TAFs), assembles on promoter in the first step. Both TBP and TAFs are able 
to recognize many sequences present in core promoters and in such way TFIID is 
strongly involved in promoter recognition. Importantly, this step seems to be generic 
and TFIID has been shown to be involved in transcription of most genes in yeast 
(Huisinga & Pugh 2004). A second step involves TFIIA and TFIIB binding. This step 
seems to be optional in some cases, but it does increase affinity of TBP and stabilize 
the complex (Imbalzano et al. 1994). At this stage, PolII–TFIIF pre-formed complex 
combines with above proteins and DNA to form Preinitiation Complex (PIC). TFIIF 
plays a number of roles. It stabilizes many of the mentioned processes, prevents non-
specific binding of DNA and also influences TSS selection (Ghazy et al. 2004). To 
complete “closed PIC”, TFIIH and TFIIE binds as well. This is followed by use of 
ATP to open the DNA helix and create transcription bubble (aka “open PIC”). In 
presence of NTPs, transcription starts and many of these initiation factors are replaced 
by elongation factors (Fig.1-6B). 
Although transcription is a precisely controlled process, it is often highly 
dynamic. This phenomenon is called transcription noise – a variability in gene 
expression between two genetically identical cells in the same population/conditions. 
There are a number of consequences of such behaviour. For example, noisy 
transcription can be a problem for cellular identity. Cellular identity is defined by a 
number of transcription factors and their continuous fluctuation would result in a lack 
of robustness in the cell type identity (Acar et al. 2005). Some of the explanations for 
transcriptional noise include transcriptional pausing/bursting, cell cycle effect (Zopf et 
al. 2013), stochastic nature of living systems (Raj et al. 2006) and slow transition from 
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inactivate to active promoters (Golding et al. 2005). It is most likely true that these and 
many other mechanisms play a role in transcriptional noise. How do cells solve this 
problem? It seems that specific rules have evolved on distinguishing signal from noise. 
Cells and their genetic networks responds only when context (other factors), levels and 
duration of signal is correct (Sokolik et al. 2015). These are important considerations 
for construction of effective sTFs that could be used to program patterns of 
transcription. 
1.3.6 Synthetic transcription factors in cell type programing 
sTFs have been used to achieve cell type programing either when used in 
combination with ectopic gene overexpression (Balboa et al. 2015) or when used alone 
(Black et al. 2015; Chakraborty et al. 2014). However, the process remains poorly 
understood. In a large majority of these studies only single gene has been activated to 
achieve reprograming and while this is sufficient for some cell type conversions, it will 
not be enough for other transitions. Efficiencies of reprograming are often not 
enhanced over cDNA overexpression. For example, a study by Black and collegues 
demonstrated that sTFs can be used to convert MEFs into neurons by activation of 
Mytl1, Ascl1 and Brn2 (Black et al. 2016). Interestingly, the group has reported that 
both approaches (using cDNA overexpression or CRIPSR-based activation of 
transcription) create a similar amount (2-4%) of Tuj1 positive neurons. It remains 
unclear how widely such strategies can be used or if they are able to supersede cDNA 
overexpression as the main experimental approach for reprograming mammalian cell 
types 
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To make sTFs have broader utility a key missing capability is the use of 
multiplexing to test activation of many genes in parallel within the same cell. 
Multiplexing, in this context, means ability to target and activate multiple genes at the 
same time in the same cell; too often studies report activation of genes within the 
population, but it remains unclear if this means each sTF works well in individual cells. 
There are a number of reasons multiplexing is important. Firstly, some programing 
events can only happen if multiple genes are involved (like in iPSC reprograming 
using OSKM). Secondly, if very large numbers of genes would be activated, efficiency 
of the programing might increase. After a cell is exposed to 3 or 4 reprograming 
factors, they activate a number of downstream genes, which then activate other genes 
and so on until cells’ genetic profile starts to resemble that of different phenotype. In 
theory, it might be possible to activate all of these genes simultaneously and in such 
way, force a more rapid lineage conversion.  
A further reason why sTFs might have lot of potential in forcing cell type 
change is because repression of endogenous genes can be triggered at the same time 
as activation of other gene. There is an expanding list of evidence demonstrating that 
repression of genes can be as potent method for cell type programing as 
activation/overexpression is (Ikawa et al. 2015; C. D. Pozniak et al. 2010a). 
Importantly, repressors might be even more important than activators in some cases. 
One of the instances when this might be a case is when current cell type is maintained 
by strong (potentially pioneering) network of transcription factors. For example, Ascl1 
is a transcription factor involved with neuronal lineage (Shi et al. 2016). Ascl1 is also 
able to bind closed chromatin (Raposo et al. 2015). As a result, it would be hard to 
repress any genes downstream of Ascl1, as Ascl1 would be able to bind and re-activate 
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these genes. However, the pioneer activity and cell-type maintenance capability of 
Ascl1 would not matter if it would be directly repressed itself. Therefore, one can argue 
that some programing events might happen more effectively in the context where 
strongest cell type maintainers are repressed.  Another example when repression of 
repressors might be very important is when strong direct negative feedback loop exist 
for activators. Such repressors might exist as miRNAs (Kuypers et al. 2016; Zhao et 
al. 2010) or as other transcription factors (Pozniak et al. 2010). Repressing such 
repressive loops might not only help activate some genes which are hard to activate, 
but also increase the level of activation in general by removing endogenous constrains. 
Lastly, some repressors might dominate activators indirectly by repressing the 
chromatin or regulating RNA metabolism. In such a situation, repressing these 
chromatin modulating genes might help activators achieve their function faster. 
To summarise, if sTFs are to be become potent tools for cell type programing 
a number of key issues need to be addressed. We need to learn how to robustly activate 
or repress any gene of interest, but also how to achieve sustained high levels of 
activation to raise above transcriptional noise. Moreover, if sTFs are to become highly 
efficient for cell fate programing, we need to learn how to modulate large number of 
genes at the same time in the same cell. Exploring these issues is the focus of this 





1.4 Neural stem cells and oligodendrocyte differentiation 
1.4.1 Neural stem cells can differentiate into oligodendrocytes, astrocytes and 
neurons 
For most of the 20th century the existence of neural stem cells (NSCs) in the 
adult brain was thought unlikely. During the 1990s and early 21st century, however, it 
has been demonstrated that neural stem cells can be isolated from certain adult brain 
regions, and there are likely two zones of neurogenesis that are conserved in mammals 
(Reynolds & Weiss 1992): including hippocampus and sub-ventricular zone (Eriksson 
et al. 1998; Lois & Alvarez-Buylla 1993). Importantly, nowadays we are able to 
capture and maintain these stem cells in culture (either as heterogeneous neurospheres 
or as adherent monolayer) for prolonged periods of time (Conti et al. 2005). After 
injury NSCs proliferate and may contribute to the repair of damaged regions 
(Arvidsson et al. 2002). Stimulating endogenous repair is therefore an ongoing area of 
research. 
To be able to produce new neurons throughout adult life, NSCs must balance 
self-renewal (proliferation) and differentiation. NSCs often exist in a quiescence or 
dormant state. After stimulus from the environment, quiescent NSCs re-enter cell 
cycle, proliferate and generate new neurons and glia. Each stage of this process is 
closely regulated by extrinsic signals and intrinsic regulatory networks; known 
regulatory pathways include: Wnt/β-catenin, Notch and Shh (Morrison et al. 1997; 
Ahmed et al. 2009). The balance between these pathways and how dormancy, 
quiescence, activation and proliferation are controlled in the endogenous NSCs is still 
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unclear and is an area being explored by many groups. In vitro, NSCs are expanded in 
EGF and FGF-2 driving them into a highly proliferative ‘active’ state. 
NSCs also have to be able to differentiate to generate neurons, astrocytes and 
oligodendrocytes. Knowledge of the process and pathways involved in differentiation 
have been obtained from many decades of research in developmental biology. NSCs 
self-renew in presence of EGF and FGF-2 (Reynolds & Weiss 1992). EGF withdrawal 
from the culture media can result in differentiation to all three standard CNS cell types. 
Moreover, it is possible to induce differentiation to specific lineages by exposure to 
LIF or BMP  (Bonaguidi et al. 2005) to generate astrocytes; alternatively, FGF-2, 
PDGFR-AA and Forkslin directs NSC towards oligodendrocytes.  These have become 
standard differentiation regimes for neural stem cell assays in vitro and are used in this 
thesis. However, a major issue is variability between lines and for oligodendrocyte 
differentiation a lack of efficient differentiation. Thus, improved methods to control 
NSC differentiation are needed. 
A number of different markers are used to monitor differentiation state. Nestin, 
Sox1 and Sox2 are often used as NSC markers; β-tubulin as a neuronal marker 
(detected using the antibody TuJ1); the intermediate filament protein GFAP is an 
astrocyte marker; oligodendrocyte progenitors are marked by Sox10, PDGFRα or O4 
(early markers), while terminally differentiated oligodendrocytes express myelin basic 
protein (MBP) (Conti et al. 2005).  
1.4.2 Genetic profile of oligodendrocytes 
Oligodendrocytes (OLs) are one of the key cell types produced by NSC 
differentiation. Their role is to ensure efficient and fast propagation of action potential 
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in central nervous system by myelinating neurons. OLs arise from precursor cells 
known as oligodendrocyte precursor cells (OPCs) which themselves arise from sub-
ventricular cells in the brain (Emery 2010). Differentiation of OPCs to OLs in vivo is 
under strict temporal and spatial regulation and also goes through an intermediate stage 
of OLs which are premyelinating (Richardson et al. 2006) (Figure 1-7). Loss of 
myelinating OLs results in neuron degradation as seen in demyelinating diseases, such 
as multiple sclerosis and various leukodystrophies. Obtaining a consistent large-scale 
ex vivo source of OPCs and OLs would potentially open new ways to treat these 
diseases using cell-based therapies (Givogri et al. 2006). To better understand how we 
can generate these cell types, we need to better understand mechanisms of lineage 
commitment and differentiation in OPCs and OLs. 
 
Figure 1-7 | Generic summary of key markers and regulatory proteins during OPC specification 
























Gene Gene function Reference 
Sox10 Involved in the development of 
neural crest; specific to 
oligodendrocyte in CNS glial cells. 
Najm et al. 2013 
Christine D Pozniak et al. 2010 
Olig2 Protein interacts with Sox10 and 
Nkx2-2; involved in 
oligodendrocyte differentiation 
Yang et al. 2013 
Maire et al 2009 
Nkx2-2 Repress neuron differentiation; 
Involved in oligodendrocyte 
development; involved in astrocyte 
differentiation 
Wang et al. 2014 
Najm et al. 2011a 
Nkx6-2 Involved in oligodendrocyte 
differentiation; role in CNS 
myelination 
Cai et al. 2005 
Cai et al. 2010 
Ascl1 Involved in neurogenesis; involved 
in oligodendrocyte differentiation. 
Braun et al. 2015 
A. Raposo et al. 2015 
Table 1-2 | Key transcription factor ‘master regulators’ involved in the oligodendrocyte lineage.  
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Some of the key genes involved in OPCs include: Sox10, Olig2, Nkx2-2 and 
Ascl1 (Table 1-2). This has been explored by investigating ESC and iPS cell 
differentiation and key events in mouse development. During transition from neural 
rosettes (early neuroprogenitors derived from ESCs) to OPCs, Pax6, Sox9 and 
Neurog1 is downregulated, Ascl1 remains at similar levels, while Nkx2.2, Sox10, 
Sox17, Olig2, Olig1 and PDGFRα are up-regulated (Emery 2010; Wegner 2008; Najm 
et al. 2011b). During differentiation of OPCs to premyelinating OLs and then to 
myelinating oligodendrocytes, MBP, Plp1 and Mag are upregulated, while expression 
of Sox10, Olig2, Olig1, Ascl1 and Nkx2.2 are maintained in postmitotic OLs (Emery 
2010; Wegner 2008). Knock-out of either Olig2 (Lu et al. 2002) or Sox10 has been 
shown to result in loss of oligodendrocytes. Moreover, loss of myelin gene regulatory 
factor (MRF) has been linked to impaired OPC-OL transition (Emery et al. 2009), 
while other genes, like Sox6, Hes5, Id4 and Id2 have been shown to play an active role 
in preventing OPCs from differentiating further (Emery 2010). Together, these 
transcription factors and associated gene regulatory networks define OPC and 
oligodendrocyte identity (Fig. 1-7). 
1.4.3 Methods for generation of oligodendrocytes ex vivo 
Multiple methods have been developed to allow OPC and OL production from 
mouse or human foetal NSCs – often trying to mirror events used in development in 
the culture dish. The most basic approach is exposing NSCs to FGF and PDGF-A 
which results in about 20% of cells becoming PDGFRα positive OPCs (Glaser et al. 
2007). This protocol has been further optimized by a various groups (Franco et al. 
2015; Neri et al. 2010; Wang et al. 2015). In a number of studies, ectopic 
overexpression of either Sox10 (C. D. Pozniak et al. 2010a; Wang et al. 2014), Olig2 
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(Copray et al. 2006; Maire et al. 2009) or both (Liu et al. 2007) has been shown to 
facilitate or even induce NSC differentiation toward oligodendrocyte linage. However, 
this approach cannot provide immunologically matched cell types for cell therapy due 
to difficulty of obtaining adult NSCs. 
 Oligodendrocytes have also been successfully generated by directed 
differentiation of ESCs. A number of studies have defined protocols for deriving OLs 
from ESCs (Neman & de Vellis 2012; Najm et al. 2011b; Sundberg et al. 2010). These 
methods usually make use of complex growth medium and can last for up to 48 days 
to make mature OLs. Moreover, it is relatively hard to calculate efficiency of these 
protocols accurately as unknown number of cells die and proliferate during the 
differentiation protocol. 
Similarly to OL differentiation from ESCs, methods has been developed for 
turning patient iPSCs to oligodendrocytes (Wang et al. 2013; Douvaras et al. 2014). 
As these cells are taken through normal developmental process, protocols are very 
lengthy often lasting for over 100 days to make OLs (Wang et al. 2013). The process 
involves a number of different growth mediums which have to be added at specific 
time points (Wang et al. 2013). Although these methods have a lot of promise for 
therapeutic potential, they are very lengthy and labour-intensive. Thus, it is of the 
utmost importance to find new ways to bypass the inherent variability, lack of 
efficiency, long time-scales and experimental difficulties of current pluripotent and 
multipotent stem cell differentiation protocols. One interesting aspect is forward 
programing of iPSC. This involved overexpression of key lineage master regulators 
(Sox10 in case of OPC/OL lineage) and then inducing differentiation. Such approach 
has been reported recently to be highly efficient in driving OPC production from 
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hiPSC. In the study by Pawlowski and colleagues, overexpression of SOX10 and 
OLIG2 gave raise to CNPase and PLP positive cells in 20 days (Pawlowski et al. 2017). 
One alternative is transdifferentiation. This has been reported for mouse 
embryonic fibroblasts to OPCs and OLs (Najm et al. 2013; Yang et al. 2013). In the 
methods described for NSC and iPSC, scientists are usually making use of growth 
factors to generate OPCs and OLs. However, to achieve transdifferentiation, 
overexpression of specific transcription factors is used – and is more reminiscent of 
the ‘Yamanaka’ type approach. This is often called direct reprograming. In these 
studies, overexpression of three cell type specific transcription factors (Sox10, Olig2 
and Nkx6-2 or Sox10, Olig2 and Zfp536) was sufficient to achieve direct cell type 
conversion. The resulting OLs had markers like PLP1, O4, MBP and were capable of 
making myelin sheets after transplantation. The efficiency, however, remains 
relatively low, with less than 1% of original cells becoming OPCs.  
The major focus of this thesis is to test if sTFs can enhance NSC differentiation 
to OPC/OLs and be used to induce efficient MEF transdifferentiation to OPC/OLs. i.e 





1.5 Aims and hypothesis 
We hypothesize that sTFs when delivered in pools of activators and/or 
repressors will be capable of transcriptional resetting to drive cell type lineage 
conversions. 
In particular, we have focused on the following specific questions: 
1. Can we activate expression of endogenous Sox10, Olig2 and Nkx6-2 in 
mouse neural stem cells and embryonic fibroblasts using sTFs? 
2. Can we development an improved ‘toolkit’ for delivery of multiple sTFs? 
3. Can we simultaneously activate and repress distinct target genes using 
sTFs? 
4. Can we steer differentiation of NSC to OPC using sTFs? 
5. Can we trigger transdifferentiation of MEFs to OPC by sTFs? 
 












2 Methods and Materials 
2.1 Cell culture 
2.1.1 Neural stem cell culture medium 
Mouse neural stem cells (NSCs) were cultured using self-renewal medium 
(DMEM/F-12 supplemented with Glucose, Non-Essential Amino Acids (NEAA), 
Pen/Strep, HEPES, 75 mg/ml BSA solution, 2-mercapthoethanol, B27 and N2 
supplements, 1ng/ml EGF, 10ng/ml FGF, 1µg/ml laminin) as previously reported 
(Conti et al. 2005). Cells were split using Accutase (Sigma, #A6964) every 2-3 days 
or when reaching ~80% confluence. Typically, cells were used around 10-30 passages. 
2.1.2 Mouse embryonic fibroblast cultures 
Mouse embryonic fibroblasts (MEFs) lines were established from E13.5 mouse 
limbs. Limbs from 13.5 days old mouse embryos were dissected and incubated in 
0.25% Trypsin/EDTA for 30 min at 37°C. The cell suspension was triturated using a 
P1000 to disrupt tissue and dissociate cells. The cells were passed through a cell 
strainer prior to plating in flasks (Greiner Bio-one, #542042). Harvested cells were 
incubated in MEF culture medium (see below). 
2.1.3 MEF culture medium 
MEFs were cultured using AmnioMAX C-100 Basal medium (Thermo Fisher 
Scientific, #17001-074) with AmnioMAX C-100 supplement (Thermo Fisher 
Scientific, #12556-023). MEFs were passaged every 2-3 days. 0.25% Tripsin/EDTA 
was used to harvest cells from plates. 
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2.1.4 HEK293T culture medium 
Human embryonic kidney (HEK293T) cells were incubated in DMEM 
medium containing 10% Fetal Bovine Serum (Life Technologies, #10270106), 
0.045g/ml penicillin/streptomycin (Life Technologies, #15140122), 100x non-
essential amino acids (Life Technologies, #11140050), 1mM Sodium Pyruvate 
Glutamate (Life Technologies, #11360088) and 2mM L-Glutamine (Life 
Technologies, #25030123). HEK293T cells were grown in 37°C incubator and split 
every 2-3 days using Accutase. 
2.1.5 Freezing and thawing cell lines 
For short term cryopreservation of cells, they were stored in -80°C (2-3 
months).  Liquid nitrogen was used for longer archiving. Cells were frozen down by 
resuspension in DMEM containing 10% DMSO and immediately transferred to -80°C. 
To thaw the cells a cryo-vial was rapidly warmed in a 37°C (water bath) and 10ml of 
warm growth medium gently added to the cell suspension. The resulting solution was 
centrifuged to remove DMSO and debris and cells were resuspended in an appropriate 
volume of warm growth medium on tissue culture plastic. 
2.1.6 NSCs differentiation medium and protocol 
NSCs were triggered to differentiate to OPCs using following differentiation 
protocols. The day prior to differentiation the cells were seeded at 2x104 cells per each 
well of a 6-well plate. The next day, fresh culture media lacking EGF but containing 
10µM Forskolin (Cambridge BioScience; #11018) and 10ng/ml PDGF-AA (R&D 
System, #221-AA-010) and FGF-2 (10ng.ml) was added. Cells were left in such 
 68 
differentiation medium for four days. After four days, cells were either analysed or 
induced to differentiate to OLs using medium described below. 
 To differentiate OPCs to OLs, the following medium was used. Medium 
lacking all growth factors, but containing 30ng/ml T3 (Sigma; #T6397) and 200µM L-
Ascorbic acid (Sigma; #A4544) was added to cells. Cells were analysed after four 
days. 
2.1.7 MEF transdifferentiation to OPCs  
We attempted transdifferentiating MEFs to OPCs using the following protocol: 
cells were transfected (see below) and left in MEF culture medium for three days. After 
three days, the MEF culture media was exchanged with MEF transdifferentiation (TD) 
media. TD media contained following: DMEM/F12 (Invitrogen, #11320) 
supplemented with 1:100 N-2 (LifeTech; #17502-048), 1:50 B-27 (LifeTech; #17504-
044), 2mM L-Glutamine, 200ng/ml SHH (R&D Systems; #461-SH-025/CF), 20ng/ml 
FGF2 (R&D Systems), 20ng/ml PDGF-AA (R&D Systems) and 2µg/ml Laminin 
(Sigma). This media should be permissive for OPCs. 
To force transdifferentiating MEFs to differentiate to OL, after 14-21 days in 
TD media the cells were incubated in the following medium for 3 days: DMEM/F12 
(Invitrogen, #11320) supplemented 1:100 N-2 (LifeTech; #17502-048), 1:50 B-27 
(LifeTech; #17504-044), 2mM L-Glutamine, 40 ng/ml T3 (Sigma), 200ng/ml SHH 
(R&D Systems; #461-SH-025/CF), 200µM L-Ascorbic acid (Sigma; #A4544). This is 
adapted protocol based on previously published by Najm et al. 2013. 
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2.1.8 Clonal cell line derivation 
To derive clonal cell lines, 500-1000 cells were seeded into 10cm2 dish and left 
for 10-14 days. Colonies that grew were manually picked using a P200 and colony 
picking tips, and re-plated into each well of a 96-well plate for further expansion. After 
sufficient cells expansion, they were analysed either by genotyping, qPCR or 
immunostaining to validate positive colonies. 
2.2 Mammalian cell transfection (MEF, NS and HEK293T) 
2.2.1 Polyethylenimine (PEI) 
HEK293T cells were transfected using the PEI transfection reagent and the 
following method. A day before transfection, 5x104 cells were seeded into 24-well 
plate. On the day of transfection, 500ng of DNA and 2µl of PEI was added to 75µl 
DMEM (no supplements), mixed and incubated at room temperature for 15 min. 
Meanwhile, 1ml of pre-warmed culture medium was been added to cells. 
DNA/PEI/DMEM solution was then added to cells dropwise. Medium was exchanged 
18h post-transfection. 
2.2.2 Nucleofection 
NSCs were transfected using Amaxa Nucleofector 4D system (Lonza, #V4XC-
3032). Unless stated otherwise, 2x105 cells were resuspended with P3 or SG Solution 
transfection buffer (depending on the NSC line). 400ng of DNA was added to the 
solution and cells were transfected using the DS-113 or DN-100 transfection protocol 
using 16-well transfections strips. 80µl of culture medium was added to each well of 
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strip and all content of each well was moved to either 6-well plate or 12-well plate. An 
appropriate volume of relevant culture medium was added to each well.  
2.2.3 Lipofection 
MEFs were transfected using Lipofectamine 3000. Cells were seeded a day 
prior to transfection into a 6-well plate. On the day of transfections, 2µg of DNA was 
mixed with 250µl OptiMEM medium (Thermo Fisher Scientific; #31985062), 5µl 
Lipofectamine 3000 Reagent and 5µl P3000 reagent (Life Technologies; #L3000001). 
The DNA/Lipofectamine solution was incubated at room temperature for 15 min. After 
incubation, the DNA/Lipofectamine mix was added to cells.  
2.3 Immunocytochemistry 
Cells were washed with PBS and fixed with 4% PFA for 10 min at room 
temperature. After fixation, cells were washed three times with PBS. Cells were then 
blocked at least for 1 hour in blocking solution (1%BSA, 3%goat serum, 0.1%Triton 
in PBS unless stated otherwise). The blocking solution was removed and the primary 
antibody was added and incubated at 4°C overnight in blocking solution (see Table 2-
1). After staining with primary antibody, cells were washed three times with PBSt for 
15 min. Cells were then stained with an appropriate secondary antibody (1:1000 
dilutions) for at least 1 hour in the dark at room temperature. Cells were washed two 





Antibody Specie Dilution Supplier, cat. number 
OLIG2 Rabbit 1:400 EMD Millipore, #Ab9610 
GFP Mouse IgG1 1:400 Sigma, #G6539 
V5 Mouse IgG2b 1:1000 eBioscience, #14-6796-82 
SOX2 Rabbit 1:100 Abcam, #Ab92494 
SOX10 IgG1 1:10 Hybridoma 
SOX10 IgG1 5µg/ml R&D System, #MAB2836 
SOX10 Goat IgG 1:100 R&D System, #AF2864 
SOX10 Rabbit 1:100 Abcam, #Ab27655 
SOX10 Rabbit 1:100 Brown’s lab 
SOX10 Rabbit 1:200 Abcam, #Ab155279 
HA Mouse IgG1 1:100 Cell signalling, #2367 
O4 Mouse IgM 1:200 Charles ffrench-Constant lab 
NG2 Rabbit 200 Abcam, #Ab83178 
MBP Rat 1:250 Abcam, #Ab7349 
Table 2-1 | Summary of primary antibodies used. 
 
2.4 Microscopy and image processing 
Fluorescent microscopy images were taken using either the Operetta or Nikon 
TiE wide-field fluorescent microscopes. Images were processed using either the NIS-
Elements or Columbus software.  
2.5 Image cytometry 
Image cytometry was being used to quantify immunostaining results. Stained 
cells were screened using Operetta high content screening platform (Perkin Elmer), 
processed on Columbus software and analysed using TIBCO SpotFire software. ‘Find 
Nucleus’ protocols were unique each time as it strongly depended on the cell type, 
number of cells and confluence in the well as well as shape of the nucleus. However, 
protocol C (see Columbus software) was used as a starting point in most cases. Gating 
and signal thresholds were set using negative controls (aka non-treated cells). 
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2.6 Flow cytometry 
Cells were analysed using LSR Fortessa 5 or 4-laster flow cytometer (BD 
BioScience). Unless stated otherwise, 10,000 events were collected using forward 
scatter threshold of 5000. Fluorescence data was collected using following cytometer 
settings: 488 nm laser and B530/30-A nm bandpass filter for GFP/NeoGreen, 561 nm 
laser and YG586/15-A nm bandpass filter for mRuby2/ mCherry, 405 nm laser and 
V450/50-A nm bandpass filter for DAPI. Data was analysed using the FlowJo 
software. 
When cell surface markers were assessed, we immunostained using the 
following protocol: cells were lifted with Accutase and incubated with PBS containing 
2% FCS, 1:200 Fc block CD16/CD33 (BD Pharmingen, #553141) and appropriate 
primary antibody. Cells were left for 30 min at room temperature. After incubation, 
the cells were washed with 2% FCS/PBS and incubated with appropriately diluted (in 
2% FCS/PBS) secondary antibody (usually 1:1000). Cells were left for 30 min at room 
temperature in dark. After incubation, cells were washed with 2% FCS/PBS and 
analysed with the flow cytometer. Stained but non-treated (no transfection or 
differentiation) cells were used as negative control for gating. 
 
2.7 TaqMan quantitative RT-PCR 
2.7.1 RNA extraction 
RNA was extracted using QIAGEN RNeasy Mini Kit (Qiagen; #74104) 
according to the manufactures protocol. RNA was stored at -80°C. 
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2.7.2 Reverse transcriptase (RT) reaction 
To generate cDNA from RNA, the reverse transcriptase reaction was 
conducted using the SuperScript II Reverse Transcriptase Kit (Life Tech; #18064014). 
The detailed protocol can be found on suppliers’ website. 1-2ug of RNA was typically 
used in each RT reaction. cDNA was stored at -20°C. 
2.7.3 qPCR 
qPCR was performed using TaqMan Fast PCR Master Mix (Thermo Fisher; 
#4352042) and TaqMan assays (Table 2-2). Each reaction had a final volume of 10µl: 
5µl PCR Master Mix, 0.5µl specific TaqMan Probe, 2µl cDNA, 2.5µl water. Each 
sample was run as a technical duplicate. 
Target Assay Specie 
Gapdh Mm99999915_g1 Mouse 
Sox10 Mm00569909_m1 Mouse 
Olig2 Mm01210556_m1 Mouse 
Nkx6-2 Mm00807812_g1 Mouse 
PDGFRα Mm00440701_m1 Mouse 
Ascl1 Mm04207567_g1 Mouse 
Sox2 Mm03053810_s1 Mouse 
Sox9 Mm00448840_m1 Mouse 
Nkx2-2 Mm00839794_m1 Mouse 
GAPDH Hs99999905_m1 Human 
SOX2 Hs00366918_m1 Human 
OLIG2 Hs00300164_s1 Human 
SOX10 Hs00366918_m1 Human 
Table 2-2 | List of TaqMan assays used. 
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2.8 RNA-FISH 
For coverslip coating each coverslip was placed in a 6-well plate and incubated 
in 10µg/ml poly D-Lysine (PDL) in sterile water for 5 min at room temperature. PDL 
was removed and the coverslip was incubated in 20µg/ml laminin in DMEM overnight 
in 37°C. Cells were seeded onto the coverslip and maintained in the incubator until 
staining. Cells were washed with PBS and then fixed with 37% formaldehyde solution 
for 10 min in room temperature. Cells were permeabilized using 70% ethanol for at 
least for 1 hour at 4°C. Cells were washed with buffer A (BioSearch Technologies; 
#SMF-WA1-60) for 5 min at room temperature. Samples then were stained using 
hybridization buffer (BioSearch Technologies; #SMF-HB1-10) and RNA-FISH probe 
mixture (custom made probes or Mouse GAPDH; BioSearch Technologies; #SMF-
3002-1) overnight at 37°C in dark. Cells were washed with buffer A for 30 min in dark 
at 37°C and then stained with DAPI (1:5000) for 30 min in dark at 37°C. The coverslip 
was washed with buffer B (BioSearch Technologies; #SMF-WB1-20) for 5 min at 
room temperature. The coverslip was mounted onto the slide together with ProLong 
Gold Antifade Reagent (New England BioLabs; #9071S) and imaged on a Nikon TiE 
microscope with 60x oil objective. 
 
2.9 Molecular cloning 
2.9.1 Site-directed mutagenesis 
Site-directed mutagenesis was performed using New England BioLabs Q5 
Site-Directed Mutagenesis kit (New England BioLabs; #E0554S). The suppliers’ 
guidelines were followed. For PCR primer sequence see Appendix. 
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2.9.2 Gateway cloning 
All gateway cloning was performed using Invitrogen Gateway BP or LR 
Clonase II Enzyme kits (Invitrogen; #11789020 and #11791020) and following 
suppliers’ instructions. 
2.9.3 Gibson cloning 
For Gibson reactions, an in-house Gibson Mix was used. This mix contained: 
5x isothermal buffer (0.5M Tris-HCL (Sigma-Aldrich), 50mM MgCl2, 1mM dNTPs 
(Thermo Fisher Scientific), 50mM DTT (Life Tech), 0.25g/ml PEGC8000 (Sigma-
Aldrich), 5mM NAD (Sigma-Aldrich)), T5 exonuclease (10U/µl), Phusion DNA 
polymerase (2U/µl) and Taq DNA ligase (40U/µl). 
15µl of Gibson mix (described above) was mixed with 100ng linearized 
backbone vector and equimolar amounts of other assembly fragments. Reaction mixes 
were incubated at 50°C for 60 min. 2µl of the reaction mix was transformed with 
competent E.coli. 
DNA fragment overlaps were usually between 16-40 base pairs (over 25 base 
pairs for more complicated reactions). Overhangs were designed to have 72°C melting 
temperature (Tm). Incubation times were sometimes increased or lowered to avoid 
incorrect assembly if complicated constructs were being generated. 
2.9.4 Golden Gate Assembly 
All Golden Gate (GG) reactions have been performed using following method: 
GG enzyme master mix (10µl T4 Ligase buffer, 1µl 100xBSA, 5µl appropriate 
restriction enzyme, 10µl T4 ligase) was prepared in bulk and stored in -20°C. To 
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perform a GG reaction, 2.6µl of the enzyme master mix was mixed with 50ng empty 
entry plasmid, 50ng of each part plasmid and topped up with water to 10µl. The 
following program was run on a Thermocycler to start the reaction: 37°C for 5 min; 
15-20 cycles of 37°C for 5 min and 16°C for 10 min; 5 min at 50°C; 10 min at 80C; 
stored at 4°C. Home-made competent E.coli bacteria were transformed with 5µl of GG 
reaction mix. 
2.9.5 E. coli transformation 
To propagate plasmids, competent E.coli were transformed using following 
protocol. 25µl of competent E.coli bacteria were mixed with 2-5µl of plasmid/reaction 
solution (usually around 1-100ng of plasmid) and kept on ice for 30 min. The 
bacterial/plasmid solution was incubated at 37°C for 30s and then put back to ice for 
2 min. 300-500µl of LB (no selection) was added and mixture was incubated at 37°C 
shaker for 60 min. Transformed bacteria were either plated out on LB agar plate 
(containing appropriate selection) or mixed with larger volume of LB medium 
(containing appropriate selection) and incubated overnight at 37°C incubator or 
shaker, respectively. 
Plasmid ID Plasmid name Source 
M1 TRE_SOX10_2A_OLIG2 Cloning 
M19 CAG_mCherry Ian Chambers’ lab 
M28 CAG_dCas9_p300 Patric Kai’s lab 
M29 CAG_dCas9_KRAB Patric Kai’s lab 
M33 CAG_dCas9_VPR AddGene #63798 
M34 CAG_VRER_dCas9_KRAB Cloning 
M35 CAG_VRER_dCas9_VP160 Cloning 
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M39 Pb_dCas9_VP160_mCherry (Empty Ai1) Cloning 
M51 CAG_dCas9_SON Cloning 
M52 CAG_dCas9_tSON Cloning 
M53 CAG_dCas9_S10 Cloning 
M54 CAG_dCas9_VP160 AddGene #48227 
M55 CAG_dCas9_2SON Cloning 
M56 CAG_dCas9_3SON Cloning 
M59 CAG_dCas9_S10S9 Cloning 
M60 CAG_dCas9_S1 Cloning 
M61 CAG_dCas9_S2 Cloning 
M62 CAG_dCas9_S5 Cloning 
M63 CAG_dCas9_S6 Cloning 
M64 CAG_dCas9_S7 Cloning 
M65 CAG_mNG (Plasmid 1) Patric Kai’s lab 
M66 CAG_mNG_2A_mR2 (Plasmid 2) Patric Kai’s lab 
M67 CAG_dCas9_TAD1 Patric Kai’s lab 
M68 CAG_dCas9_TAD2 Patric Kai’s lab 
M69 CAG_dCas9_TAD3 Patric Kai’s lab 
M70 CAG_dCas9_TAD4 Patric Kai’s lab 
M71 CAG_dCas9_TAD5 Patric Kai’s lab 
M72 CAG_dCas9_TAD6 Patric Kai’s lab 
M73 CAG_dCas9_TAD7 Patric Kai’s lab 
M74 CAG_dCas9_TAD8 Patric Kai’s lab 
M75 U6-BsaI-T3 Mali et al 2013 
M76 CAG_GFP pmaxCloning™Lonza 
M77 CAG_pBase Steve Pollard’s lab 
M78 CAG_TET3G Steve Pollard’s lab 
M78 CAG_Sox10_2A_Olig2 Cloning 
Table 2-3 | List of vectors used in study.  
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2.10 Design and production of U6-gRNA expression plasmids 
gRNAs were designed using CHOPCHOP web tool 
(https://chopchop.rc.fas.harvard.edu/index.php) and appropriate overhangs for 
ligation were added to sequences. These sequences were ordered via Sigma Oligo 
Synthesis service. gRNA expressing plasmids were constructed using the following 
protocol: Synthesized oligos were phosphorylated with Fermentas T4 PNK (Thermo 
Fisher Scientific; # EK0031). In parallel, the backbone vector for gRNAs (SP149) was 
prepared by digestion with the BsaI restriction enzyme, cleaned up with MinElute PCR 
purification kit (Qiagen; #28004) and dephosphorylated with SAP enzyme (New 
England BioLabs; #M0371). To ligate the phosphorylated gRNA oligos with 
dephosphorylated backbone, T4 DNA Ligase (New England BioLabs; #M0202) was 
used. The resulting plasmids were transformed and a small amount digested with 
EcoRI and BsrGI restriction enzymes to confirm correct assembly. 
2.11 Gene tagging with V5 using single-strand oligonucleotide  
To knock in a V5 tag to create a Sox10-V5 fusion product, we designed guides 
to cut near the STOP codon. Recombinant Cas9 protein was used. The following 
protocol was used to deliver reagents:  0.8µl of crRNA (250 picomoles/µl) was mixed 
with 0.8 µl of tracrRNA (250 picomoles/µl) and 3.4µl water. The mix was incubated 
at 95°C for 5 min and then 30 min at room temperature. 2.5µl of above mix was mixed 
with 10µg purified CAS9 protein and left for 10 min at room temperature. The above 
solution was then mixed with 0.6µl ssDNA (50 picomoles/µl stock) and transfected 
into NSC cells using DN-100 Nucleofector protocol.  
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To test if tagging was successful, genomic DNA of the transfected cells was 
harvested using DNeasy extraction kit (Qiagen; #69504). PCR reactions were 
performed using harvested genomic DNA as template and specific PCR primers which 
bind V5 (reverse) and Sox10 exon (forward) sequence. The PCR product was run on 
an agarose gel to identify the correct band size.
3 Regulating mouse gene expression using sTFs  
3.1 Activating Sox10, Olig2 and Nkx6-2 in mouse NS cells and 
MEFs 
3.1.1 Construction of U6-driven gRNA expression vectors 
To activate gene transcription using dCas9, gRNAs need to be targeted to the 
proximal promoter of the target gene of interest. More specifically, the 50bp to 450bp 
upstream of the TSS has been reported to be optimal for transcription activation 
(Gilbert et al. 2014). We therefore initially designed gRNAs within this region to target 
the three oligodendrocyte lineage regulators, Sox10, Olig2 and Nkx6-2 (Fig. 3-1 A). 
Importantly, past studies have shown great variability in the levels of activation 
when using gRNAs. Thus, not every gRNA will be functional. We first designed ten 
distinct gRNAs spanning this region. ChopChop software has been used for this 
purpose (Fig. 3-1 B-D). gRNAs were selected based on their quality scores, taking into 
account GC content, self-complementary tendencies, off-targets, and their distribution 
across a range of positions within the promoter region. 
For testing in mammalian cells the gRNAs were cloned into a mammalian 
expression plasmid (SP149). This contains a U6 promoter, gRNA scaffold and 
termination sequences and was originally reported in the study by Mali et al (Mali, 
Esvelt, et al. 2013). Cloning was achieved by linearizing the empty expression plasmid 
with BsaI-HF restriction enzyme, dephosphorylating this linearized backbone and 
ligating it with an annealed and phosphorylated oligos (Fig. 3-2 A). Successful 
plasmids were identified using test restriction enzyme digestions with BsrGI and 
EcoRI restriction enzymes (Fig. 3-2 B).  
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Figure 3-1 | gRNA placement for Sox10, Olig2 and Nkx6-2 gene activation.  
(A) Strategy for design of gRNAs for transcriptional activation. (B, C and D) gRNA position along the 
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Figure 3-2 | gRNA-expression plasmid construction. 
(A) Schematic representation of the process of cloning gRNAs into the U6 expression plasmid via 
digestion and ligation reactions. (B) Agarose gel electrophoresis to assess the restriction digestion 
product of cloned gRNA-expressing plasmids using BsrGI and EcoRI restriction enzyme; green arrows 
indicate correctly assembled plasmids, red arrows mean negative, yellow arrow indicate 
contaminated/mixed clones.  
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3.1.2 Sox10, Olig2 and Nkx6-2 activation in mouse NS cells and MEFs 
To investigate if any of the designed gRNAs were functional when co-
delivered with dCas9-VP160 in activating transcription of the target genes, we first 
assessed transfection of all ten gRNAs together using qPCR assays. This was carried 
out in both mouse neural (NS) cells and mouse embryonic fibroblasts (MEFs), in order 
to compare cell context effects. Based on the mRNA fold change, it was clear that 
Sox10 can be activated in both cell types (>27.9-fold change in NSC and >14.1-fold 
change in MEF). By contrast for Olig2 and Nkx6-2 we could achieve increased 
expression only in the MEFs, (>184.8-fold change in mRNA for Olig2 and >46.8-fold 
change for Nkx6-2) (Fig. 3-3 A). 
Thus, some gRNAs which are validated as functional cannot work in other cell 
types, most likely due to cell specific biological restrictions in the transcriptional 
networks or epigenetic state of the target locus. Although Nkx6-2 gene is not 
transcribed in either cell type, we find that only in MEFs can it be effectively activated 
(Fig. 3-3 A). This differing result means there must be some restriction in NS cells to 
the activity of gRNAs for Nkx6-2. This is unlikely to be due to differences in gRNA 
target sequences, as it would be unlikely that SNPs or other somatic mutations would 
be distributed across the TSS at so many distinct PAM sites. Possible reasons will be 
outlined in Discussion chapter.   
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Figure 3-3 | Sox10, Olig2 and Nkx6-2 activation using sTFs in mouse neural stem cells (mNSCs; 
blue) and mouse embryonic fibroblasts (MEFs; red). 
(A) qPCR results 3 days after transfection with dCas9-VP160 and pool of 10 different gRNAs for each 
of the target genes: Sox10, Olig2 and Nkx6-2, two different cell lines, n=3. (B) Immunocytochemistry 
for OLIG2 3 days after transfection of mNSCs and MEFs with dCas9-VP160 and a pool of 10 gRNAs 
for Olig2 (g11-g20). (C) qPCR results 3 days after transfection with dCas9-VP160 alone (“No gRNA”) 
or dCas9-VP160 with either single gRNA (“g1”, “g2”, “g3” etc.) or a combination of 10 gRNAs 
(“Pool”) targeting Sox10, n=1. (D) Single gRNA screen for Olig2 (same setup as described for Sox10 
in C). (E) Single gRNA screen for Nkx6-2 (same experimental setup as described for Sox10 in C). Fold 
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Furthermore, the results from Olig2 activation suggest that it is difficult to 
overexpress a gene that is already being transcribed. Olig2 is high expressed by non-
transfected NS cells, it is well established to be associated with the proliferative NS 
cell phenotype. However, it is fully repressed in MEFs. From activation experiments, 
it is evident that gRNAs targeting Olig2 are functional as it can activate transcription 
in MEFs (Fig. 3-3 A-B). However, it shows no effect in NS cells, suggesting that if 
gene transcription is already high, over-activation is difficult. It seems easier to 
activate a non-expressed gene, then to overexpress an existing active gene using dCas9 
sTFs. This observation has been reported in other studies as well (Fidanza et al. 2017; 
S. Lin et al. 2015).  
To determine the relative activity of each individual gRNA MEFs and NSCs 
were transfected with dCas9-VP160 and each gRNA alone. The results reveal that 
from the pool of 10 gRNAs, 4 different gRNAs for Nkx6-2, 4 gRNAs for Olig2 and 4 
gRNAs for Sox10 were effective in strongly activating transcription (Fig. 3-3 C-E).  
There was a trend towards increased activity of the gRNAs correlating to their 
proximity to the TSS. For each gene, the top 3 or 4 gRNAs (those that could activate 
>5-10 fold) were proximal to the TSS.  This data also suggests that single gRNAs, 
even when functional, cannot achieve activation levels as high as the pool of 10 
gRNAs. Consistent with the results from the pool of 10 gRNAs, individual gRNAs 
were unable to activate Olig2 further from the high levels already present in NS cells. 
For Nkx6-2 we could not activate transcription using single gRNAs at all in NS cells, 
despite MEF activation working well.  
The greater levels of activation when using pools of gRNA can be explained 
by either synergistic or additive effects. To explore this further we next tested if co-
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delivery of different combinations of the most active gRNAs is able to achieve same 
activation levels as a pool of 10 gRNAs (2 gRNAs were used for Nkx6-2 and 3 for 
Olig2). This was again explored in both MEFs and NSCs. Cells were transfected (MEF 
– Lipofectamine; NSC – Nucleofection) with dCas9-VP160 and either a pool of 10 
gRNAs or a pool of 2 for Nkx6-2, or 3 for Olig2.  
For both Nkx6-2 and Olig2 gene activation in MEFs we found that a combination 
of 2-3 most potent gRNAs (g16-g18 in case of Olig2 and g29-g30 in case of Nkx6-2) 
is able to achieve similar level of transcription activation as a pool of 10 gRNAs. 
However, large variations between fold-changes in each biological replicate was 
observed which made it hard to directly compare different experiments statistically 
(Fig. 3-4).   
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Figure 3-4 | Comparing small and large pools of gRNAs in their ability to activate Olig2 and Nkx6-
2 in mouse NSCs and MEFs. 
qPCR results 3 days after transfection with dCas9-VP160 and either combination of 2 (g29-g30 for 
Nkx6-2) or 3 gRNAs (g16-g18 for Olig2) or a combination of 10 gRNAs (g11-g20 for Olig2, g29-g38 
for Nkx6-2), each dot represents biological replicate (for statistical comparison, two-tail t-test was done, 
p-values noted in the graph). 
  





























3.2 Exploring the synergistic versus additive effects of multiple 
gRNAs using single cell assays 
The experiments in section 3.1 confirmed that dCas9-VP160/gRNAs can 
effectively activate transcription in genes of interest, and that effective design works 
best when gRNAs are proximal to the TSS. However, there are clearly cell type 
differences in the ability of these to activate. Finally, the data suggest that 
combinations of two or more gRNAs can work better than individual gRNAs.  
qRT-PCR assays provide an average level of expression across the population. 
Therefore, it remains difficult to determine using this assay if only a few cells are 
activated to high level or all cells in the population to a lower level. The correlation 
between amount of sTF and target gene activation is therefore difficult to determine. 
To better understand whether there is an optimal level of expression and if sTFs work 
additively or synergistically we used immunocytochemistry and quantitative image 
cytometry.  
3.2.1 Optimising a quantitative immunocytochemistry (‘image cytometry’) 
assay 
Immunocytochemistry can provide single cell level data regarding relative 
levels of protein. To quantify the intensity of immunopositive cells we explored image 
cytometry tools that have become available with advances in automated microscopy 
and analysis software (Operetta, PerkinElmer). This technique is akin to flow 
cytometry in the type of data that is acquired. Using automated capture of large sets of 
microscopy images and subsequent image analysis many thousands of cells are scored 
at single cell level for levels of protein expression (Fig. 3-5 A). It removes many of 
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the biases of working with limited fields of view when using manual microscopy. A 
description of the image cytometry protocol can be found in the Materials and Methods 
chapter.  
We first explored this methodology using mouse NSC. Cells were stained for 
DAPI and OLIG2, followed by analysis (Fig. 3-5 B). Analysis includes nucleus 
segregation and identification followed by collecting information of staining intensity. 
The cell nucleus identification and appropriate segregation is the most important part 
of analysis. Some cells (e.g. HEK293T cells due to clumping) require larger amount 
of effort to make identification possible while other cells (NSC and MEF) are less 




Figure 3-5 | Graphical representation of the image cytometry workflow. 
(A) Cell culture plates (usually 24-well Corning® Costar® plates) are stained using 
immunocytochemistry and scanned on Operetta system to collect >10 images per well/condition. This 
usually cover at least 10,000 cells. Images are then analyzed using Columbus to identify and count cells 
(based on DAPI staining) and collect intensity measurements of fluorescence (which represents protein 
levels). Collected data is visualized and analyzed on Tisco Spotfire software. (B) Example image 
demonstrating one of the protocols and image analysis tool for identifying cell nuclei and then using 
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3.2.2 Transcriptional activation of OLIG2 in HEK293T using multiple gRNAs 
We next tested if delivery of multiple gRNAs gives high activation due to a 
synergy between gRNAs or an additive effect (i.e. the sum of individual gRNA 
activities). For this purpose, we decided to use HEK293T cells and OLIG2 as a target 
as these cells are easy to transfect and validated OLIG2 antibodies exit. Five plasmids 
targeting OLIG2 were constructed, containing either 3 gRNAs (g181, 182, and 183), 
2 gRNAs (g181 and g182) or each individually. For the multiple gRNAs, these were 
cloned into a single vector with each driven by an individual U6 promoter (Fig. 3-6 
A). These plasmids were generated using the Golden Gate assembly approach that is 
described in detail in Chapter 4; they were generated in alongside the work reported in 
that Chapter. It was important to include all the gRNAs on a single plasmid as co-
transfection of separate plasmids is often unreliable. 
HEK293T cells were transfected with these plasmids and OLIG2 mRNA levels 
were measured using RT-qPCR. Plasmids containing individual gRNAs (S5, S6 or S7) 
triggered on average 36-fold (g181), 30-fold (g182) and 3-fold (g183) mRNA change, 
respectively. By contrast, plasmid S1 – containing all three gRNAs – activated 
transcription to the highest level (average of 309.8-fold change). Plasmid S2, which 
differed from S1 in lacking g183 achieved on average 173-fold change which is a 56% 
less activation compared to S1 (Fig. 3-6C). The differences between these distinct 
combinations are not explained by additive effects, and instead suggest synergy. 
Do these synergistic effects arise because the majority of cells have 
consistently higher levels, or instead, are there a small number of cells that activate to 
a very high level?  Does the presence of additional gRNAs increase the number of cells 
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activating the target genes, or is it the same number but with increased levels of 
activation at an individual cell level? Or are both these effects observed? To address 
these questions we used image cytometry to score OLIG2 protein in individual cells. 
Importantly, we have checked transfection efficiencies by staining for dCas9 positive 
cells and saw that all cells have similar amounts of dCas9 positive cells (Fig. 3-7 C). 
With delivery of multiple gRNAs we clearly see more cells being activated 
within the population: S1 plasmid gives on average 52.9% OLIG2-positive cells, while 
S5 gives on average 35.5% OLIG2-positive cells (Fig. 3-6 D). This suggests that 
increased diversity of gRNAs increases the chances that sTFs can activate expression.  
The relative amounts of OLIG2 protein (OLIG2 immunostaining intensity) in the 
OLIG2-positive cells was also increased by increasing the number of gRNAs (Fig. 3-
6 E). This data suggest that delivery of multiple gRNAs results in both activation of a 
larger proportion of cells, but also, that these will then have greater chance of higher 
levels of expression. 
We have also explored whether there was a correlation between absolute levels 
of dCas9 in individual cells and the level of OLIG2. Transfected HEK293T cells were 
co-stained for the HA tag (HA-dCas9-VP160) and OLIG2. Interestingly, there was 
only weak positive correlation between level of dCas9 and level of OLIG2 (Fig. 3-7 
B; weak positive correlation; Spearman r = 0.5674). Evidently, some cells which have 
high dCas9-VP160 levels do not activate OLIG2 transcription, while some cells which 
have very low dCas9 levels activate OLIG2 transcription to high levels (Fig. 3-7 A-
B). This suggests that dCas9-VP160 protein levels are not a limiting factor for efficient 
gene activation. Rather having a diversity of gRNAs enables higher proportions of 
cells to activate the target gene and at higher levels.  
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Figure 3-6 | OLIG2 activation in HEK293T using multiple gRNAs. 
(A) Graphical representation of plasmids constructed for testing the effects of co-delivery of multiple 
gRNAs. (B) Immunocytochemistry of OLIG2 in HEK293T cells 3 days after transfection with plasmid 
S1. (C) qPCR of HEK293T cells 3 days after transfection with one of the plasmids, n=1. (D) 
Quantification of OLIG2 positive HEK293T cells 3 days after transfection with one of the plasmids, 
n=4 (two-tail t-test; p-values: * < 0.001, ** = 0.005). (E) Increases in the average OLIG2 intensity in 
OLIG2-positive cells after transfection with different plasmids. Data shown as a percentage change in 
comparison to negative control, n=3; each dot represents biological replicate.  
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Figure 3-7 | HA-dCas9-VP160 levels in transfected HEK293T.  
(A) Immunocytochemistry of OLIG2 and HA-dCas9-VP160 in HEK293T cells 3 days after transfection 
with plasmid S1. (B) Image cytometry quantifying protein levels for dCas9 and OLIG2 in individual 
cells after transfection with the S1 plasmid (three gRNAs). Each dot represents a cell. Spearman 
correlation analysis was performed. (C) Quantification of HA-dCas9-VP160 positive HEK293T cells 
after transfection with one of the plasmids, n=3 (S1 and S2 two-tail t-test p-value = 0.919; S1 and S5 
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3.2.3 Quantification of absolute mRNA levels within single cells using RNA-
FISH 
To further investigate how dCas9 and target gene levels correlate, we have used 
an RNA-FISH technique. This technique enables visualization and counting of 
individual mRNA molecules in each cell by the process of RNA hybridization (Fig. 3-
8 A). 30 to 40 unique fluorescent probes are designed to target specific mRNA 
sequence. Cells are then imaged at high magnification and Z-stack images are 
collected. After image deconvolution, individual fluorescent dots, which represent 
single mRNA molecules, can be quantified to score absolute levels of mRNA (Raj & 
Tyagi 2010). 
To first establish the procedure, we have used MEFs and probes against Gapdh 
(Fig. 3-8). Using this method, we could calculate that on average, the MEF cell 
contains ~2000 Gapdh mRNA molecules/cell (Fig. 3-8 E) 
3.2.4 dCas9 and Sox10 mRNAs molecules do not always co-localize in single 
MEF cells 
The immunocytochemistry for OLIG2 protein levels following sTF activation 
in HEK293T suggested that HA-dCas9-VP160 and OLIG2 protein levels correlate 
only weakly (Fig. 3-7). However, this disparity might be explained by 
posttranscriptional regulatory differences between the two proteins.  We therefore 
wanted to see if the same trend was observed at the mRNA level. For this purpose, we 
transfected MEF cells with dCas9-VP160 and 10 gRNAs targeting Sox10 gene (g1-
g10). Three days after transfection cells the processed for imaging using RNA-FISH 
protocol (see Methods chapter for details) (Fig. 3-9). We could identify cells which 
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were positive for both Sox10 and dCas9 mRNA (Fig. 3-9 A). However, consistent with 
the results we saw for OLIG2 immunocytochemistry in HEK293T, we also noted little 
correlation between absolute levels of Sox10 and dCas9-VP160 mRNA levels in MEFs 
(Fig. 3-9 B). Cells which had low levels of dCas9 mRNA sometimes had high levels 
of Sox10 mRNA (cell #3-5) and vice versa: low levels of dCas9 and low levels of 
Sox10 (cell #8-10), low levels of dCas9 and no Sox10 (cell #11-12) and high levels of 
both mRNAs (cell #1) (Fig. 3-9 B).   
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Figure 3-8 | Workflow and optimization of RNA-FISH using Gapdh probes in MEFs. 
(A) Graphical representation of how RNA-FISH works. Cells of interest are fixed and permeabilized. 
Probes against specific mRNA transcript are added to cells to allow hybridization. Cells then are imaged 
at 60X magnification and images are processed for analysis. (B) Images obtained with Nikon (oil, 60x) 
demonstrating samples with and without probes against Gapdh mRNA transcript in MEFs. (C) Images 
demonstrating how the process of deconvolution enhances image resolution and combines Z-stacked 
image layers. (D) Example image of scoring mRNA molecules in samples treated and non-treated with 
probes. (E) Quantification of Gapdh mRNA molecules per MEF cell, n=3 cells.  
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Figure 3-9 | Co-RNA-FISH for Sox10 and dCas9 in MEFs after activation of Sox10 with sTFs. 
(A-B) Images of MEFs 3 days after transfection with dCas9-VP160 and 10 gRNAs targeting Sox10 
proximal promoter (g1-g10). MEFs were stained for probes against Sox10 (red) and dCas9-VP160 

























































































3.3 Olig2 activation in differentiating neural stem cells 
3.3.1 Characterisation of a PDGFRα-GFP (PG1.1) cell line 
It was evident from initial experiments that increasing expression levels of 
Olig2 beyond levels of endogenous transcription is not possible in NSCs. A negative 
correlation between activation potential and basal expression has been reported by 
other groups as well (S. Lin et al. 2015). However, it is known that Olig2 levels drop 
during NSC differentiation (Fig. 3-11 D). We wondered, therefore, whether activation 
of Olig2 during NSC differentiation might be effective in blocking the normal 
downregulation that occurs, and biasing the differentiation toward OPC 
differentiation. A recently established PDGFRα–GFP reporter cell line (PG1.1) was 
used to assay OPC commitment as PDGFRα is a known marker of OPCs (Fig. 3-10). 
PG1.1 reporter NSCs were derived by previous PhD student Dr. Bartlomiej 
Baranowski by using foetal forebrain NSCs from an established mouse strain 
(Hamilton et al. 2003). This mouse strain was originally constructed by inserting H2B 
histone protein tagged with GFP (H2B-GFP) under the control of PDGFRα (Fig. 3-10 
A) (Hamilton et al. 2003). As a result, after PG1.1 cells are forced to differentiate to 
OL lineage, some cell nucleus becomes GFP positive (Fig. 3-10 B-D). This can be 
scored by live imaging (Fig. 3-10 C), flow cytometry (Fig. 3-10 D) and 
immunocytochemistry (Fig. 3-11 B). As PDGFRα is not expressed in undifferentiated 
NSCs and is absent from astrocyte and neuronal cells, this NSC cell line is a useful 
reporter for OPC lineage. This was confirmed, as OPC markers such as Olig2 and 
Sox10, are highly enriched in the GFP positive cells after four days of differentiation, 
sorting and qPCR (Fig. 3-10 E.)  
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Figure 3-10 | Introduction to PDGFRα-GFP (PG1.1) cell line. 
(A) Schematic of the PG1.1 reporter mouse NS cell line. PG1.1 cells were originally derived by Dr. 
Bartlomiej Baranowski (Pollard lab, unpublished). (B) Schematic of PG1.1 differentiation and 
activation of the GFP reporter. Under self-renewal conditions (presence of both FGF-2 and EGF) cells 
lack fluorescence; however, upon differentiation (removal of EGF and addition of FGF-2 plus PDGF-
AA and Forskolin; 4 days) cells upregulated PDGFRα and become GFP positive. (C) Live phase 
contrast and fluorescence overlay of PG1.1 cells 4 days after differentiation. (D) Flow cytometry 
analysis of differentiation (Day 4) of PG1.1 cell line (day 0 is control, left panel). (E) qPCR data 
showing mRNA levels for various OPC markers in GFP positive cells after differentiation (cells were 








































































3.3.2 Olig2 activation during PG1.1 differentiation to OPCs or astrocytes 
We first tested that PG1.1 cells can be differentiated reliably in the absence of 
sTFs. As anticipated, during differentiation a proportion of cells extinguished OLIG2 
expression, as evident by immunostaining (Fig. 3-11 D). Quantification of levels of 
OLIG2 using image cytometry was then tested. Prior to differentiation (black dots) all 
NS cells are OLIG2 positive and PDGFRα-GFP negative. Following differentiation 
(green dots), the population splits into at least two compartments including the double 
positive OLIG2/PDGFRα-GFP (Fig. 3-11 B). 
We next tested if delivery of the sTF to activate Olig2 can work during 
differentiation (i.e. differentiation was triggered immediately after transfection). We 
hypothesized that it might be possible to activate Olig2 in cells which lose OLIG2 
levels during differentiation. To test if Olig2 can be activated in differentiating NSC 
cells, the PG1.1 reporter cell line was transfected with dCas9-VP160 and gRNAs 
targeting Olig2 (g11-g20). These were compared to a control cells which were 
transfected with only dCas9-VP160. Four days after starting differentiation, these cells 
were stained for OLIG2 and GFP and analysed by image cytometry (Fig. 3-11 B-C). 
After repeating and quantifying 4 independent differentiations/transfections, we 
could not see any statistically significant increase in the proportion of OLIG2 positive 
cells with the presence of sTF (Fig. 3-11 E-F). However, in three out of four 
experiments there was a trend to have an increase in the proportion of OLIG2 positive 
cells within the experiment (Fig.3-11 E, lines represent related experiments).  
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Figure 3-11 | Olig2 activation during PG1.1 differentiation to OPCs. 
(A) Outline of experimental workflow. Cells were transfected with dCas9-VP160 and 10 
gRNAs for Olig2 (g11-g20) or dCas9-VP160 alone (control). The next day cells were induced to 
differentiate for 4 days and then ICC was performed for OLIG2 and GFP (for PDGFRα-GFP) levels; 
data was quantified using image cytometry. (B) Results of image cytometry: each dot represents a single 
cell, visualizing levels of OLIG2 and PDGFRα-GFP before (black dots) and after (green dots) 
differentiation. Cells transfected with dCas9-VP160 alone (“Control”). (C) Cells transfected with 
dCas9-VP160 and 10 gRNAs for Olig2 activation (“Activation”). (D) Immunocytochemistry staining 
for OLIG2 and PDGFRα-GFP in the PG1.1 cell line before (Day 0) and after differentiation (Day 5). 
(E) Quantification of image cytometry data demonstrating the percentage of OLIG2 low and OLIG2 
high cells in each condition. Lines link data from same experiments, n=4. (F) Quantification of image 
cytometry data demonstrating the percentage of OLIG2/GFP high cells in each condition. Lines link 
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An alternative differentiation regime for NS cells is to expose them to BMP4 at 
low density. This triggers a uniform differentiation to astrocytes; >95% of cells express 
GFAP, exit the cell cycle and Olig2 expression is extinguished in all cells (Fig. 3-12 
C). We tested if activating Olig2 with the sTFs can override the astrocyte promoting 
effects of BMP4. Cells were transfected either with dCas9-VP160 alone or with a pool 
of 10 gRNAs (g11-g20) and dCas9-VP160 and induced to differentiate next day by 
BMP4 exposure (Fig. 3-12 A). At Day 4 (three days of differentiation), cells were 
analysed by qPCR and immunocytochemistry. We found no difference in Olig2 
transcription following delivery of sTFs at mRNA (Fig. 3-12 B) or protein level (Fig. 
3-12 E). Altogether, these results suggest that Olig2 sTFs are not potent enough to 




Figure 3-12 | Olig2 activation during PG1.1 differentiation to astrocytes. 
(A) Outline of experimental workflow. PG1.1 mouse NS cells were transfected with dCas9-VP160 
(“Control”) alone or together with 10 gRNAs for Olig2 (g11-g20). The following day cells were induced 
to differentiate for three days in presence of BMP4. Cells are imaged for OLIG2 and parallel wells were 
used for mRNA analysis by qPCR. (B) qPCR results 4 days after transfection with either dCas9-VP160 
alone (“BMP Control”) or dCas9-VP160 and 10 gRNAs for Olig2 (“BMP activation”) and 3 day 
treatment with BMP4 or no BMP4 (“Control”), n=3. (C) Immunocytochemistry for OLIG2 in BMP4-
untreated non-transfected (“Control”), BMP-treated transfected with dCas9-VP160 alone (“BMP 
control”) and BMP-treated transfected cells with dCas9-VP160 and Olig2 gRNAs (“BMP Activation”). 
(D) Image cytometry graph showing quantification of OLIG2 immunocytochemistry of treated and non-
treated cells, (E) Quantification of (d), n=1.  
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3.4 Investigating potential of different transcription activating 
domains (TADs) to overcome biological restrictions for 
activation 
3.4.1 Screening of new transcription activating domains (TADs) 
The results in chapter 3.3 suggested that sTFs can work well to activate some target 
genes, but have cell type dependent effects. For example, Nkx6-2 could be easily 
activated in MEFs, but not at all in NS cells. Moreover, even when using functional 
gRNAs we did not observe ‘overexpression’ over physiological levels (Olig2 in NSC). 
One explanation for each of these findings could be that the VP160 effector is not 
strong enough to achieve transcriptional activation in some situations. Alternative 
transcriptional activation domains (TADs) are often used and suggested to give 
stronger activation e.g. p300  and VPR (Chavez et al. 2016). Thus, we next explored 
whether novel and previously reported TADs might work well in NS cells and MEFs.  
Firstly, we screened eight novel TADs for their ability to activate Sox10 in PG1.1 
NSC line, using the gRNAs already validated with VP160. TADs were designed and 
constructed by a postdoc in the Pollard lab (Dr. Andrea Martella). These contained 
various versions and combinations of previously reported domains that have a role in 
transcription activation (Fig. 3-13 A). To test their potential, we transfected PG1.1 
NSCs with a pool of 10 gRNAs targeting Sox10 (g1-g10), and used VP160 as a 
normalisation positive control. From the qPCR data, it is evident that none of the novel 
designed TADs were able to activate Sox10. However, p300 and VPR effectors 
outperformed VP160 as expected and showed significantly higher level of activation: 
more than 3 times over VP160 (Fig. 3-13 B).  
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Next, we were interested to see if stronger effector (p300 and VPR) would be able 
to overcome biological restrictions in NSC and activate Nkx2-2 and Nkx6-2. Both of 
these genes could be activated in MEFs (Fig. 3-13 D and Fig. 3-3), which means that 
gRNAs are functionally capable to activate transcription. However, Nkx6-2 could not 
previously be activated in NSCs with VP160. PG1.1 NSC were transfected with either 
a pool of gRNAs targeting Sox10 promoter, Nkx2-2 promoter, Nkx2-2 enhancer or 
Nkx6-2 promoter and either VP160 (green), p300 (red) or VPR (blue). Neither Nkx2-
2 or Nkx6-2 could be activated in NSC. Moreover, even activation of Nkx2-2 in MEFs 
is not significantly enhanced by using stronger effector (Fig. 3-13 D). Thus, we 
confirmed that alternative activators can work more effectively than VP160 in some 
cases, however, effector strength does not seem to be the explanation for the failure to 
activate some other genes. Instead, some difference in promoter use or epigenetic 





Figure 3-13 | Screening of new transcription activating domains (TADs). 
(A) Table summarising the types of novel TADs that were explored. TADs were constructed by Dr. 
Andrea Martella (Pollard lab). (B) qPCR data showing Sox10 transcription levels in the PG1.1 cell line 
3 days after transfection with 10 gRNA (g1-g10) and dCas9 containing one of the specified TADs, n=2. 
(C) qPCR data showing transcription levels of each target gene in PG1.1 cell line 3 days after 
transfection with either dCas9-VP160 (green), dCas9-p300 (red) or dCas9-VPR (blue) and pool of 10 
gRNAs targeting named genes, n=1. (D) qPCR data showing transcription levels of Nkx2-2 genes in 
MEFs 3 days after transfection with either dCas9-VP160 (green) or dCas9-VPR (blue) and pool of 10 







































































































































3.5 Mouse gene repression in NSC using dCas9-KRAB 
3.5.1 gRNA placement for gene repression 
In addition to transcriptional activation, transcriptional repression using sTFs has 
also been reported by a number of groups. These are created by fusing repressor 
domains such as KRAB to the dCas9 (Gilbert et al. 2014). We were interested in testing 
whether combining activation of some targets with repression of others would be 
possible, as this might improve the efficiency of programing or reprograming cell fate. 
For this purpose, I selected the Sox9 gene as one of the candidates for testing 
repression, due to its reported role in repressing Sox10, a known master regulator of 
OPC cell fate (C. D. Pozniak et al. 2010b). Such repression, if successful, might help 
drive terminal differentiation of OPCs. 
Genome-wide libraries have been used to define the design rules for effective 
repression using sTFs with KRAB domains (Gilbert et al. 2014). gRNAs were found 
to be effective when targeted to -50 to 200bp around the TSS. Six gRNAs, spanning 
this region for Sox9 were cloned into expression vectors using the method described 
in Figure 3-2 (Fig. 1-14).  
3.5.2 Sox9 repression in SOX9-V5 NS cell line 
To test if repression of Sox9 is possible, we made use of a SOX9-V5 NS cell line 
(constructed by Dr. Pooran Dewari). After optimizing the transfection efficiency for 
this new cell line (Fig. 3-15 A), cells were either transfected with dCas9-KRAB and 6 
gRNAs targeting the proximal Sox9 promoter, or with dCas9-KRAB alone. 3 days 
after transfection, cells were analyzed by V5 immunocytochemistry and qPCR (Fig. 
3-15).  
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After quantifying SOX9-V5 low and high cells, as defined by the specific intensity 
threshold (Fig. 3-15 C), it was evident that after transfection there was indeed an 
increase in the V5 low/negative population in cells transfected with gRNAs compared 
to cells which only got dCas9-KRAB (Fig. 3-15 D). This data suggested that dCas9-
KRAB repress SOX9 in approximately 10% of the cells.  
However, this could not be confirmed by qPCR 3 days after transfection, as no 
difference between two conditions could be observed (Fig. 3-15 E). It is not clear why 
this is the case, but similar observation when dealing with repression was also made 
by previous PhD student in the lab as well. The repressors were not explored further 
in the programming and reprogramming experiments in chapter 5.  
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Figure 3-14 | gRNA placement for Sox9 gene repression. 
(A) Strategy for a design of gRNAs for transcriptional repression. (B) gRNA positioning along Sox9 
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Figure 3-15 | Sox9 repression in SOX9-V5 cell line. 
(A) Nucleofection protocol optimization for the SOX9-V5 cell line using a GFP reporter plasmid. The 
SOX9-V5 cell line was constructed and validated by Dr. Pooran Dewari (Pollard lab). (B) 
Immunocytochemistry for V5 in SOX9-V5 cells after transfection with dCas9-KRAB alone (“Control”) 
or dCas9-KRAB and 6 gRNAs (g147-g152) targeting Sox9 transcription start site (“Repression”). (C) 
Image of stained V5 in SOX9-V5 cells to demonstrate gating strategy based on SOX9 intensity. 
Anything below intensity threshold of 95 is considered as SOX9-V5 low/negative and vice versa. (D) 
Quantification of image cytometry data showing percentage of SOX9-V5 high cells with (“Repression”) 
and without (“Control”) repression, n=3 (two-tail t-test, p-value = 0.017). (E) qPCR data of Sox9 mRNA 
levels 3 days after cells were transfected with either dCas9-KRAB alone (“Control”) or with dCas9-
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3.6 Concluding remarks 
In this Chapter I have explored whether sTFs can be used in MEFs and NS 
cells to activate genes of interest. Several important findings and conclusion have been 
made. Firstly, we show that some gRNAs can function individually in successfully 
activating gene transcription and that large difference in potential to activate 
transcription exists even between very proximal gRNAs. Moreover, pools of gRNAs 
give higher transcription activation compared to single functional gRNAs. This is 
important finding because level of gene transcription activation might be important to 
successfully modulate biological functions. Interestingly, a combination of gRNAs 
which individually are minimally functional can still function well in a “pool”, 
suggesting that synergy between gRNAs exist. After we looked closer into synergy 
between gRNAs, we have surprisingly found that combining functional gRNAs 
together increase a number of cells which are activated and also level of activation 
within those cells.. Lastly, we demonstrate evidence that suggest that levels of dCas9-
VP160 are not limiting factor for successful transcription activation. After single cell 
image cytometry analysis, we report that weak positive correlation exists between 
target gene levels and dCas9-VP160 levels, suggesting that other factors (like gRNA 
concentration and variation) play more important role in gene activation. 
Furthermore, we have shown that different effectors can have significantly 
different activation strengths. As observed by Sox10 transcription activation in NSC, 
p300 and VPR were capable of significantly higher level of transcription activation 
compared to VP160. That being said, this is not always a case as Nkx2-2 activation 
with VP160 and VPR in MEFs has shown. Evidently, we demonstrate that even 
strongest effector (VPR) might not be able to significantly outperform weaker VP160 
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effector in some contexts. This is important observation as it shows that other 
potentially limiting factors need to be explored instead (such as alternative promoters). 
Thirdly, in addition to technical limitations, biological restrains seem to play a 
significant role in gene activation using sTFs. Firstly, genes cannot be over-activated 
if it is already transcribed, as we have seen with Olig2 in NSC. Importantly, we looked 
into the prospect of such gene transcription activation in situations in which its’ 
transcription levels are lowered – e.i. during differentiation – which has not been 
investigated before. Surprisingly, even if levels of transcription are lowered in these 
cases (via differentiation), we could not find statistically significant differences (on 
average) between control and treated cells. That being said, when we looked into 
individual experiments, we saw that in 3 out of 4 experiments we detected more 
OLIG2 positive cells after treatment. Secondly, additional biological constrains exist 
that makes gRNAs which are functional in one cell line, non-functional in another cell 
line as we have observed with Nkx6-2 activation in NSCs and MEFs. These biological 
constrains cannot be overcome by using stronger effectors which might indicate that 
dCas9/gRNA binding to DNA could be a key a limiting factor.   
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4 Multiplex delivery of sTFs: a new toolkit for plasmid 
assembly  
4.1 Design and validation of an all-in one plasmid for multiplex 
transcriptional activation 
In chapter 3 our observations suggested it would be beneficial to deliver 
multiple gRNAs simultaneously to achieve efficient transcriptional activation. Such 
multiplexing may also be required for multiple distinct targets genes to be activated 
concurrently. This would typically require co-transfection of tens of plasmids 
simultaneously and would likely result in a heterogeneous population of cells with 
variable amount and proportions of each plasmid (Fig. 4-1A). 
This problem was highlighted to us when we directly tested co-transfection of 
two separate plasmids constitutively expressing either GFP and mCherry using the 
Amaxa Nucleofection. Analysis using flow cytometry unexpectedly revealed that the 
majority of cells only expressed one or the other plasmid; a smaller fraction than 
anticipated were co-expressing (Fig. 4-1B). Thus, it is easy to predict that by increasing 
a number of plasmids that is being transfected, the ratio of cells expressing all plasmids 
would most likely decrease even further – limiting the success of multiplexing using 
transient transfection. 
 
4.1.1 Designing and validating a novel extensible Mammalian Modular 
expression plasmid Assembly (EMMA) system 
To tackle the multiplexing problem and make screening of different effectors 
and gRNAs easier, we developed a novel system for plasmid assembly which we 
named “Extensible Mammalian Modular Assembly” or EMMA (Martella et al. 2017). 
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The overall EMMA approach was developed by Andrea Martella, a postdoc in the 
Pollard/Cai laboratory. I worked closely with Andrea to exploit EMMA and to validate 
many of the newly ‘domesticated’ core expression vector parts (Martella et al. 2017). 
I performed the experiments to assemble and test sTFs using EMMA. 
EMMA employs Golden Gate (GG) restriction enzyme/ligation reactions to 
enable large number of compatible vector parts to be assembled in a single step 
reaction. The GG reaction is based on the use of type IIS restriction endonucleases, 
ligase and multiple rounds of digestion and ligation. 
A large library of parts from existing vectors were ‘domesticated’,  i.e. 
synthesized to remove type II sites and create the appropriate overhangs and linkers. 
These parts included: various promoters (CAG, EF1, U6 etc.), fluorescent proteins 
(mRuby, NeoGreen etc.), localization signals, tags etc. Each part is surrounded by a 
BsmBI restriction site with a unique overhang (Fig. 4-2A). This allows parts to be 
assembled in a specific order which is important for functionality; e.g. the promoter 
always sits adjacent to the coding sequence. These parts were cloned into intermediate 
plasmids and stored for later use. 
To make a new plasmid using EMMA, the appropriate parts are selected from 
the library of plasmids.  These are assembled with an empty backbone plasmid in a 
one-step GG reaction (see Methods for details).  Using this system Martella et al., were 
able to routinely generate expression plasmids with 15-25 different parts in a single 
reaction. Non-assembled backbones cannot be propagated as transformed bacteria will 
die due to the ccdBS negative selection cassette being present (Fig. 4-2B). The whole 
process only takes two days: one day for the GG reaction (3-8 hours depending on part 
numbers), and one day for transformation (Fig.4-2C). Final vectors were validated by 
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restriction digestion and sequencing. EMMA has been designed to accommodate up 
to three separate transcription units, can use polycistronic elements, and is compatible 
with multiple delivery methods (transposase, targeting vector, transient, viral etc.). The 





Figure 4-1 | Lack of effective co-transfection poses a hurdle for multiplex delivery of sTFs. 
(A) Graphical representation of the problems around co-transfecting a large number of plasmids together. 
The resulting population is heterogeneous with cells having different proportions of each plasmid. (B) Flow 
cytometry data of PG1.1 NSCs three days after co-transfection with CAG_GFP and CAG_mCherry 





















Figure 4-2 | Summary of an Extensible Mammalian Modular Assembly (EMMA) system and the 
process of assembly. 
(A) Graphical representation of how EMMA plasmid parts of interest are surrounded by BsmBI 
restriction sites and unique overhangs that allow efficient assembly. (B) After parts with unique 
overhangs are created they are used in a Golden Gate (GG) reaction (digestion and ligation cycles). This 
reaction allows assembly of the desired plasmid. (C) Overview of whole process. Plasmids containing 
parts with specific overhangs are created (see A) which are then assembled into a full plasmid using GG 
reaction. Assembly products are transformed and bacteria colonies are picked. Correctly assembled 
plasmids are tested by restriction digestion and sequencing. 
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To validate that it is possible to assemble functional plasmids using the EMMA 
system, we first assembled a number of different expressions plasmids, including two 
plasmids presented in Figure 4-3 (plasmids were assembled by Dr. Andrea Martella; I 
performed all functional testing presented in the Figures).  
The first plasmid that was built was a simple green fluorescence protein 
NeoGreen, tagged with membrane localization signal. This cassette was driven by a 
CAG promoter. HEK293T cells were transfected and live cells imaged three days later. 
As expected, the HEK293T cell membrane (and vacuoles) were tagged with green 
fluorescence protein (Fig. 4-3B). 
To further validate EMMA, more elaborate plasmids were constructed. For 
example, a CAG promoter with two fluorescence proteins  downstream – green 
NeoGreen and red mRuby – the former with a localization signal for mitochondria 
while mRuby had no localization signal. Both fluorescent proteins were driven by the 
same promoter but separated using the P2A translational cleavage sequence (Fig. 4-
3C). As predicted, HEK293T cells transfected with such plasmid had red cytoplasm 
and green mitochondria (Fig. 4-3D).  
I confirmed the success and utility of EMMA using many further examples in 
the study by Martella et al. But for simplicity I report here our efforts to use an EMMA 







4.1.2 Construction of toolkit for gene regulation in multiplex 
With the EMMA GG plasmid assembly system validated, we next moved on 
to adapt this system for construction of an ‘all-in one’ (Ai1) sTF expression plasmid 
which would be able to deliver multiple gRNAs from a single plasmid. Firstly, an 
empty Ai1 vector was made using the EMMA system (Fig. 4-4). This vector contained 
PiggyBac homology arms to enable stable integration, an mRFP expression cassette, 
dCas9-VP160 driven by the constitutive CAG promoter and an mRuby-p2A-Puro 
cassette driven by another CAG promoter (Fig.4-4A).  
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Figure 4-3 | EMMA plasmid assembly using fluorescent proteins and localization tags. 
(A) Schematic representation of Plasmid 1, which was assembled with EMMA from five parts. Plasmid 
1 contained constitutive promoter (CAG) NeoGreen fluorescent protein (mNG) tagged with membrane 
localization signal (PAL). Assembly was performed by Dr. Andrea Martelli. (B) Live imaging of 
HEK293T cells three days after transfection with Plasmid 1. (C) Graphical representation of Plasmid 2, 
which was assembled with EMMA from seven parts. Plasmid 2 contains constitutive promoter (CAG), 
NeoGreen fluorescent protein (mNG) tagged with mitochondria localization signal (MLS), p2A 
sequence and mRuby fluorescent protein (mR2). (D) Live imaging of HEK293T cells three days after 
transfection with Plasmid 2. These experiments were designed to confirm functionality of key 











































Figure 4-4 | Making and validating empty All-in one (Ai1) vector for multiplex gene activation.  
(A) Table of parts that has was used to assemble the entry Ai1 plasmid capable of harboring gRNAs 
cloned in via replacement of the mRFP cassette. (B) Test digestion of empty Ai1 plasmid clones. 
Simulated agarose gel of correct clone digestion is shown on the left (S). Correct clones are indicated 
by green arrows. (C) Sequencing results of empty clone 2 of Ai1 plasmid showing correct part assembly. 
(D) A picture of agarose plate with E.coli transformed with Ai1 after GG reaction. Red bacteria colonies 
(blue arrows) indicate empty Ai1 plasmids (still contain RFP cassette between GG restriction sites), 
white bacteria colonies (green arrows) indicate assembled Ai1 plasmids (RFP cassette replaced by 
gRNAs). (E) Flow cytometry data showing intensity of mRuby reporter in PG1.1 NSC two weeks after 
transfection with empty Ai1 vector and PiggyBac Transposase. (F) qPCR data showing mRNA levels 
of Sox10 in PG1.1 NSCs three days after transfection with a pool of 10 gRNAs targeting Sox10 and 


































































After assembly of the empty Ai1 plasmid, multiple clones were tested by 
restriction digestion (Fig. 4-4B) and 4 out of 9 (giving estimated efficiency of 44%) 
clones were correctly assembled in this 8-part EMMA reaction. Clone 2 was 
sequenced to further validate correct assembly of the parts (Fig. 4-4C). 
To further test if these parts are functional, a number of tests have been 
performed.  
Firstly, the mRFP cassette was tested. Bacterial colonies transformed with an empty 
Ai1 had a red appearance (Fig. 4-4B). Importantly, mRFP was surrounded by BsmBI 
restriction sites, which allows multiple gRNA units to be added to this site using 
Golden Gate reaction, as long as these units have correct overhangs to allow ligation 
(Fig. 4-5). In such a way, the RFP cassette allows to make a selection of correctly 
assembled plasmids easier as transformed colonies which contained plasmids with 
added gRNAs were white and not red (Fig.4-4D). 
Secondly, mRuby expression and PiggyBac integration was tested by 
transfecting NSCs with empty Ai1 plasmid plus PiggyBac transposase. Two weeks 
later, cells were analyzed using flow cytometry (Fig. 4-4E.). A proportion of cells were 
mRuby-positive, demonstrating that mRuby reporter and PiggyBac homology arms 
are functional. 
Thirdly, functionality of the dCas9-VP160 part was also tested by comparing 
activation potential of empty Ai1 with plasmid containing only dCas9-VP160 (Fig. 4-
4F). Activation was achievable using both plasmids to comparable levels. This empty 
Ai1 vector was used as the backbone for all multiplexing experiments that follows. 
We tested how to efficiently clone multiple gRNAs into empty Ai1 plasmid by 
using the EMMA system. To achieve this, unique gRNA sequences were PCRed out 
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from corresponding gRNA-expression plasmids using PCR primers with unique 
overhangs. Those overhangs contained two restriction digestion sites (BsaI and 
BsmBI) on both sides (green and blue triangles in Fig. 4-5A respectively). This 
allowed us to firstly clone gRNAs into intermediate part vectors by BsaI-based GG 
reaction and then combine them all with empty Ai1 plasmid using second GG reaction 
based on BsmBI digestion enzyme. The resulting GG reaction products are 
transformed and correctly assembled plasmids are identified by color (Fig. 4-4B). This 






Figure 4-5 | Adaptation of EMMA system for assembly of plasmids containing multiple gRNAs 
and dCas9-VP160. 
(A) Graphical representation of how gRNAs are cloned into intermediate part vectors using GG 
reaction. (B) Graphical representation of how multiple intermediate part entry vectors containing 





One of the potential issues for constructing plasmids for multiplex gene 
regulation is repetitive sequences within such plasmids. Multiple identical U6 
promoters could increase the chances of recombination either in E.coli during cloning 
or in mammalian cells after delivery, resulting in non-functional plasmids. To 
minimize such risks, we have decided to test a system which contains single U6 
promoter and have tRNA-coding sequences separate multiple gRNAs (Fig. 4-6A). 
This strategy was inspired by the studies done in rice, however by the time this work 
was carried out there was no published methods for mammalian systems (Chun Wang 
et al. 2015; Dong et al. 2017).  
Using method described in Figure 4-5, first plasmid for multiple gene 
regulation has been constructed and it was named tSON (Fig. 4-6A). This plasmid 
contains a single U6 promoter which drives expression of a transcript containing three 
gRNAs (targeting Sox10, Olig2 and Nkx6-2) separated by tRNA sequences for Glu 
(Fig. 4-6B). After transcription, endogenous RNAse P and RNAse H cleaves this 
transcript near the ends of tRNA sequence, resulting in gRNA release from the 
transcript. We hypothesized that such gRNAs when can form complexes with dCas9-
VP160 and activate gene transcription. 
To test this hypothesis, we have transfected MEFs with either the tSON 
plasmid (“tSON”) or dCas9-VP160 and gRNA-expressing plasmids containing same 
gRNAs as ones’ present in tSON, namely g2, g17 and g30 (“Positive control”). mRNA 
fold change was measured using qPCR three days after transfection. It was clear that 
the gRNA-tRNA transcript was cleaved as intended as Olig2 and Nkx6-2 activation 
was achieved using tSON (Fig. 4-6C). Sox10 activation was not obvious in either 
conditions. Interestingly, there was a small drop in activation potential (on average) 
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when using tSON plasmid compared to positive control. This most likely was due to 
the amount of each gRNA that was transcribed in different systems. 
Although this strategy was evidently viable at small scale, we found when 
contstructing larger plasmids, containing eight tRNA-gRNA, that it was difficult to 
build these vectors complicated. After numerous cloning attempts, no correctly 
assembled plasmids were found, assumingly because of difficulties to clone highly 
repetitive sequences. In the future, it might be possible to use different tRNAs 
sequences between gRNAs to reduce recombination risk but we have decided to 




Figure 4-6 | U6-tRNA-gRNA-tRNA array system for multiplex gene regulation. 
(A) Graphical representation of tSON plasmid. Three different gRNAs are added to the tSON, each 
targeting either Sox10, Olig2 or Nkx6-2. These gRNAs are separated by sequences for Glu tRNA. (B) 
Graphical representation of how tRNA-gRNA system works. Single U6 promoter drives the expression 
of single transcript which contains tRNA-gRNA repeats. Such transcript is then spliced by RNAse P 
and RNAse H to release gRNA from tRNAs and become available for complex formation with dCas9-
VP160. (C) qPCR result showing levels of Sox10, Olig2 and Nkx6-2 mRNA in MEFs three days after 
transfection with either tSON or dCas9-VP160 and g2, g17 and g30 gRNA-expressing plasmids 











































To test gene regulation using plasmids with multiple U6 promoters, we have 
constructed three plasmids which contains increasing number of gRNAs targeting 
Sox10, Olig2 and Nkx6.2. SON plasmid contained three gRNAs (one for each gene), 
2SON contained five and 3SON contained eight gRNAs (Fig. 4-7A-C). Each gRNA 
is driven by a separate U6 promoter and proceeded by 30bp random sequence. 
To test if these plasmids encoding sTFs are able to activate Sox10, Olig2 and 
Nkx6-2 we have transfected MEFs and measured mRNA fold change three days after. 
As predicted, all plasmids were capable of activating transcription of three different 
genes (Fig. 4-7D). Moreover increasing a number of gRNAs that target Sox10 (SON 
to 3SON) increased the fold change that was observed. Interestingly, the fold change 
of Nkx6-2 decreased with increasing size of the plasmid. One explanation might be 
that multiple proximal U6 promoters might partly interfere with each other resulting 
in decreased transcriptional activity in most distal U6 promoters. However, it is hard 
to determine the precise reason from this data as more than one variable varies (number 
of gRNAs, variations of gRNAs, size of the plasmid, number of U6 promoters). One 
thing we can conclude is that multiple genes can be activated in the same cell using 
single plasmid. 
 We re-transformed 2SON plasmid which contained five U6-gRNA units, 
picked six clones and sequenced them. All of the clones were correctly assembled, 
suggesting that recombination in bacteria is not an issue at this scale (Fig. 4-8). 
Furthermore, stably integrated plasmid containing eight U6-gRNA units remained 
functional throughout multiple cell divisions (Fig. 5-4 and Fig. 5-9), suggesting low 
risk of recombination in mammalian cells as well.   
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Figure 4-7 | U6-gRNA array system for multiplex gene regulation. 
(A) Graphical representation of SON plasmid, containing three U6 promoters and three gRNAs 
targeting Sox10, Olig2 and Nkx6-2. (B) Graphical representation of 2SON plasmid, containing five U6 
promoters and five gRNAs targeting Sox10, Olig2 and Nkx6-2. (C) Graphical representation of 3SON 
plasmid, containing eight U6 promoters and eight gRNAs targeting Sox10, Olig2 and Nkx6-2. (D) qPCR 
result showing levels of Sox10, Olig2 and Nkx6-2 mRNA in MEFs three days after transfection with 

















































































Figure 4-8 | Sequencing of 2SON clones after re-transformation. 
Map and sequencing results of 2SON clones. 2SON has been re-transformed into competent E. coli 
bacteria and six clones were picked for sequencing to check for recombination events. 
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4.2 Construction and validation of system for simultaneous 
repression and activation 
By constructing Ai1 plasmids and capability to activate multiple genes using 
them we have solved one of the multiplexing and delivery problems. However, the 
second problem still remains – how can we activate and repress different genes in the 
same cell at the same time? If cells were transfected with dCas9-VP160, dCas9-
KRAB, some gRNAs targeting Sox10 for activation and some gRNAs for Sox9 
repression there would be no activation or repression as different effectors would 
compete for the same promoters (Fig. 4-9A).  
To overcome this problem, we have decided to adapt recently reported Cas9 
mutation (Kleinstiver et al. 2015). This mutation, termed VRER, is four base pair 
substitution which results in four amino acid changes. As a result, such a Cas9 has 
altered PAM specificity. Instead of looking for usual NGG, VRER Cas9 mutant looks 
for NGCG PAM sequence. If such VRER mutant is to be used together with non-
mutant Cas9, it is theoretically possible to target two genes exclusively by simply 
designing gRNAs which have different PAMs. If such mutation is to be made on 
dCas9, theoretically different gene transcription could be exclusively modulated at the 




Figure 4-9 | System for simultaneous gene activation and repression. 
(A) Graphical representation of current issue with simultaneous use of two opposing dCas9 proteins. 
As dCas9 proteins would recognize all gRNAs without specificity, dCas9-KRAB (red) and dCas9-
VP160 (green) would bind promoters of both, genes which are intended for activation (left side) and for 
repression (right side). (B) Graphical representation of the system where dCas9 proteins recognize 
different gRNAs and therefore effectors can be targeted to different promoters in exclusive manner. 
This is achieved by mutating dCas9-KRAB (red, VRER) and adjusting its PAM specificity to NGCG, 






























4.2.1 Construction and validation of VRER dCas9 mutants for altered PAM 
specificity 
To insert VRER mutation in dCas9 protein, we have used site-specific 
mutagenesis (Fig. 4-10A).  This method is based on introducing a small DNA change 
into a plasmid by using PCR primers which have mutated sequence (Fig. 4-10B). The 
PCR product is then phosphorylated and ligated. Importantly, all this is done in the 
same reaction tube which means original non-mutated plasmid which was used as PCR 
template is still present. To remove original (non-mutated) plasmid, sample is treated 
with DpnI restriction enzyme which cleaves only methylated sites. In such way, 
because PCR products are not methylated while plasmids after transformation are, only 
original plasmid is digested into pieces. This is followed by transformation and 
sequencing of the plasmids to confirm new mutation.  
After four rounds of site-specific mutagenesis, all four mutations were 




Figure 4-10 | Making VRER dCas9 mutants. 
(A) Graphical representation of the site-specific mutagenesis, which was used to create four amino acid 
substitutions in dCas9 protein. (B) Table outlining primers and their sequences which have been used 
to introduce mutations in dCas9 via site-specific mutagenesis. (C) Map and sequencing results of VRER 
dCas9 mutant plasmid demonstrating that four amino acid substitutions (VRER) have been successfully 






To check if VRER mutations would make dCas9 specific to gRNAs with 
NGCG PAM, we needed two sets of gRNAs targeting same promoter – one with NGG 
and one with NGCG PAMs. We already had gRNAs that can activate Sox10 in NSC 
and these gRNAs have NGG PAM (green boxes in Fig. 4-11A). Additionally, we have 
designed another set of gRNAs around the same location, but these gRNAs have 
NGCG PAM (red boxes in Fig. 4-11A). PG1.1 were transfected with either dCas9-
VP160 or mutant VRER-dCas9-VP160 and either gRNAs with NGG PAM (g1-g10) 
or gRNAs with NGCG PAM (g153-g157). Three days after transfection, mRNA levels 
were measured (Fig. 4-11B). From the data, it is clear that NGCG gRNAs do not work 
with dCas9-VP160 while NGG gRNAs do. However, neither gRNAs worked with 
VRER-dCas9-VP160. This might be because NGCG gRNAs were not functional as 
even slight location change can have a dramatic effect on gRNA potency. 
As our second gene for VRER validation, we have chosen Nkx6-2. Just as for 
Sox10, we have designed new gRNAs with NGCG PAM for Nkx6-2 (Fig. 4-11C). 
MEFs were transfected with either NGG or NGCG gRNAs and either dCas9-VP160 
or VRER-dCas9-VP160. Three days after transfection cells were harvested and Nkx6-
2 mRNA fold change was measured. As predicted, VRER-dCas9-V160 was able to 
activate Nkx6-2 transcription only if NGCG gRNAs, but not NGG gRNAs, were used 
(Fig. 4-11D). To large extent, opposite was true for dCas9-VP160. However, a small 
level of activation was seen when using dCas9-VP160 with NGCG gRNAs (17-to-30 
fold change). Although this is significantly lower compared to NGG gRNAs (249-to-
4755 fold change), but it is still evident. Such findings suggest that although PAM 
specificity is strongly favored but some overlap might still exist between gRNAs with 
NGCG and NGG PAM.  
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Figure 4-11 | Validating VRER exclusivity using dCas9-VP160. 
(A) gRNA positioning along Sox10 proximal promoter and transcription start site (TSS) for transcription 
activation. g153-g157 (red) have PAM NGCG which should be specific to VRER-dCas9, g1-g10 
(green) have PAM NGG which should be specific to dCas9. (B) qPCR results showing Sox10 mRNA 
levels in PG1.1 NSC three days after transfection with either dCas9-VP160 or VRER-dCas9-VP16 and 
either gRNAs g1-g10 or g153-g157, n=2. (C) gRNA positioning along Nkx6-2 proximal promoter and 
transcription start site (TSS) for transcription activation. g159-g163 (red) have PAM NGCG which 
should be specific to VRER-dCas9, g29-g31 (green) have PAM NGG which should be specific to 
dCas9. (D) qPCR results showing Nkx6-2 mRNA levels in MEFs three days after transfection with 
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4.2.2 Mouse gene repression in NSC using VRER-dCas9-KRAB 
After validating the VRER system, we went further to create VRER-dCas9-
KRAB mutants and investigate if such dCas9 can repress genes. Firstly, we focused 
on Sox9 repression as we have already achieved it using non-mutant dCas9-KRAB 
(Fig. 3-13).  
For this purpose, we have designed gRNAs for proximal Sox9 promoter which 
had NGCG PAM (Fig. 4-12A). To test if these gRNAs could repress Sox9, SOX9-V5 
NSCs were transfected with VRER-dCas9-KRAB and a pool of four gRNAs (g94-
g97). Four days after transfection, cells were analyzed by immunocytochemistry and 
qPCR.  
As observed previously, we could not see any significant change at mRNA 
level (Fig. 4-12E). However, more SOX9-low/negative cells were found after 
immunostaining (Fig. 4-12C and D). Approximately 25-8% more cells were SOX9-
low based on three independent biological replicates. 
To gain more confidence in the VRER-dCas9-KRAB ability to repress 
mammalian genes, we have conducted experiments to repress Olig2 in PG1.1 NSC 
line. Same methodology was used as for Sox9 repression and similar results were 
found. Although repression was not evident at mRNA level (Fig. 4-13F), more OLIG2-
low/negative cells were observed after transfection with VRER-dCas9-KRAB and a 
pool of gRNAs (Fig. 13E).  
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Figure 4-12 | Sox9 repression using VRER-dCas9-KRAB in SOX9-V5 NSC line. 
(A) gRNA positioning along Sox9 transcription start site (TSS) for transcription repression. (B) 
Graphical representation of experimental setup. (C) Immunocytochemistry for V5 in SOX9-V5 cells 
after transfection with VRER-dCas9-KRAB and 4 gRNAs (g94-g97) targeting Sox9 transcription start 
site (“VRER-dCas9-KRAB”) or non-transfected cells (“Control”). (D) Quantification of image 
cytometry data showing percentage of SOX9-V5 high cells after transfection with VRER-dCas9-KRAB 
and 4 gRNAs targeting Sox9 (“VRER-dCas9-KRAB”) or in non-transfected cell (“Control”), n=3. (E) 
qPCR data of Sox9 transcription levels four days after cells were transfected with VRER-dCas9-KRAB 





































































Figure 4-13 | Olig2 repression using VRER-dCas9-KRAB in PG1.1 cell line. 
(A) gRNA positioning along Olig2 transcription start site (TSS) for transcription repression. (B) 
Graphical representation of experimental setup. (C) Immunocytochemistry for OLIG2 in PG1.1 cells 
after transfection with VRER-dCas9-KRAB and 6 gRNAs (g175-g180) targeting Olig2 transcription 
start site (“VRER-dCas9-KRAB”) or non-transfected cells (“Control”). (D) C) Image of stained OLIG2 
in PG1.1 cells to demonstrate gating strategy based on OLIG2 intensity. Examples of low and high 
OLIG2 cells are shown with yellow arrows. (E) Quantification of image cytometry data showing 
percentage of OLIG2 high cells after transfection with VRER-dCas9-KRAB and 6 gRNAs targeting 
Olig2 (“VRER-dCas9-KRAB”) or in non-transfected cell (“Control”), n=2. (E) qPCR data of Olig2 
transcription levels four days after cells were transfected with VRER-dCas9-KRAB and 6 gRNAs 

















































































4.3 Construction of a Sox10-V5 tagged NSC line for multiplexing 
validation  
4.3.1 Evaluating SOX10 antibody specificity in our cell lines 
To test the multiplex capability of activating and repressing genes at the same 
time (in the same cell), we were required to find antibody for SOX10 that works in our 
system. We have tested a number of different antibodies which have been reported to 
work in other cell lines (Fig. 4-14A). However, after testing these antibodies in 
differentiated PG1.1 NSC, we could not see any staining that was not a background 
(Fig. 4-14B-C). Importantly, we knew that differentiating PG1.1 NSC line had 
increased Sox10 mRNA levels. Therefore, we have concluded that none of the 
antibodies are functional. To overcome this hurdle, we decided to epitope tag Sox10 
gene with V5 tag knock-in using CRISPR. 
4.3.2 Tagging Sox10 with C-terminus V5 in PG1.1 and BL6 NSC lines 
None of the antibodies that we tested worked on PG1.1 cell line. Therefore, we 
decided to tag Sox10 with V5 to allow SOX10 protein visualization. To achieve this, 
we have used Cas9 protein, gRNAs targeting Sox10 C-terminus and single-stranded 
donor DNA (ssODN) which contained sequence V5 tag. Tagging works based on the 
following principle. After transfecting cells with all three components, Cas9 and 
gRNAs cause double-strand break (DSB) which is then repaired with a help of ssODN. 
As a result, the gene of interest is tagged with V5 peptide at the end of C-terminus to 




Figure 4-14 | Evaluating SOX10 antibodies. 
(A) Table summarizing tested anti-SOX10 antibodies. (B) Immunocytochemistry of SOX10 and 
PDGFRα-GFP seven days after differentiation. AB155279 antibody was used in this example. (C) 
Image cytometry analysis of SOX10 immunocytochemistry in self-renewal conditions (grey), four days 
after differentiation (green) or seven days after differentiation (red). AB155279 antibody was used in 
this example. (D) qPCR results showing mRNA levels of Sox10 either after activation with dCas9-
VP160 and specified gRNAs (g6-g8 and g1-g10) or of differentiated PG1.1 GFP-positive and GFP-


































































To validate if gene targeting was successful, genotyping was performed using 
the strategy outlined in Figure 4-15B. After genotyping transfected PG1.1 cells, a band 
was observed at expected 600bp size while parental line (non-transfected PG1.1 NSC) 
did not produce band of such size (Fig. 4-15C). To validate SOX10 tagging using 
immunocytochemistry, we differentiated tagged PG1.1 cells to OPCs and stained for 
V5 and PDGFRα-GFP (control for differentiation). Although cells differentiated and 
became PDGFRα-GFP positive, no V5-positive cells could be identified (Fig. 14-5D). 
We reasoned that derivation of clonal lines might be necessary as if only low 
percentage of cells were tagged and only 20% of those differentiated, it might be hard 
to find positive cells without deriving clonal lines. 
We have seeded 1x103 PG1.1 SOX10-V5 cells into 10cm2 dish and cultured 
them for 7-12 days. Colonies which grew were picked and plated into 96-well plate 
for further expansion. After we had enough cells, genomic DNA was extracted from 
eight different clonal lines and genotyping was performed. Two out of eight clonal 
lines were positive (Fig. 4-16A), which gives an estimated tagging efficiency of 25%. 
These two clonal lines (C2 and C7) showed normal NSC morphology (Fig. 4-16B). 
However, no V5-positive cells were found after differentiation of either of the clonal 
lines (Fig. 4-16C). To continue our work, we decided to test a indpendent NSC line 
called Black 6 (BL6), which can more efficiently differentiate into mature Sox10 




Figure 4-15 | Strategy for V5 tagging of C-terminus of Sox10 using CRISPR-Cas9 protein and in 
vitro transcribed gRNAs in PG1.1 NSC line. 
(A) Graphical representation of the process of V5 tagging, which involves cutting near Sox10 stop codon 
to initiate homology directed repair (HDR)-mediated insertion of single strand donor containing V5 tag 
sequence. (B) Genotyping strategy. One primer is placed inside Sox10 exon and second one is placed 
on V5. If tagging was successful, genotyping using these primers and DNA from treated cells as 
template will generate 592bp band on agarose gel. (C) Genotyping results of PG1.1 NSC which were 
tagged with V5 at the C-terminus of the Sox10. Parental (non-treated) cells were used as negative 













































Figure 4-16 | Derivation of PG1.1 SOX10-V5 clonal cell lines. 
(A) Genotyping of clonal PG1.1 SOX10-v5 cell lines (C1 to C8). “Population” is population of PG1.1 
SOX10-V5 cells (positive control) and “Parental” is parental PG1.1 NSC line (negative control). (B) 
Phase contrast picture demonstrating NSC morphology of clone 2 (C2) and clone 7 (C7). (C) 
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Using the same experimental strategy described above, we tagged Sox10 in 
BL6 NSCs with a V5 tag. We have used two different gRNA sets (#1 and #2) and both 
gave cell populations which were genotyped positively for the V5 tag (Fig. 4-17A). 
After forcing these two populations to differentiate into OPCs, we could only find a 
couple V5-positive cells in population #1 and no V5-positive cells in population #2 
(Fig. 4-17C). After picking and genotyping clones, we found two clonal lines (C6 from 
population #1 and C4 from population #2) to be successfully tagged (Fig. 4-17B). 
Importantly, after inducing these clones to differentiate, a proportion of C6 cells were 
observed to be V5-positive, while clone C4 did not have any V5 positive cells. Such 
result could potentially be explained by difference in capability to differentiate 
between clonal lines or by some genomic abnormalities that were caused at Sox10 
locus during tagging process when using #2 gRNA set. 
The BL6 SOX10-V5 C6 clonal line will be used in the future studies for 
multiplexing experiments to test if multiple genes can be activated and repressed in 
the same cell using systems that we have built; but time constraints meant we did not 




Figure 4-17 | Derivation of BL6 SOX10-V5 clonal cell lines. 
(A) Genotyping of tagged BL6 cells. Pop#1 and Pop#2 are two populations of BL6 SOX10-V5 cells 
(tagged using two different gRNAs), “Parental” is parental BL6 NSC line (negative control) and “PG1.1 
SOX10-V5” are tagged populations of PG1.1 SOX10-V5 cells (positive control). (B) Genotyping of 
clonal BL6 SOX10-V5 cells. (C) Immunocytochemistry of differentiated BL6 SOX10-V5 tagged NSC 



















































































































4.4 Concluding remarks 
Interesting findings and lessons from the work in Chapter 4 will be highlighted 
in the following paragraphs. Firstly, we have successfully built an easy-to-use and 
rapid system for adding multiple gRNAs into the plasmid with dCas9-V160. Up to 
eight U6-gRNA units (highly repetitive sequence) have been added in an array 
without any evidence of recombination in E.coli or mammalian cells. By the time 
this work was performed, only six gRNAs have been reported to be successfully 
multiplexed using single plasmid. Importantly, using this all-in-one plasmid, we have 
successfully activated three different genes (Sox10, Olig2 and Nkx6-2) from a single 
vector in MEFs. This was significant improvement over present state-of-art methods, 
as it was more modular (easier manufacturing with possibility to expand a number of 
gRNAs used) and included dCas9 in the same vector. 
Secondly, we have successfully built the capability for directing dCas9 proteins 
to different gRNAs (and therefore promoters) in almost exclusive manner. This was 
achieved by introducing four mutations into dCas9 protein. Such mutant dCas9, called 
VRER dCas9, has been reported to have a new PAM specificity (NGCG instead of 
NGG). We have validated strong preference of VRER-dCas9 to NGCG PAM, 
however non-mutant dCas9 also recognizes NGCG PAM to some extent. Importantly, 
using VRER-dCas9-KRAB we have successfully repressed SOX9 and OLIG2 in NSC 
lines. 
Thirdly, we have built Sox10-V5 NSC cell lines for easier SOX10 detection. 
This was necessary because none of the commercial antibodies against SOX10 were 
functional in our hands. As a result, we have generated PG1.1 and BL6 NSC lines 
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which had SOX10 tagged with V5 based on the genotyping results. We have identified 
BL6 NSC clonal cell line which were successfully tagged, as confirmed by genotyping 
and V5 staining upon induction of differentiation. Interestingly, we have also observed 
multiple times that it is misleading to rely solely on genotyping results, as a number of 
clones had correct bands in genotyping but were demonstrated to be negative by 
immunostaining.  
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5 Programing and reprograming cell identity using sTFs 
5.1 Directing NS cell differentiation by overexpression or sTF-
driven activation of key OPC master regulators 
The preceding chapters have demonstrated biochemical activity and 
transcriptional activation of target genes can be achieved in NS cells and MEFs for 
some of the key OPC ‘master regulators’, such as Sox10, Olig2 and Nkx6-2. In this 
chapter, we explore whether activation of these genes can be sufficient to direct cell 
fate. We explore two different contexts. First, the ‘programing’ of differentiation of 
NS cells to see if OPCs/OL can be made at increased efficiencies. i.e. can we control 
the differentiation pathways. Second, can we directly reprogram MEFs into OPCs? 
5.1.1 Construction of PG1.1 cell line with inducible SOX10 and OLIG2 
overexpression (PG1.1-SO) 
To test if transcription activation and overexpression can force NSCs to 
differentiate into OPCs and OLs, we have made use of the OPC reporter NSC cell line 
PG1.1 (described in Chapter 3). Following transfer to differentiation conditions (EGF 
withdrawal; plus FGF, PDGF-AA and Forskolin), ~20% of cells become GFP positive. 
These GFP positive cell are early OPCs, as the H2B-GFP cassette is driven by the 
endogenous PDGFRα promoter. Neurons, astrocytes and neural stem cells do not 
express PDGFRα. Unless otherwise stated, this cell line was used in the following 
experiments. SOX10 and OLIG2 are two of the critical reprograming factors that have 
been described in past work using cDNA. As a positive control for our sTF 
experiments we created a new NS cell line that enabled inducible overexpression of 
the cDNA encoding these two factors.  
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Figure 5-1 | PDGFRα-GFP (PG1.1) reporter cell line. 
(A) Graphical representation of PG1.1 reporter mouse NS cell line. The PG1.1 cell line was constructed 
by Dr. Bartlomiej Baranowski (a previous PhD student in the Pollard lab). (B) Under self-renewal 
conditions (presence of FGF and EGF) PG1.1 cells lack any GFP fluorescence; however, upon 
differentiation (presence of FGF, PDGF-AA and Forskolin) cells with upregulated PDGFRα becomes 
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This was achieved by constructing plasmid M1, which drives expression of 
SOX10 and OLIG2 after addition of DOX (using the TETON 3G system). This plasmid 
also harbours PiggyBac recombination sites (inverted repeats) and a blasticidin 
resistance cassette (Fig. 5-2 A-B). To generate a stable cell line, we transfected PG1.1 
NSCs with the M1, PB_CAG_Tet3G plasmid together with the CAG_Pbase plasmid 
(encoding the transposase). Cells were cultured for two weeks in the presence of 
1µg/ml blasticidin to select for positive cells (Fig. 5-2C). The resulting pool of 
transfected cells has been named PG1.1-SO. 
To validate that PG1.1-SO cells are co-expressing SOX10 and OLIG2 after 
addition of DOX, we have conducted DOX dose response experiments over a time-
course and performed qPCR for the transgenes (Fig. 5-2D). As it is evident from the 
data, increasing concentrations of DOX indeed triggers increased levels of SOX10 and 
OLIG2 expression from these cells. At Day 1 expression levels are low (100-fold over 
no DOX control), as transcriptional and translational processes did not have enough 
time to reach maximum rate. By Day 2 we see higher levels of expression (200 to 500-
fold over no DOX control), while expression at Day 3 is highest (1500 to 7500-fold 
over no DOX control). However, the PG1.1-SO cell line was leaky, as the transgene 
was expressed even without addition of DOX (data not shown). To minimize leakage 
and therefore potential side-effects of the leakage, we needed to establish clonal cell 




Figure 5-2 | Construction of PG1.1 cell line with DOX inducible SOX10 and OLIG2 (PG1.1-SO). 
(A) Map of constructed M1 plasmid which was used to generate the DOX-inducible SOX10 and OLIG2 
cell line (PG1.1-SO). (B) Sanger sequencing confirmed correct assembly of M1 plasmid. (C) Phase 
contrast images demonstrating survival of PG1.1-SO cells in presence of 1µg/ml DOX after selection 
with 1µg/ml blasticidin, while control non-transfected cells were killed. Prior to selection, PG1.1 cells 
were transfected with Tre_SOX10_p2A_OLIG2 (M1), CAG_pBase and Pb_CAG_TeT3G plasmids and 
cultured for two weeks. (D) qPCR data showing mRNA levels of SOX10 and OLIG2 after PG1.1-SO 
cells were exposed to different DOX concentration. Results were normalized to 0 DOX control. RNA 
was collected at Day 1, Day 2 and Day 3, n=1.  
  














































To develop cell lines with minimal leaky expression we generated four clonal 
PG1.1-SO cell lines and tested SOX10 mRNA by qPCR without adding DOX (Fig. 5-
3A). Some of the clonal PG1.1-SO lines had high levels of SOX10 expression even 
without DOX (>504-fold in c1 and >5572-fold in c3 over parental cell line) while in 
other cell lines there was minimal leakage (>183-fold in c2 and >71-fold in c4 over 
parental cell line). We decided to use PG1.1-SO c4 clonal line for further experiments 
as this had lowest leakage levels. 
It is well known that differentiation can be triggered at high cell densities – 
even in the presence of EGF. To ensure that the effect on differentiation that we will 
be investigating is from overexpression and not due to secondary effects of enhanced 
proliferation/density, we have compared PG1.1-SO c4 growth rates to that of parental 
PG1.1 cell line with and without DOX (Fig.5-3B). After calculating slopes (± Standard 
Error) for each growth curve it became obvious that DOX addition has detrimental 
effect on cell growth rate; this is either due to killing cells, differentiation, or slower 
cell cycle. Moreover, PG1.1 SO c4 cells proliferated twice as fast as parental PG1.1 
cells (slope of 2.26 versus 1.15). To control for these effects, in the following 
differentiation experiments we have used a lower seeding density to minimize 




Figure 5-3 | Construction and characterization of PG1.1-SO clonal cell lines. 
(A) qPCR data showing mRNA levels of SOX10 in different PG1.1-SO clonal lines which have not 
been exposed to DOX, n=1. These are normalized to parental PG1.1 cell line (negative control) which 
has no SOX10 expression (CT value 40) (B) Growth curves of PG1.1-SO_o c4 and parental PG1.1 cell 



























































5.1.2 Construction of PG1.1 cell line for Sox10 activation with dCas9-VP160 
(PG1.1-3SON) 
After constructing cell lines capable of SOX10 and OLIG2 overexpression 
(positive control) we went on to construct another cell line which contained sTFs 
targeting same OPC master regulators – idea being that we will compare these lines 
(and therefore cDNA and sTFs) head-to-head in their ability to drive PG1.1 
differentiation. 
To construct such line, we have transfected PG1.1 cells with 3SON (contains 
mRuby reporter gene and PiggyBac homology arms) and CAG_pBase. Cells were 
cultured for two weeks and sorted for mRuby (Fig. 5-4A). mRuby positive cells (now 
named PG1.1-3SON) were then further cultured as a pool of trasnfectants. Three 
weeks after initial transfection, mRNA was harvested and expression of Sox10, Olig2 
and Nkx6-2 was tested using by qPCR (Fig. 5-4B). In comparison to PG1.1 parental 
line, Sox10 mRNA levels in PG1.1-3SON cells were significantly upregulated as 
expected, levels of Olig2 and Nkx6-2 remained the same. 
To summarize, we now have constructed (i) PG1.1-SO cell line which 
massively overexpress SOX10 and OLIG2 in response to DOX and has a small leakage 
of these transgenes in absence of DOX (20x lower in comparison to cells exposed to 
DOX); and (ii) PG1.1-3SON cell line which has sTFs targeting and activating 
endogenous Sox10 expression (with no direct effect on other genes). Next, we compare 





Figure 5-4 | Construction of stable PG1.1 cell lines containing 3SON sTFs (PG1.1-3SON). 
(A) Graphical representation of the experiment. PG1.1 cells were transfected with plasmid 3SON and 
CAG_pBase and cultured for 2 weeks. mRuby positive cells (reporter present in 3SON plasmid) were 
sorted and cultured further. (B) qPCR data showing Sox10, Olig2 and Nkx6-2 mRNA levels in parental 
PG1.1 cells (Control) and Ruby sorted cells (PG1.1-3SON), n=1 
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5.1.3 Effect of SOX10 and OLIG2 cDNA overexpression and Sox10 activation 
with sTFs on mouse neural stem cells in self-renewal conditions 
We next tested whether the forced expression of SOX10-OLIG2 and 
endogenous activation of Sox10 can trigger the anticipated increases in OPC 
specification in NSCs. Following experiments were performed (Fig. 5-5A). PG1.1-SO 
c4 (SOX10 and OLIG2 cDNA overexpression) and PG1.1-3SON (endogenous Sox10 
transcription activation using sTFs) cells were seeded at very low density (Fig. 5-5B) 
into 6-well plates with normal NSC growth medium (containing EGF and FGF). 
Parental PG1.1 cells were used as a control. 24hr later, 1µg/ml of DOX was added to 
some of the PG1.1 and PG1.1-SO cells. These cells were then analysed by flow 
cytometry for presence of PDGFRα-GFP positive cells to determine whether these 
factors could override self-renewal conditions and trigger differentiation. At each time 
point, fresh self-renewing PG1.1 cells were used to set gating (for example, first box 
from left in Fig. 5-5D).  
These experiments showed that as expected the parental PG1.1 cell line (Figure 
5.5 blue) –  which served as a negative control – showed no GFP positive cells at Day 
2 or Day 4. By Day 5, we observed ~10-15% of cells becoming GFP positive, 
presumably due to the spontaneous differentiation triggered by confluence.  
PG1.1-SO c4 cells (which expressed SOX10 and OLIG2 cDNA) increased GFP 
every day. At Day 2, PG1.1-SO c4 cells (with or without DOX) were on average 
around 7% GFP positive. This number increased over time and reached 24.2% to 
47.1% at Day 5. Interestingly, we observed a difference in differentiation rates 
between PG1.1-SO c4 cells with (green) and without DOX (red). PG1.1-SO c4 cells 
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which have not been exposed to DOX (red) were able to differentiate to PDGFRα-
GFP positive cells even at low confluence (Day 2 to Day 4). This could be explained 
by SOX10 (but not OLIG2) expression leakage in these cells (Fig. 5-5C, red). Such 
findings suggest that SOX10 alone is sufficient to drive NSC differentiation or at least 
prime the cells by turning on PDGFRα. Importantly, if DOX is added to these cells, 
the number of PDGFRα-GFP positive cells is lowered (Fig. 5-5C, green versus red).  
We speculate that this could be explained either (i) by detrimental effect of 
extremely high levels of transgene expression or (ii) by high levels of OLIG2 which 
might interfere with differentiation and push NSC to maintain their multipotency. 
Considering that OLIG2 is one of the key master regulators of NSC identity, this could 
explain such observations. Thus, it seems that low level expression of SOX10 cDNA 
is sufficient to direct NSC differentiation to OPC lineages. 
Lastly, and most importantly, we tested if endogenous Sox10 transcription 
activation by sTFs (dCas9-VP160) was also able to drive NSC differentiation towards 
OPC lineage in the PG1.1-3SON cell line (Fig. 5-5 D-E). In this cell line, Sox10 
transcription is constitutively activated by sTFs (pink in Fig.5-5C) to levels which are 
higher than SOX10 cDNA overexpression without DOX (red in Fig.5-5C) but lower 
to those after DOX addition (green in Fig.5-5C). Importantly, such Sox10 activation 
by sTFs was sufficient to drive NSC differentiation into PDGFRα positive cells (Fig.5-
5 D-E).  
The levels of forced NSC differentiation were similar between using SOX10 
cDNA (red) and sTFs (pink) targeting Sox10 (46.9% and 50.8%, respectively), but 
significantly lowered if OLIG2 overexpression (green) was included (30.2%).   
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Figure 5-5 | Effect of SOX10 and OLIG2 overexpression and Sox10 activation on mouse neural 
stem cells in self-renewal conditions. 
(A) Schematic representation of the experiment. Cells were seed in 6-well plate at low density (2x10^4 
cells/well). Next day, 1µg/ml of DOX was added to some of control cells (PG1.1) and SOX10-OLIG2 
overexpressing cells (PG1.1-SO). Cells were harvested at 4 different time points. (B) Phase contrast 
images demonstrating cell density at Day 2 and Day 5. (C) qPCR data demonstrating levels of Sox10 
and Olig2 mRNA at day 2, n=1. (D) Flow cytometry data showing amount of cells positive for 
PDGFRα-GFP at Day 5. Fresh PG1.1 cell (black) were used to set gating for positive cells. (E) 
Quantification of flow data, each dot represents biological replicate.  
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5.1.4 Effect of SOX10 and OLIG2 cDNA overexpression and Sox10 
transcription activation (sTFs) on mouse neural stem cells in OPC 
differentiation conditions 
To test if SOX10 overexpression and Sox10 activation could also enhance NSC 
differentiation when delivered during conditions which favour differentiation, the 
following experiments were done (Fig. 5-6A). Cells were seeded at low density and 
induced to differentiated next day by addition of FGF, PDGF-AA and Forsklin. Some 
cells were exposed to 1µg/ml DOX. Four days after induction, cells were analyzed 
using flow cytometry for PDGFRα-GFP positive cells (Fig. 5-6B). 
The following observations were made: parental cells (blue) showed around 
20% of cells that became GFP positive as expected. PG1.1-SO c4 cells (SOX10 cDNA 
overexpression; red) had on average 52.5% of cells GFP positive, while if these cells 
were exposed to DOX (SOX10 and OLIG2 cDNA overexpression; green), the number 
of GFP positive cells dropped to 31.4% on average. PG1.1-3SON cells (Sox10 sTFs; 
purple) were able to generate over 70% PDGFRα-GFP positive cells on average (Fig. 
5-6C).   
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Figure 5-6 | Effect of SOX10 and OLIG2 cDNA overexpression and Sox10 activation on mouse 
neural stem cells in OPC differentiating conditions. 
(A) Schematic representation of the experiment. Cells were seed in 6-well plate at low density (2x10^4 
cells/well). Next day, 1ug/ml of DOX and OPC differentiation medium (FGF, PDGF-AA, Forsklin) 
was added to cells. Cells were analyzed 4 days after differentiation induction. (B) Flow cytometry data 
showing amount of cells positive for PDGFRα-GFP at Day 5. (C) Quantification of flow data, each dot 
represents biological replicate. 
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Under these conditions cells which had Sox10 transcription activated by sTFs 
(PG1.1-3SON) had more differentiating cells than cells with SOX10 cDNA 
overexpression (PG1.1-SO c4 with no DOX). Such observation could be explained by 
higher Sox10 levels in PG1.1-3SON cells compared to that of PG1.1-SO c4 without 
DOX (Fig. 5-5C, red and purple). Although the highest SOX10 levels were seen after 
PG1.1-SO c4 was exposed to DOX we might expect this condition to have most 
PDGFRα-GFP positive cells if differentiation is directly linked to SOX10 levels, but 
this is not a case. We speculate that in these cells (PG1.1-SO c4 with DOX) too high 
SOX10 and/or OLIG2 levels interfere with differentiation process. sTFs can therefore 
clearly program cell fate (NSC differentiation) in a comparable manner to cDNA 
overexpression. 
To test if the GFP expressing cells are fully specified OPCs or are they just 
‘primed’ NSC which have activated the marker PDGFRα we tested them for a number 
of additional OPC and OL specific markers: MBP, O4 and NG2. Parental PG1.1 
(control) and PG1.1-SO c4 (SOX10 cDNA overexpression) cells were seeded at low 
density (2x104 cells/6-well plate well) and induced to differentiate to OPCs by addition 
of FGF, PDGF-AA and Forsklin. Four days after induction, medium was changed to 
drive OL differentiation. This medium contained T3 and L-Ascorbic acid. Four days 
later, cells were analysed by immunocytochemistry (Fig. 5-7A). We have found that 
although PG1.1-SO c4 cells generated MBP and O4 positive cells, PG1.1 (parental) 
cells failed to do so. Moreover, morphology of O4 positive cells did not resemble 
standard OPC or OL morphology (Fig. 5-7B). For this reason, and to test observed 
effects of Sox10 transcription activation in NSC with different genetic background, 
used an independent Black6 (BL6) NSC line.  
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Figure 5-7 | Differentiation of PG1.1 and PG1.1 SO c4 NSC to OL lineage. 
(A) Schematic representation of the experiment. (B) Immunocytochemistry of PG1.1 cells after 
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5.1.5 Effect of Sox10 transcription activation by sTFs on BL6 NSC 
differentiation towards OL lineage 
To test observed effects of Sox10 activation in NSC with an independent cell 
line with a different genetic background, we performed similar experiments using a 
newly established Black6 (BL6) NSC line. This is a non-transgenic wild-type primary 
adult NSC culture. BL6 cells were exposed to a range of different culture conditions 
known to induce differentiation, including: basal NSC growth medium lacking any 
growth factors, containing 2% FCS or standard OL differentiation conditions as 
described before. After ICC for O4, it was evident that standard OL differentiation 
conditions gave raise to large number positive cells, as well as some MBP positive 
cells (Fig. 5-8). The other two conditions gave rise to a lower number of OLs.  
To repeat Sox10 transcription activation experiments in BL6, we constructed a 
new sTF Ai1 plasmid (S10) which contained dCas9-VP160 and 8 gRNAs targeting 
Sox10 promoter (Fig. 5-9A). By increasing the number of gRNAs targeting Sox10, we 
were hoping to increase the number of cells which have Sox10 gene activated.  
To make a stable cell line containing these sTFs targeting Sox10, we have 
transfected BL6 NSC cells with S10 and CAG_Pbase plasmids and cultured them for 
couple weeks. To test if Sox10 could be activated in these cells, we harvested some 
RNA and performed qPCR. As expected, these cells had Sox10 gene activated (Fig. 5-
9B). Next, we sorted for mRuby positive cells (reporter for S10 plasmid) to enrich the 
population of cells with had Sox10 activated. About 1.4% of cells were mRuby positive 
(Fig. 5-9C). This new cell line (BL6-S10) had normal NSC morphology (Fig.5-9D).  
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Figure 5-8 | Characterizing BL6 cell line differentiation potential in different differentiation 
inducing growth mediums. 
Immunocytochemistry performed for NG2, O4 and MBP on BL6 cell 8 days after differentiation 
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Figure 5-9 | Constructing stable BL6 cell lines expressing sTFs targeting Sox10 (BL6-S10). 
(A) Map for the S10 plasmid containing 8 gRNAs (g1-g8) targeting proximal Sox10 promoter and 
dCas9-VP160. (B) qPCR data showing levels of Sox10 mRNA in BL6-S10 stable cell line, n=1. (C) 
mRuby positive cells (reporter for S10 plasmid) were sorted 8 days after BL6 cell were transfected with 
S10 plasmid and CAG_Pbase. (D) Live phase contrast image showing normal BL6-S10 cell 
morphology.  
  


















































While BL6 cells alone (parental/control) were able to generate O4 positive 
OPCs/OLs (Fig. 5-10B), we were interested to investigate if Sox10 transcriptional 
activation with sTFs would be able to enhance this process. To test this, BL6 (control) 
and BL6-S10 (contain sTFs) cells were induced to differentiate to OPCs using standard 
8 day two-step protocol used earlier. Cells were analysed for O4 positive cells using 
flow cytometry (Fig. 5-10C) and it was evident that there was no significant difference 
in a number of O4 positive cells between parental BL6 cells (blue) and BL6-S10 cells 
which had Sox10 gene activated by sTFs (green). In both conditions, around 60% of 
cells were positive for O4 while BL6 in self renewal conditions had <1% of positive 
cells (Fig.5-10D).  
As we could not observe any effect of the sTF-driven activation of Sox10, we 
reasoned that this differentiation protocol is already so efficient that system is 
saturated; Sox10 activation cannot enhance it further. We therefore tested these two 
cell lines in sub-optimal differentiation medium (as shown in Fig. 5-8) and used 5% 
FCS, instead of T3 and L-ascorbic acid, to force last stage of differentiation (Fig. 5-
10E). Parental BL6 cells (blue) only gave 10.1% of O4 positive cells on average, while 
BL6-S10 cells (contain sTFs) gave 27.4% O4 positive cells on average (Fig. 5-10F). 
Thus, Sox10 activation by dCas9-sTFs has a clear effect on NSC differentiation 
towards OPC and OL lineage, but this effect is only significant when using sub-optimal 
OPC differentiation conditions.  
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Figure 5-10 | Effect of Sox10 activation on NSC differentiation to OL lineage. 
(A) Schematic representation of first set experiments. (B) Immunocytochemistry images after O4 
staining on differentiated BL6 NSC cells at Day 9. (C) Flow cytometry data of BL6 and BL6-S10 cells 
after the differentiation. (D) Quantification of flow cytometry data of experiment described in A, each 
dot represents biological replicate. (E) Schematic representation of second set of experiments. (F) 
Quantification of flow cytometry quantification of experiment described in E, each dot represents 
biological replicate.  
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5.2 Effect of Sox10, Olig2 and Nkx6-2 transcription activation on 
MEF transdifferentiation to OL 
5.2.1 Generation of MEF lines from mouse embryos 
Given the sTFs could affect differentiation program in NS cells, we next tested 
if they could trigger the more challenging reprogramming event: transdifferentiation 
of MEFs to OPCs. For the following transdifferentiation experiments, numerous fresh 
MEF cultures were generated from 13.5-day old mouse embryos (Fig. 5-11A), by 
dissecting distal limb fibroblasts (Fig. 5-11B). The full protocol can be found in 
Method and Materials chapter. 
MEFs showed standard fibroblast morphology (Fig. 5-11C). We have 
compared levels of Nkx2-2, Nkx6-2, Sox10, Olig2, Ascl1 and Sox9 in two separately 
generated MEF lines to those in NSC (Fig. 5-11D). All cells had low levels of Nkx2-
2, Nkx6-2 and Sox10. MEFs also had low levels of Olig2 and Ascl. All cells had high 
Sox9 levels. 
MEFs are known to be hard to transfect using Nucleofection. Therefore, we 
have tested transfection efficiency with different reagents. Transfection with PEI 
showed only 10% transfection efficiency (data not shown), while transfecting 
CAG_GFP to MEFs with Lipofectamine 3000 gave almost 30% of transfection 
efficiency as demonstrated by flow cytometry data (Fig. 5-11E). This method was used 




Figure 5-11 | Generating MEF lines from mouse embryos. 
(A) Schematic representation of MEF harvesting method. Limbs are removed from the 12.5-day old 
mouse embryo and placed in the 0.25%Tripsin/EDTA for dissociation. Cells then are plated and 
cultured in AmnioMax medium. (B) Image showing limb separation from the embryo. (C) Phase 
contrast image of cultured MEFs 10 days after harvesting. (D) dCT values for various genes in MEF 
and NSC, n=1. (E) Flow cytometry date of non-transfected MEFs and MEFs transfected with 
























































5.2.2 MEF transdifferentiation to OPC/OLs after Sox10, Olig2 and Nkx6-2 
activation with sTFs (3SON) 
To test if Sox10, Olig2 and Nkx6-2 activation can force MEF 
transdifferentiation, the following experiments have been performed (Fig. 5-12A). 
MEFs were seeded and next day either transfected with 3SON and CAG_Pbase or not 
transfected. Three days after transfection, some cells were harvested for analysis by 
qPCR, while the remaining cells were incubated in MEF transdifferentiation medium 
(see Methods and Materials). Some cells were also harvested for qPCR at Day 9. At 
day 14, some cells were harvested for qPCR while remaining cells were induced to 
differentiate to OLs for 3 days. Subsequently, cells were analysed by flow cytometry 
and immunocytochemistry at Day 17. 
From the qPCR marker analysis, it was clear that activation of all three genes 
was occurring at each of the three time points; thus, transfection and target gene 
activation by the sTFs was successful (Fig. 5-12B). Phase-contrast images, at Day 14 
indicated that transfected cells had morphological changes from flat MEF-like shape 
to spindle OPC-like shape in a small subset of cells (Fig. 5-12C).  
To test if MEFs induced to transdifferentiate expressed the OPC/OL marker 
O4, we have conduced ICC and flow cytometry at Day 17. ICC indicated only very 
small number of cells were O4 positive; yet, encouragingly, these cells did display a 
morphology reminiscent of OPCs (Fig. 5-13A). After analysing transfected and non-
transfected MEFs, we found that transfected MEFs had 3.2% of O4 positive cells, 
while non-transfected MEFs only had 0.9%. Although there is a small difference 
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between two conditions, this is too small to be confident that transdifferentiation 
happened.  
We hypothesed that levels of gene transcription might have been too low for 
efficient transdifferentiation. In an attempt to boost transcription levels, we tested 
additional combinations of sTFs and cDNA. In addition to using 3SON sTFs, we have 
also included three other conditions: overexpression of SOX10 and OLIG2 cDNA by 
itself; 3SON sTFs supplemented with overexpression of SOX10 and OLIG2 cDNA; 
and 3SON sTFs together with the addition Sox10 sTFs (S10 plasmid) – to boost levels 
of SOX10. Secondly, we increased transdifferentiation times from 17 days to 24 days 
(Fig. 5-14 A). 
After repeating this transdifferentiation, we indeed have found cells which 
morphologically are similar to OPC/OL cells in all conditions, except in non-
transfected but induced control (Fig. 5-14 B). More importantly, after analysing these 
cells by flow, we have found that all conditions had over >10% of O4-positive cells, 
while less than 1% O4-positive cells were found in controls (Fig. 5-15C). Also, by 
increasing transdifferentiation protocol from 17 to 24 days, we manage to double the 
amount of OPCs generated when using 3SON sTFs (3.2% to 6.9%). Moreover, by 
adding additional sTFs targeting Sox10 (and thus increasing Sox10 expression levels), 
we managed to increase efficiency of transdifferentiation process from 6.9% to 17.9%. 




Figure 5-12 | MEF transdifferentiation to OPCs/OLs after Sox10, Olig2 and Nkx6-2 activation 
with 3SON. 
(A) Schematic representation of the experiment. Cells are transfected on Day 0 with 3SON vector and 
CAG_pBase. At Day 3, some cells are harvested for qPCR, while the rest is induced to transdifferentiate 
by addition of MEF TD medium. At Day 9 and Day 14, some cells are analysed by qPCR. 
Transdifferentiation events are scored using immunocytochemistry and flow cytometry at Day 17. (B) 
qPCR data showing levels of Sox10, Olig2 and Nkx6-2 mRNA 3, 9 and 14 days after transfection, each 
dot represents biological replicate. (C) Phase contrast images at Day 3, Day 9 and 14 of Control and 
Transfected MEFs.  
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Figure 5-13 | MEF transdifferentiation to OL after Sox10, Olig2 and Nkx6-2 activation with 
3SON. 
(A) Immunocytochemistry of O4 in transfected MEFs at Day 17. (B) Flow cytometry for O4 in 
transfected and non-transfected MEFs 17 days post transfection. For positive control, differentiated BL6 
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Figure 5-14 | Optimized MEF transdifferentiation to OL after Sox10, Olig2 and Nkx6-2 
activation with sTFs. 
(A) Outline of experimental workflow. MEFs have been transfected with following plasmids: “cDNA 
(Overexpression)” (CAG_Sox10_Olig2 plasmid); “cDNA + sTFs (3SON)” (CAG_Sox10_Olig2, 
3SON and CAG_PiggyBac plasmids); “sTFs (3SON)” (3SON and CAG_PiggyBac plasmids); “sTFs 
(3SON + S10)” (3SON, S10 and CAG_PiggyBac plasmids). (B) Phase contrast images of OPC-like 
cells in different conditions at Day 22. (C) Flow cytometry data for levels of O4-positive cells in 
different conditions, day 24, n=1.  
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5.3 Concluding remarks 
In this chapter we have explore if the sTFs produced in Chapter 3 and 4, have 
biological activity in redirecting cell fate – either by programing NS cell 
differentiation, or directly reprograming MEFs to OPCs.  
We successfully confirmed that overexpression (cDNA) or activation (sTFs) of 
Sox10 in mouse NSC drives them towards OL lineage. In two different cell lines, we 
have increased both PDGFRα and O4 positive cells after SOX10 overexpression or 
activation of Sox10 endogenous gene. Importantly, this effect was observed both in 
self renewal conditions and in differentiation inducing conditions. However, we have 
also observed that if differentiation level is high due to optimal differentiation 
conditions, Sox10 activation does not have any observable effects on the number of 
O4 positive cells appearing at the end of differentiation process. 
Secondly, we have demonstrated a successful transdifferentiation of MEFs into 
OPC-like cells, which was the main aim of this research. We have observed O4-
positive cells arising from transdifferentiating MEFs after activating Sox10, Olig2 and 
Nkx6-2 with sTFs. At 17 days post transfection, we have found 3.2% O4-positve cells 
while at day 24 we have found 6.9-17-9% of O4-positive cells depending of what sTFs 
have been used. Furthermore, these cells had OPC-like morphology and were 
distinguishable from MEFs. Remarkably, these sTFs can activate target genes in a 
manner that has profound consequences on cellular phenotypes. 
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6 General discussion 
6.1 Understanding dCas9 synthetic transcription factors 
CRISPR/Cas9-based sTFs have been under intensive development in the past 
few years. To date, they have been used in proof of principle studies across a number 
of applications and our understanding of how they work is increasing rapidly. In this 
thesis, we have explored their utility in reprograming and have identified both 
opportunities and limitations of current sTF approaches. We report successful 
activation of multiple master regulators in both MEFs and NS cells as well as an 
efficient method for construction of all-in one system for multiplexing. Importantly, 
we demonstrate that sTFs can direct both differentiation and transdifferentiation of 
cells. 
6.1.1 sTFs have cell-type specific functional constrains that limits predictive 
design rules 
It is known that a number of biological constraints limit sTF activity. In our 
studies, we have confirmed and extended past studies. We noted a large variation in 
activation potential between biological replicates, variation between cell types, and an 
effect of basal transcription level of the target gene as key factors influencing sTF 
activity. 
Firstly, it became evident from early experiments and was observed throughout 
all our experiments that there is a large variation of how well we can activate the gene 
from one experiment to another. In some cases, variable responses could be explained 
by technical limitations. For example, it is hard to compare activation levels at 
population level in MEFs and NSC as transfection efficiency differs greatly between 
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these two cell lines (>20% and >70%, respectively). However, even when controlling 
for this and many other conditions (e.g. transfection efficiency, qPCR variability and 
cell density) we still observed very different levels of activation; there seems to be 
inherent variability in the ability and extent to which cells activate target gene 
transcription. This may vary as much as couple hundred-fold difference between 
seemingly identical conditions. We would speculate a major contributor to the 
variability is the inherent stochastic nature of transcription and sTFs as well as 
transcription bursting. Varying levels of sTFs on a per cell basis are likely to 
dramatically influence the level of activation and is difficult to control using plasmid 
transient transfection. 
We have observed significant differences in ability of same sTFs to act in 
different cell types. An example of this variability is Nkx6-2. This is not expressed in 
either in MEFs or NSC. However, while we were able to achieve significant 
transcription activation in MEFs, we could not observe any activation in NSC. In 
addition, Nkx2-2 gene activation shown similar patterns. Furthermore, activation of 
Sox10 was variable when assessed between different NS cell lines: BL6 NSCs showed 
a weaker activation compared to PG1.1 NSC. Thus, the cell context and likely 
transcriptional and epigenetic status of the host cell drives the major differences in 
response to the same sTF. The major challenge to making effective sTFs lies in 
understanding the competence of the host cell. As 3D topology, enhancer usage, 
promoter usage, TSS, pre-existing transcriptional circuits, and epigenetic marks (DNA 
methylation, chromatin state) will all influence gene expression – it remains unclear 
which, if any, of these is the dominant predictor of sTF activity. 
 180 
Chromatin accessibility and epigenetic modifications, including DNA 
methylation and nucleosome positioning, might be one of the most important factors. 
Compacted chromatin has been shown to prevent transcription factor binding in a 
number of cases (Iwafuchi-Doi & Zaret 2016). That being said, a number of studies 
have shown that CRISPR/Cas9 is able to bind condensed chromatin (Polstein et al. 
2015). It is still possible that although Cas9 is able to bind condensed chromatin, it 
might not be able to function as sTF in such environment – competence of the TAD to 
recruit Pol II preinitiation complex might be impaired. Another important epigenetic 
factor to consider is nucleosome positioning. It has been reported by a number of 
studies that nucleosomes strongly interfere with CRISPR/Cas9 activity (Hinz et al. 
2015; Horlbeck et al. 2016; Isaac et al. 2016). In the study by Horlbeck and colleagues, 
they have demonstrated that in vitro, not only Cas9 cannot cut on DNA sites containing 
nucleosomes but that even binding of dCas9 is inhibited by nucleosomes. Importantly, 
after addition of nucleosome remodelling enzyme yChd1, ability of Cas9 to bind and 
cut DNA was restored (Horlbeck et al. 2015). As nucleosome positioning might differ 
between cell types, this could explain some of the biological constrains observed. It 
would be interesting to tether yChd1 enzyme to dCas9 as an addition effector and see 
if this would give dCas9 a stronger pioneering function. Thirdly, it might be possible 
that genes exploit different promoters and/or TSS sites in different cells lines. That 
might explain why Nkx6-2 can be activated in MEFs but not in NSC. Fourthly, the 
presence of other regulators actively interacting with promoter might also play an 
important role; dominant repressive factors (transcription factors, repressive miRNAs 
etc.) may be expressed in NSC, but not MEFs, to regulate Nkx6-2, this might interfere 
with functional sTFs. If this is true, using repressive sTFs to repress the repressors 
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might be a solution. Moreover, key activating co-factors might be missing that are 
expressed in cell type specific manner. This could result in transcriptional pausing and 
therefore inability of sTF to fully activate target gene transcription. Lastly, mRNA 
stability and translation capacity might be important factors to consider. Inability to 
maintain transcribed mRNA and prevent its decay might explain why we cannot detect 
any mRNA increase after targeting promoters. Further works needs to be performed 
to test such hypothesis. 
One consistent observation from our studies – and also observed in past work 
(Konermann et al. 2014) – is that a gene that already being actively transcribed, cannot 
be easily activated further. A clear example of this is activation of Olig2. Olig2 gene 
is silent in MEFs but highly expressed in NSC. We could significantly activate 
transcription of Olig2 in MEFs using sTFs; however, the same sTFs had no effect on 
transcription in NSC, as levels were already very high. To investigate this further, we 
decided to lower Olig2 transcription in NSC by forcing them to differentiate after 
delivering sTFs. Some interesting observations were made. In 3 out of 4 experiments 
we saw that differentiating NSCs (containing sTFs) had higher percentage of OLIG2 
positive cells as compared to differentiation NSC lacking sTFs. This would suggest 
that Olig2 activation was successful. However, on average there was no statistical 
difference between these two conditions. One of the reasons for such contradictory 
observations’ is the variability in the differentiation process itself (typically 5-20%). 
Thus, we do not have enough evidence to claim that Olig2 activation in NSC during 
differentiation was reliable and significant. 
The main mode of action for sTFs to activate transcription is by recruiting 
hosts’ transcription machinery to the promoter. Therefore, it is not surprising that sTFs 
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have no effect on genes which already have such machinery recruited and operating. 
sTFs maybe therefore be most productive in recruiting the basal machinery to activate 
a non-expressed gene; but they are not able to increase levels of expression. It might 
be possible that sTFs would still have an effect in cases where transcription is 
happening but the rate is limited because some of the transcription partners are missing 
or restricted. In such cases, sTFs might compensate for lacking parts and increase the 
rate of transcription. Moreover, it might be possible that novel sTFs which act to 
remove transcription rate constraints would be able to force gene over-activation, but 
it remains to be seen if this is possible. Thus, our initial experiments showed sTFs can 
work extremely effectively, but mainly for non-expressed genes (with dramatic 
influence of host cell on their effectiveness); already expressed genes cannot be 
activated to higher levels. 
 
6.1.2 Delivery of multiple gRNAs increases the success of transcriptional 
activation 
In all cases we have observed the use of multiple gRNAs, which target very 
proximal sites on the promoter, gives better gene activation as compared to using a 
single gRNA. The first examples of this came from using pools of 10 different gRNAs 
to target either Sox10, Olig2 or Nkx6-2. These pools strongly outperformed individual 
gRNAs as measured by qPCR. Furthermore, combining 2 to 3 gRNAs together also 
showed greater fold change compared to those gRNAs individually in all instances 
that we have tested. This suggests that some kind of cooperative effect exist between 
different gRNAs. However, as all of these observations have been made by co-
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transfecting relatively large numbers of plasmids it is hard to control for homogenous 
plasmid delivery. Moreover, the assay of activation is performed at population level, 
providing only the average level across cells.  
Do multiple gRNAs activate genes to higher level or do they just activate the 
gene in more cells? To answer this we performed single cell analysis on OLIG2 
activation in HEK293T cells. In these experiments, we used plasmids which contained 
either 1, 2 or 3 different gRNAs. Similar to past observations, at population level the 
more gRNAs are delivered, the higher fold-change is observed. Moreover, fold-change 
differences could be consistent with a synergistic effect of gRNAs (individual gRNAs 
activate ±30-fold while all three gRNAs together activate to ±300-fold). However, 
when we explored levels of OLIG2 protein in individual HEK293TT cells, we do not 
see synergetic patterns. Although, we see more OLIG2 positive cells using multiple 
gRNAs (52.9%), this was not dramatically different from the single gRNA (±40% of 
OLIG2 positive cells). Therefore, the effect of multiple gRNAs seems to be an increase 
in a number of individual cells being activated. A similar trend is observed after 
measuring OLIG2 intensity in OLIG2 positive cells: enhancement/cooperation is 
observed if multiple gRNAs are used, but the difference is not significant enough to 
suggest synergy. To sum up, although at population level (qPCR data) synergy seems 
to exist, this is not confirmed by single-cell protein data. From single cell protein level 
analysis, we found that using multiple gRNAs increases both the number of cells that 
are activating the gene and the level of activation in those cells. However, although 
statistically significant, increase is too small to suggest synergy. Rather, a cooperation 
between different gRNAs to slightly increase activation potential is a better 
explanation. At population level, this might create an illusion of synergy.  
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There are some unknowns in these experiments which we could not control 
technically and should be considered. Although we co-delivered gRNAs as a single 
vector, we do not know the absolute levels of expression for each gRNA in each cell. 
Furthermore, the assembly of the dCas9-VP160/gRNA complex is another variable 
which we cannot technically control or measure. However, we would not expect either 
of these to differ significantly. 
Based on the observations we have made, we propose the following working 
hypothesis on how multiple gRNAs cooperate at the transcriptional level. Firstly, by 
increasing the amount of gRNA, the chance of dCas9-VP160/gRNA complex 
formation (Fig.6-1A-B, blue arrow) or complex binding to the DNA is increased 
(Fig.6-1 A-B, pink arrow). At some point, this reaches threshold; increasing gRNA 
amount further has no further effect. However, by introducing new gRNA sequences 
which binds to surrounding DNA, the chances of complex forming and binding to 
DNA increases even further (Fig.6-1C). Thus, a diverse set of gRNAs is likely to have 
a greater chance of accessing and binding in the dynamic region around the promoter; 
i.e. there is greater chance of binding in a permissive state. Having multiple targets on 
the promoter allows dCas9-VP160/gRNA complex to bind to the promoter even if 
some of the target sequences are temporary restricted (Fig.6-1D), which would 
strongly interfere with sTF activity if only single target (gRNA) is available. Lastly, 
to initiate transcription, sTF has to attract multiple partners to the TSS. By increasing 
the number of sTFs bound on the DNA, the chance and the rate of transcription 
machinery assembly might increase as well.  
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Figure 6-1 | Working hypothesis for how multiple gRNAs enhance transcription activation. 
(A) A single sTF has to bind DNA to facilitate transcription initiation. At this stage, dCas9-
VP160/gRNA complex formation (blue arrow) and complex binding to/dissociation from DNA (purple 
arrow) are some of the function defining reactions. (B) By increasing the amount of gRNA and dCas9, 
both of the reactions can be enhanced therefore enhancing activation potential. (C) By adding new 
gRNAs to the system and increasing targetable area, another rate enhancing feature is created. (D) 
Moreover, by providing additional targets when using multiple gRNAs, the chances that all of the 
targeted DNA sites will be blocked is decreased therefore increasing the chances of strong activation. 
(E) For a sTF to operate it needs to recruit a number of co-factors (like RNA PolII, TFIID etc.) to the 













6.1.3 dCas9-VP160 amount does not seem to be a key limiting factor 
We have looked for a correlation between amount of dCas9-VP160 and the amount 
of target gene (OLIG2) after the activation in HEK293T cells. We observed low 
positive correlation. Certain cells which had high levels of dCas9-VP160 had low 
levels of OLIG2. In other cells, opposite was observed. This was further confirmed by 
RNA-FISH data in MEFs showing that some cells which have high amounts of Sox10 
mRNA have low amounts of dCas9 mRNA and vice versa. Thus, while the diversity 
and the absolute amounts of gRNAs plays a critical role in transcription activation, the 
absolute amount of dCas9-VP160 does not seem to be a limiting factor. 
These data suggest that although presence of dCas9-VP160 is essential for 
transcription activation, its’ levels are not limiting for the target transcription 
activation. Considering that only a single dCas9-VP160 copies are needed at the target 
site, and that high levels are produced from the expression plasmids, it is easy to 
understand why dCas9 levels are not limiting factor in gene activation. Our findings 
further suggest the diversity of gRNAs used is more important. 
6.1.4 Stronger TADs allow higher gene activation but are still restricted by 
biological barriers 
Another important consideration in design of effective sTFs is the effector that 
is attached to the dCas9 protein. We mainly used VP16 or multi-copy variant of it 
(VP160). Recently, a number of different novel TADs have been reported, which show 
significantly stronger activation of targeted genes than VP16 variants. We tested a 
number of different TADs in our systems side-by-side. We observed that TADs like 
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p300 and VPR are much stronger activators of some genes. In particular, p300 and 
VPR activated Sox10 in NSCs to significantly higher levels compared to VP160. One 
of the likely reasons why VPR and p300 outperforms VP160 is by increasing the 
variation and the number of effectors which can attract transcription machinery, sTF 
is made more potent transcription activator. This is the same reason why VP16 
outperforms VP160. In other words, this effect is similar to that of using single gRNA 
versus multiple gRNAs – the chances of recruiting the necessary basal transcription 
machinery is increased. Other groups have reported that increasing the amount and 
variation of TADs beyond that what VPR has no effect on activation potential. Such 
observations suggest that TAD potency is no longer a key limiting factor after certain 
point. 
Although using stronger TADs works really well in some cases, at other times 
it has only minimal effects. One of the examples is Nkx2-2 activation in MEFs. Nkx2-
2 is not transcribed in MEFs and it is possible to activate it with VP160. However, 
level of activation is relatively low. Interestingly, if VPR is used instead of VP160, 
activation is not enhanced as significantly as we have seen with Sox10 activation in 
NSC. This suggests that in some cases biological constraints remain dominant, even 
for the stronger TADs. Another example which also supports this finding is Nkx2-2 
and Nkx6-2 activation in NSC. Although both genes can be activated in MEFs even 
with VP160, neither of the genes could be activated in NSC either with VP160, p300 
or VPR. Stronger TADs therefore can be useful, but do not consistently enable 
successful activation of target genes. This has also been demonstrated by others in 
recent studies. For example, Zhou and colleagues have reported that VPR strongly 
outperforms VP64 in activation of Neurog2, but Ascl1 activation cannot be strongly 
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increased by strengthening effector (Zhou et al. 2018). Considering all of our 
experiments and work done by others, it is most likely that such failure is due to 
nucleosome positioning and presence of alternative TSS sites/promoter. Larger gRNA 
screen and use of chromatin remodelling enzymes should be tested to see if such 
hypothesis is correct. 
6.1.5 Epigenetic modifications as a main limiting factor for efficient and robust 
sTF function. 
From our and other group work some common limiting factors seem to 
emerge. Although we have not directly investigated nucleosome positioning in our 
experiments, there is an ample of studies which have directly showed that adding 
nucleosomes to DNA strands in vitro makes them inaccessible to Cas9 and dCas9 
(Horlbeck et al. 2015; Isaac et al. 2014). Moreover, if nucleosome remodelling 
enzymes are used (such as yChd1, RSC or SNF2), Cas9 becomes capable of 
efficiently binding and cutting the target site. Interestingly, if distal parts (liner areas) 
of nucleosomes are targeted, Cas9 is able to cut DNA strand (Isaac et al. 2014). 
Considering that pioneering factors have an ability to remodel nucleosome 
positioning within hours of being expressed – as shown by Ascl1 ATAC-seq results 
hours after overexpression – it would be extremely beneficial to give such pioneering 
function to Cas9 by tethering it to appropriate remodelling enzyme (Wapinski et al. 
2017). Although nucleosomes have been shown to be key for Cas9 binding, 
information regarding other epigenetic marks and their influence on Cas9 is unclear 
For example, Hu and colleagues have reported that although TALE- and CRISPR-
based transcriptional activation of Oct4 is possible in HEK293T cells, but DNA 
methylation that is found on the Oct4 promoter was not removed during this process 
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(J.Hu et al. 2014). However, more recent evidence shows that histone and DNA 
methylation can be altered by sTFs (Black et al. 2016). Further investigations will 
need to be undertaken to fully understand how DNA methylation might effect sTF 
functionality. 
 
6.2 Toolkit for simultaneous gene activation and repression in 
multiplex 
Our long-term goal remains to be ability to effectively activate and repress 
multiple target genes simultaneously in an individual cell. A number of sTF limitations 
have become obvious from the early experiments. Firstly, to activate genes in a reliable 
and robust manner a combination of gRNAs need to be used. It is difficult to predict 
this in advance; each must be screened to empirically determine the best activity in the 
right cell type. To test multiple gRNAs against multiple target genes simultaneously a 
new delivery system has to be developed; transient co-transfection would not suffice. 
Furthermore, gene repression would be highly desirable: not only does it play an 
important role directly in the cell fate reprograming, but also repression of repressors 
might be essential for some master regulators to overcome biological constrains. For 
these reasons, we developed an all-in one (Ai1) system and VRER dCas9 mutant 
proteins. 
6.2.1 An Extensible Mammalian Modular Assembly (EMMA), system for 
simple and rapid construction of expression plasmids 
To robustly and homogenously deliver multiple sTFs into cells, we needed to 
employ a cloning system which would allow rapid and modular assembly of many 
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parts with high efficiency. Expression plasmids need to be produced containing 
multiple unique gRNAs, plus a dCas9-Effector. With a help of Andrea Martella 
(Pattrick Cai and S. Pollard Lab) we have constructed “EMMA: an Extensible 
Mammalian Modular Assembly” (Martella et al. 2017). EMMA is based on the Golden 
Gate cloning system, but is highly optimised for multipart assembly, with a large 
collection of validated mammalian parts. Using EMMA we have made expression 
vectors with various levels of complexity and tested them in HEK293T cells. This has 
demonstrated that complex expression vectors can be readily produced using this 
cloning strategy. 
 We went on to adapt this system for assembly of sTFs expression plasmids. 
Firstly, we constructed an empty Ai1 vector, which contains: cloning sites for gRNA 
insertion, CAG promoter-driven dCas9-VP160, PiggyBac homology arms for stable 
integration and a reporter mRuby gene. After validating functionality of its parts, we 
went on to test capacity for gRNA insertion. 
6.2.2 Simultaneous activation of multiple endogenous genes by driving 
expression of three gRNAs-tRNA units from single U6 promoter 
For the first set of sTFs, each gRNA was driven by a single U6 promoter. In 
addition to that, they also had gRNA scaffold fragments and termination sequences. 
This composition of sTF expression would generate a highly repetitive encoding DNA 
sequence if simply concatamerised, leading to recombination in the plasmid or cell. 
To avoid this anticipated problem, we decided to use a single U6 promoter which is 
followed by gRNAs separated by tRNA sequences (Xie et al. 2015). Transcription 
produces a long gRNA-tRNA transcript, but the activity of RNAse H and RNAse P 
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excise the flanking tRNA sequence leading to release of functional gRNAs, which then 
can form complexes with dCas9-VP160. This approach would not only make the sTFs 
plasmid sequence less repetitive (if different tRNAs would be used), but also minimise 
the length of it by a third (as tRNA sequence is 81bp long while U6 promoter is 264bp 
long).  
This work was inspired by another group which managed to construct U6-
tRNA-gRNA and used it successfully to cut multiple genes with Cas9 in rice (Xie et 
al. 2015). However, at the time we constructed our first U6-(tRNA-gRNA)1-….-
(tRNA-gRNA)n, there was no published work in mammalian systems nor was it ever 
used to activate rather than cut genes. By the time of writing this thesis, tRNA-gRNA 
systems have been used in mammalian cell for gene editing but not for gene activation 
(Dong et al. 2017; Xu et al. 2017).  
Our first gRNA-tRNA construct contained the Glu-tRNA sequence and three 
gRNAs targeting Sox10, Olig2 and Nkx6-2. After transfecting MEFs and checking for 
activation of those genes, we have found that all three genes were activated. This proof 
of principle experiment has demonstrated not only that the tRNA-gRNA sequence are 
properly transcribed but also cut in a way that leaves remaining gRNAs functional. 
After this early success, we decided to construct a more elaborate gRNA-tRNA 
sequences which contained 8 different gRNAs. After a number of cloning efforts, we 
could not successfully make such a plasmid. We assumed this was because construct 
sequence was too repetitive (causing homologous recombination to occur during 
cloning process) and therefore switched to an original approach of using multiple U6 
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promoters. In the future, this problem could be solved by using different tRNA 
sequences instead of just using Glu-tRNA in all of the constructs.  
6.2.3 All-in one plasmid, driven by multiple U6 promoters, for simultaneous 
activation of multiple endogenous genes 
A second method which we developed was based on putting multiple U6-
gRNA repeats into empty Ai1 vector. By the time of writing this thesis, other groups 
have published impressive methods for development of all-in one plasmids for sTF 
delivery. For example, Shao and colleagues have constructed all-in one plasmid 
containing 20 gRNAs targeting 20 different genes. They have managed to activate and 
repress 10 genes separately using such plasmid (Shoa et al. 2018). To construct such 
multiplexing capacity, we started by adding three repeats which contained three 
different gRNAs targeting Sox10, Olig2 and Nkx6-2 (placed in that order). After 
successful activation of targeted genes in MEFs, we built larger plasmid which 
contained 2 gRNAs for Sox10, 2 gRNAs for Olig2 and 1 gRNA for Nkx6-2 (2SON). 
This again worked in MEFs and gave larger activation of Sox10 and Olig2, but slightly 
lower average activation of Nkx6-2. A third Ai1 plasmid was constructed, termed 
3SON, and it contained eight U6-gRNA repeats: 3 gRNAs targeting Sox10, 3 gRNAs 
targeting Olig2 and 2 gRNAs targeting Nkx6-2. These genes could all be activated 
from this plasmid. However, Olig2 and Nkx6-2 had a lower level of activation 
compared to 2SON. This suggests that the longer Ai1 construct is, the lower activation 
from distal U6-gRNA units can be observed – although more variations and testing 
would be needed to confirm this.  We speculate that there might be transcriptional 
competition or interference from surrounding U6 promoters. Future experiments might 
make use of addition of insulators or larger linker spaces between individual U6-gRNA 
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units. However, for the purpose of this thesis, not only have we shown that 
construction of such Ai1 plasmids is possible but also that they are able to activate 
multiple genes from the single expression vector delivering multiple guides for each 
gene. 
6.2.4 VRER mutant dCas9 recognizes NGCG instead of NGG PAM 
A second problem that we have set out to tackle was construction of a sTF 
system which would allow activation and repression of different genes using dCas9 
simultaneously. A simple CRISPR/dCas9 system would be incapable of segregating 
repressive and activating functions as both dCas9 proteins would compete equally for 
gRNAs – a mixture of activators and repressors for each promoter/gene would emerge. 
To be able to direct dCas9-Activator and dCas9-Repressor to distinct target genes in 
the same cell dCas9 with distinct PAM sequence recognition would be needed.  This 
could either be achieved by using different orthologues of dCas9 (from different 
bacterial species) or by protein engineering to mutate dCas9 protein to adjust its PAM 
preference (Kleinstiver et al. 2015). Another approach was recently reported that 
enables different effectors to be bound to the gRNA via use of RNA-Protein scaffolds 
(Konermann et al. 2014). This system is called SAM, and it allows construction of 
activating and repressive sTFs which can work in same cells. We have decided to 
choose first approach and mutate dCas9 protein, adjusting its PAM specificity in such 
a manner. Although this has been done with Cas9 (creating a VRER-Cas9 mutant) to 
show almost exclusive PAM specificity, it has not yet been used with dCas9 for 
transcriptional activation and repression, or multiplexed within the same cell. 
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We successfully introduced four amino acid substations (VRER) into dCas9 to 
produce the VRER-dCas9-VP160 and VRER-dCas9-KRAB versions of it. To test if 
VRER-dCas9-VP160 recognizes NGCG PAM instead of original NGG PAM, we have 
created gRNAs for both types of PAM, targeting Nkx6-2 and Sox10. When targeting 
Nkx6-2 in MEFs, we observed expected results: VRER-dCas9-VP160 could only 
activate Nkx6-2 if ‘NGCG’ binding gRNAs were used and not if ‘NGG’ were used. 
To a large extent the opposite was true for dCas9-VP160. That being said, this was not 
quite so stringent, as dCas9-VP160 was still able to slightly activate Nkx6-2 gene 
transcription (around 20-fold change) with the ‘wrong’ NGCG gRNAs. However, this 
was significantly lower compared to NGG gRNAs (around 4000-fold different). To 
some extent this agrees with results presented by authors of original study as they also 
saw small activity cross-PAMs. For example, recent work by Hu and colleagues have 
reported similar trends (J.Hu et al. 2018). They have used continues evolution in E.coli 
cells to force new mutations in Cas9 (and dCas9) protein and some of these were 
recognizing new PAM sequences. After direct head-to-head comparison of various 
mutants, they have found that some cross-reactivity remains (gRNAs with wrong PAM 
are able of activation). Although, as authors claim, such dCas9 characteristic is an 
important development for expanding target repertoire, but this might also have a 
negative effect on use of these reagents for simultaneous gene activation and 
repression as some competition for gRNAs will be present. However, it is likely that 
the specificity will be strong enough for cross-PAM recognition not to have a 
significant effect.  
Our results were not so promising for Sox10.  dCas9-VP160 managed to 
activate Sox10 transcription if gRNAs containing the NGG PAM (original) were used, 
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but not if NGCG (new) PAMs were used. However, none of the gRNAs could activate 
Sox10 gene with the mutant VRER-dCas9-VP160. While we would not expect NGG 
gRNAs to work, it was strange that NGCG gRNAs did not work as well. This may be 
because NGCG gRNAs could not be designed to completely target same promoter 
base pairs as NGG gRNAs. Considering that even small positional shift of gRNA 
location might make it completely non-functional – mainly because of nucleosome 
positioning but also because of possible secondary structure formation - we 
hypothesize that this is a reason for such results. 
We went on to test if we can repress genes using VRER-dCas9-KRAB. For 
candidate gene targets, we have chosen Sox9 and Olig2. In both case we managed to 
see a drop in positive cells after transfection with VRER-dCas9-KRAB and 
corresponding gRNAs. Although this was evident at protein level in a number of 
biological replicates, we could not observe any difference at mRNA level. We are 
unsure the explanation for this observation, but similar trend has been shown by a 
previous PhD student in our lab as well (S. Gogolok). One explanation could be related 
to the extent of the repression. Firstly, instead of observing more negative cells, we 
found more cells which are low in either of the proteins (as measured by the intensity 
of immunostaining). This means transcription is not completely turned off but rather 
slowed down. Secondly, this shift was observed only in small proportion of cells (less 
than 15%). Taken together, these results might explain why we see difference at single 




6.3 Programing and reprograming NSC and MEFs using synthetic 
transcription factors 
In recent years, a number of groups have reported successful programing and 
reprograming of cell fate using sTFs. The best and most impressive example to date is 
work done by Black and colleagues. They have demonstrated that difficult direct 
lineage conversion from MEFs into neurons can be facilitated by using 12 gRNAs 
targeting Ascl1, Brn2 and Mytl1 gene transcription (Black et al. 2016). Although this 
was impressive study demonstrating strong potential of sTFs in cell fate programming, 
a number of features still have to be improved. In this study, multiple plasmids have 
been used which results in heterogeneous delivery of sTFs potentially compromising 
cell programming efficiency (considering each element is essential for sTF 
functionality). Furthermore, lentiviral-based delivery systems have been used which 
have limited cargo capacity. To target higher number of genes (which might assist with 
lineage conversion dynamics), plasmid or artificial chromosome-based delivery will 
need to be used. 
For the last part of this work, we have tested if sTFs could have any biological 
effect on cell differentiation or phenotype – both NS cell programing to OPCs and 
MEF transdifferentiation towards OPCs/OLs. We have observed functional changes 
in both MEF and NSC after target gene activation using sTFs. In this work, we have 
used all-in one plasmids which are capable of delivering at least 8 different gRNAs 
and dCas9-VP160 within single plasmid. 
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6.3.1 Sox10 overexpression or activation drives NSC differentiation towards 
OL lineage 
To test if Sox10 overexpression or activation has any effect on NSC 
differentiation, we have constructed stable cell lines harbouring appropriate cDNA 
overexpression or gene activation (sTF-based) system. Firstly, to have positive control 
in differentiation experiments we have established a cell line which was upregulating 
SOX10 and OLIG2 expression in presence of DOX. We had a number of problems 
minimizing leakage of these two genes in absence of DOX, and although we managed 
to find clones which were not significantly leaky, some basal expression of SOX10 
was still observed. Similarly, we constructed NSC lines which were constitutively 
activating Sox10 due to expression of the dCas9-VP160 based sTFs.  
Firstly, we tested if PDGFRα-GFP expression could be induced in NS cells 
under self-renewal conditions and if this could be enhanced to higher levels during 
differentiation. Under self-renewal conditions, cells which had SOX10 upregulated 
(either by cDNA overexpression or sTF-based activation) were able to generate 
increased numbers of PDGFRα positive cells. Similar increases were observed when 
using differentiation inducing conditions. Thus, cells with activated Sox10 gene (sTF) 
or overexpressed SOX10 cDNA were able to generate significantly more PDGFRα-
GFP cells at every time-point.  
There are couple of important caveats for these results. Firstly, we have 
observed that all cell lines which had high SOX10 were also proliferating faster 
compared to parental cells. To overcome this problem during our experiments, we have 
seeded cells at very low density (20,000 cells per 6-well plate at Day 0) which kept 
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cells at low confluence. In such a way, the effect on differentiation was coming more 
directly from gene regulation rather than changes in density. Secondly, PDGFRα is a 
marker of early stage OPCs rather than OLs. Moreover, SOX10 directly controls 
PDGFRα expression. Because of these reasons, described experiments on PG1.1 NS 
cell line were not conclusive enough to state that Sox10 is able to enhance NSC 
differentiation to OL lineage. At best, we could speculate that Sox10 
overexpression/activation was priming NSC to become OPCs. 
To test if Sox10 transcription activation (by sTFs) can enhance NSC 
differentiation to OLs, we have repeated the experiments on a different non-
manipulated NSC line, called BL6, and forced them to differentiate fully to OLs. In 
the initial experiments, we have used a two-step differentiation protocol (FGF-2, 
PDGFR-AA and Forskolin followed by a switch to T3 and Ascorbic acid) and they 
resulted in a high frequency of O4 positive cells. Using this protocol, we could not see 
any differences between cells which had Sox10 gene activated and cells which did not 
(both gave about 60% O4 positive cells). However, when using a sub-optimal 
differentiation protocol (addition of 5% FCS) we observed a dramatic increase in the 
levels of O4 positive cells comparing with and without the Sox10 activating sTF. 
Activation of Sox10 transcription by sTFs gave ~10% more O4 positive cells in these 
conditions. Further work would need to be undertaken to fully understand the genes 
required to force NSC differentiation under different conditions (i.e. there still seems 
to be some rate limiting event that limits total numbers of possible O4 positive cells 
specified). Thus, we demonstrated a significant impact on differentiation programs 
using sTFs in NSCs. 
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6.3.2 Sox10, Olig2 and Nkx6-2 activation by sTFs drive MEF 
transdifferentiation towards OL lineage 
The second use of sTFs we explored for cell fate programing was to apply sTFs 
to drive MEF transdifferentiation to OPCs/OLs.  
Two key published studies have shown that Sox10, Olig2 and Nkx6-2 or Zfp653 
overexpression in MEFs can trigger a subset of cells to become OL-like cells. These 
cells were positive for a number of OL markers; displayed a typical oligodendrocyte 
morphology; they were able to generate myelin sheets when transplanted into mice. In 
each of these studies the protocols used were similar, but not identical: cells were 
infected with the cDNAs expressed from viral vectors, and then maintained in MEF 
medium for 3 days. These were then seeded into Laminin coated plates containing 
transdifferentiation inducing medium. Media composition varied between two key 
studies. 14 to 24 days after TD–inducing medium addition, cells were scored for 
transdifferentiation events by flow cytometry and immunostaining for OL markers O4 
and PLP1. Although the authors claimed that it is difficult to know the exact 
transdifferentiation efficiency (as many cells replicate and die throughout the process), 
but they have reported between 4-36% (17% on average) of O4 positive cells at day 
21 in one study (Yang et al) and around 9% of O4 positive cells at day 24 in another 
study (Najm et al).  
We have set out to repeat these findings by using our sTFs which are able to 
activate Sox10, Olig2 and Nkx6-2 in MEFs. For our experiments, we have used 
protocol described by Najm et al. Cells were transfected with sTFs at Day 0. All three 
genes were activated in MEFs at Day 3, 9 and 14 as shown by qPCR. However, at Day 
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17 we only saw 3.2% of O4 positive cells after using 3SON sTFs. After increasing the 
transdifferentiation protocol from 17 days to 24 days, we have found that this 
percentage increased to 6.9%.  
There are couple important points requiring further discussion. Firstly, the level 
of gene activation seems to play a key role in transdifferentiation. In previous studies, 
couple thousand-fold change in gene transcription has been seen while our 3SON sTFs 
were able to activate Sox10 to couple hundred-fold at most. Interestingly, 
supplementary data from Najm et al study shows that if any of three factors are 
missing, amount of PLP positive cells at day 21 drops to 4.7 – 7.6%. Following these 
observations, we decided to strength our sTFs by additional sTFs targeting Sox10 gene 
(S10 vector). By doing so, we managed to increase the proportion of O4-postive cells 
from 6.9% to 17.9%. To even further enhance the effect, stronger effectors could be 
used as well. Secondly, length of transdifferentiation protocol plays important role. In 
the study by Yang et al, they have seen only 2.0 – 8.5% of cells expressed PLP at day 
7. Furthermore, recent study which replicated findings from first Najm et al and Yang 
et al have reported even longer times required for transdifferentiation. In one case, 
they have left MEFs for over 30 days (Lee & Park 2017). We have also observed 
similar trends. Last thing which is important to mention is transdifferentiation medium 
composition. In our studies, we have used medium described by Najm et al. It would 
be interesting to see if using medium defined by Yang et al would make any difference.  
6.4 Future work 
Here we report an effort to build and screen multiple sTFs for the purpose of 
activating Sox10, Olig2, Nkx6-2 and Nkx2-2 in neural stem cells and mouse embryonic 
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fibroblasts. We have tested these sTFs in different contexts including NS cell self-
renewal and differentiation as well as MEF transdifferentiation induction. 
Furthermore, we have designed and built tools for multiple gene modulation from a 
single plasmid as well as mutant sTF variants which allows to adjust target specificity. 
Lastly, we investigated how multiple sTF cooperate to activate target genes. 
To summarize, we have successfully achieved the following. We have 
activated Sox10 gene in NS using dCas9-VP160 and multiple gRNAs. After 
investigating potency of these cells to differentiate into OPCs and OLs, we showed 
that Sox10 transcription activation allows more cells to differentiate to OL-lineage. 
Next, we have built a system which allows to generate expression plasmids containing 
dCas9-VP160 and up to eight different gRNAs in the same plasmid. This allowed 
activation of three different genes (Sox10, Olig2 and Nkx6-2) from a single plasmid in 
MEFs. Furthermore, we have built and validated dCas9-VP160 mutant, VRER, which 
has modified PAM specificity and therefore searches for alternative target sites. Such 
mutant was almost exclusively recognizing gRNAs with NGCG PAM while ignoring 
its natural targets with NGG PAM. Next, we show preliminary single-cell results 
demonstrating that using multiple gRNAs to activate OLIG2 in HEK293T cells not 
only allows more cells to be activated but also activation level within these cells is 
higher as compared to using single gRNA. Lastly, we have shown that sTF-driven 
activation of Sox10, Olig2 and Nkx6-2 endogenous transcription can drive MEF 
transdifferentiation to O4-positive OPC-like cells in 24 days.  
While our work helped to better understand sTFs and their potential role in cell 
fate reprograming, there are still many things which need to be further validated and/or 
optimized. Some of the directions for future work we will undertake includes (i) better 
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understanding what impact different TADs have on gene activation at single cell level, 
(ii) optimizing the MEF transdifferentiation protocol and confirming that functional 
oligodendrocytes can be produced. Other important areas which needs further 
investigation include: testing multiplexing limits for Ai1 expression vectors; 
investigating potential of using different tRNAs in Ai1 expression vectors; 
investigating the SAM system for gene repression; testing multiplexing system for 
simultaneous gene activation and repression. Altogether the sTF technologies show 
great promise for controlling endogenous gene activation and repression. In the future 
these will likely provide important tools and reagents for steering mammalian cell fate 
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8.1 Sequences of gRNAs used in this study 
gRNA ID Target gene Target Sequence (5’-3’) 
g1 Sox10 TGGCATCTGGTGTGAGCATG 
g2 Sox10 GTCTGGGAAGGGAGAGATAC 
g3 Sox10 GGACCCTAAACCATTGCCAC 
g4 Sox10 GTTGACAAAGGACTGGAGAG 
g5 Sox10 GGAGAGTGGATAACTTGAAA 
g6 Sox10 TGCGGTGCCTAGCACACAGT 
g7 Sox10 AGGGAGGGAAGGGCAGAAGG 
g8 Sox10 GGGGATGAAGGCAGCGCTGG 
g9 Sox10 GGGCAGAGTGGAGGCGTCCT 
g10 Sox10 GACGGGCCTAGGCAGCAGTG 
g11 Olig2 GGTCGGCAGCGGGAAACAGG 
g12 Olig2 GCTAGCAAAAACTCCAGGTG 
g13 Olig2 GAATCTGCAAACTCGTCCGA 
g14 Olig2 TGTAGCGTCAGGCCAGGGTA 
g15 Olig2 GGGGCTGCTAAAGAAGTCTG 
g16 Olig2 GGGCGAGCTGAAGAAGCGGG 
g17 Olig2 GACCTGGGCAGGGAGAGGAA 
g18 Olig2 GATTCGCGAGGAGGGATGGG 
g19 Olig2 TGCTGAGAGGAGGCGTGTGC 
g20 Olig2 ATGGCTGAGAATGAACACCG 
g29 Nkx6-2 GGGGGCGCGCGCAGACGGGC 
g30 Nkx6-2 GAAGGGCCCATTAGCGAGGC 
g31 Nkx6-2 GGGCAAATTTACAGTCCCGG 
g32 Nkx6-2 CGGGATTTATTTCATCTCTA 
g33 Nkx6-2 AGTTAGGCAAAGGTTTTAAT 
g34 Nkx6-2 GCATACTGAGCTTGAGCTTT 
g35 Nkx6-2 GTTCAGGGAAGAGCCTGGGA 
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g36 Nkx6-2 GGGCACTCCATCTTGGATCA 
g37 Nkx6-2 AGCCCACACCACCACGAGCT 
g38 Nkx6-2 GGAACCCCAGTACAGGGCTT 
g39 Nkx2-2 (promoter) GAGGGGGGAGGGGGAGAAAA 
g40 Nkx2-2 (promoter) GGAAAAGAGGGAGGGGGTCG 
g41 Nkx2-2 (promoter) GAGAGAGGGGTGAAAAAAAG 
g42 Nkx2-2 (promoter) GACATTAAAACCGCAAAGGT 
g43 Nkx2-2 (promoter) GGCGGGTCTTGGGAGTCAAG 
g44 Nkx2-2 (promoter) AGATGTGAAATTGTGGGTTT 
g45 Nkx2-2 (promoter) GCCCTCTAGAGCAAGATGAG 
g46 Nkx2-2 (promoter) GTCAATTAATTGCAAAGATG 
g47 Nkx2-2 (promoter) GTGTGGACTCGAGAGCGACG 
g48 Nkx2-2 (promoter) TAAGATGCAATTTGTTAAAA 
g49 Nkx2-2 (enhancer) TGTTAAGTGGGGCGAACAAG 
g50 Nkx2-2 (enhancer) GCTTAGCCTGGGGTGGGGGG 
g51 Nkx2-2 (enhancer) GTTCTGCTTCGCCTGGACTA 
g52 Nkx2-2 (enhancer) GCTCACAGCTGCTTGGGCCG 
g53 Nkx2-2 (enhancer) AGGCTCTAGAAACCCGGGGG 
g54 Nkx2-2 (enhancer) GTCACCCACGTCACATACTG 
g55 Nkx2-2 (enhancer) GCGTCCTGGGTGGTCGGACC 
g56 Nkx2-2 (enhancer) TGCTAAGCTGCGGACAATGA 
g57 Nkx2-2 (enhancer) GACAAATGTCCCGCTCCTGT 
g58 Nkx2-2 (enhancer) GAAGAGATAGTCCATTGAAA 
g94 Sox9 TGCCTGGAAACTTCTGTGGG 
g95 Sox9 CTGGAAGTCGGAGAGCCGAG 
g96 Sox9 TTCCAAAATCCGGTCCAATC 
g97 Sox9 CCCGGGTCCCCCGCTTGCCC 
g147 Sox9 GGGTGACGAGACAGGAGGGG 
g148 Sox9 TGGACCGGATTTTGGAAGGG 
g149 Sox9 AGCTCTTGAGTCATCAGTGT 
g150 Sox9 CGAGGTATCTAACGTGAAGG 
g151 Sox9 GGCTCTCCGACTTCCAGCTC 
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g152 Sox9 GAACTGCCTGGAAACTTCTG 
g153 Sox10 GGGCAGAAGGTGGAGCCTCC 
g154 Sox10 TGGGTGTTGGGGATGAAGGC 
g155 Sox10 GGGGGGCTGGGCAGAGTGGA 
g156 Sox10 GAGACGGGCCTAGGCAGCAG 
g157 Sox10 GTCTGATACCTACTGCAGGC 
g159 Nkx6-2 CACTCCATGAAGGGCCCATT 
g160 Nkx6-2 CAGCGTCCGGCCCGTCTGCG 
g161 Nkx6-2 GCTGATTGGCTGAAGGCACT 
g162 Nkx6-2 CCTTCATGGAGTGCATGGCC 
g163 Nkx6-2 TGGAGTGCATGGCCGGCGGG 
g175 Olig2 GCTGGGCCGGCCCGAGGGGC 
g176 Olig2 TCGGGCCGGCCCAGCTCATT 
g177 Olig2 GGGCCCGGCGGGTTTCATTG 
g178 Olig2 TGGCGGTGGTCCGGGCGGGG 
g179 Olig2 TTACAGACCGAGCCAACACC 
g180 Olig2 AGAGCCAGGTTCTCCTCCGC 
g181 OLIG2 ACGGCGGCAGCGGTGGCG 
g182 OLIG2 CCTGGCGAGTTTCATTGA 
g183 OLIG2 CCACCACAGAGTCAGGTTG 
g184 Sox10 (for Sox10 tagging) CGACTCTATCCCGACCTTAG 
g185 Sox10 (for Sox10 tagging) ACTCTATCCCGACCTTAGAG 
Table 8-1 | List of gRNAs used in this study and their sequences. 
8.2 List of custom-made RNA-FISH probes and their sequences 
Target gene Probe # Probe Sequence (5’ to 3’) 
Sox10 1 tgataggtcttgttcctcg 
Sox10 2 ctgttccttcttgaccttg 
Sox10 3 cacggggaacttgtcatcg 
Sox10 4 tcatgggcctcttgacgtg 
Sox10 5 ctgtgcccacaccatgaag 
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Sox10 6 tactggtcggctagctttc 
Sox10 7 tgagctcagcattgtggag 
Sox10 8 agagcttgcctagtgtctt 
Sox10 9 ttgtcactttcgttcagca 
Sox10 10 ctcagcctcctcaatgaag 
Sox10 11 gatggtcctttttgtgctg 
Sox10 12 ccgaggttggtacttgtag 
Sox10 13 tgagcctgaatagcagcag 
Sox10 14 tgggttcccatctgacatg 
Sox10 15 gactgcagctctgtctttg 
Sox10 16 cacgttgccgaagtcgatg 
Sox10 17 ccatgttggacattacctc 
Sox10 18 ccagctcagtcacatcaaa 
Sox10 19 cgttgggtggcaggtattg 
Sox10 20 cgagtagctacccacatgg 
Sox10 21 tggtggcttggagatccag 
Sox10 22 ctttggcatccacaccagg 
Sox10 23 cgatctgggaagtggacgg 
Sox10 24 gcagactgagggaagtgta 
Sox10 25 atggaggggaaggcggagc 
Sox10 26 tagtcaaactggggtcgtg 
Sox10 27 cctgagggctgatggtcag 
Sox10 28 cctgcatggccataatagg 
Sox10 29 gagatggcagtgtagaggg 
Sox10 30 tgtgtgggactgtgggatt 
Sox10 31 aaggtcgggatagagtcgt 
dCas9 1 aagatctcttgcagatagcaga 
dCas9 2 ctcttccagtctgtggaagaag 
dCas9 3 gtcgaagttgctcttgaagttg 
dCas9 4 gtcgtatctcttgatcatagag 
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dCas9 5 aaatctctttgtacttctcagg 
dCas9 6 gtccttcaggaatgggtaaaaa 
dCas9 7 gttcttatcgaagttggtcatc 
dCas9 8 tatacacggtgaagtactcgta 
dCas9 9 tcacgtatttcactttggtcag 
dCas9 10 tccttgataattttcagcagat 
dCas9 11 cagcacgatatcttccagaatg 
dCas9 12 gatcatctctctgtcctcaaac 
dCas9 13 tcatcactttgtcgtcgaacag 
dCas9 14 catgaagtttctgttggcgaag 
dCas9 15 catttcgatcacgatgttctcg 
dCas9 16 attctgcaggtagtacaggtac 
dCas9 17 gatggagtcgtccttcagaaag 
dCas9 18 tcagattgtcgaactttctctg 
dCas9 19 ttgtcattctcgtcgtacttag 
dCas9 20 ttcagggtgatcactttcactt 
dCas9 21 gaaatccttccggaaatcggac 
dCas9 22 tgatctcgcgcactttgtaaaa 
dCas9 23 cttagggtactttttgatcagg 
dCas9 24 ctttttcacgatattcacttgg 
dCas9 25 caggatagactctttgctgaag 
dCas9 26 tttcacactcttcagtttcttg 
dCas9 27 cagaaagtcgatgggattcttc 
dCas9 28 tacttaggcagcttgatgatca 
dCas9 29 ggtacaggaagttcacatattt 
dCas9 30 aaacagctgtttctgctcatta 
dCas9 31 caggatcactctcttggagaac 
dCas9 32 gacagcactttgtccagattag 
dCas9 33 agggtaaacaggtggatgatat 
Table 8-2 | List of custom-made RNA-FISH probes and their sequences. 
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8.3 List of key PCR primer used in this study 
 
Table 8-3 | List of PCR primers used for construction of Ai1 vectors
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PCR name Sequence (5’ to 3’) Used for 
D1135V_F CGGCGGCTTCgtgAGCCCCACCG Site-specific mutagenesis 
D1135V_R TACTTCTTAGGGTCCCAGTCCTTCTTTC Site-specific mutagenesis 
G1218R_F GGCCTCTGCCagaGAACTGCAGAAG Site-specific mutagenesis 
G1218R_R AGCATTCTCTTCCGGCCG Site-specific mutagenesis 
R1335E_F CGACCGGAAGgagTACACCAGCAC Site-specific mutagenesis 
R1335E_R ATGGTGGTGTCAAAGTACTTG Site-specific mutagenesis 
T1337R_F GAAGgagTACagaAGCACCAAAGAGGTG Site-specific mutagenesis 
T1337R_R CGGTCGATGGTGGTGTCA Site-specific mutagenesis 
Sox10_F GGAGATCAGCCACGAGGTAA V5 genotyping 
V5_R ACCGAGGAGAGGGTTAGGGAT V5 genotyping 
Table 8-4 | List of PCR primers used for site-specific mutagenesis.  
